<SEC-DOCUMENT>0001558370-22-013560.txt : 20220815
<SEC-HEADER>0001558370-22-013560.hdr.sgml : 20220815
<ACCEPTANCE-DATETIME>20220815070946
ACCESSION NUMBER:		0001558370-22-013560
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220815
DATE AS OF CHANGE:		20220815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		221162288

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20220630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8167.22744 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/14/2022 9:21:23 PM -->
      <!-- iXBRL Library version: 1.0.8167.22751 -->
      <!-- iXBRL Service Job ID: 89069ef9-ca7b-4b1d-bb22-71d500697b7b -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" xs:nil="true" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_D9pLUZgDkEe5scajs-aR4A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" xs:nil="true" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_8lY80BgnTUa4R0U4WKYNJg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" sign="-" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_K1UiCHy9GUyJUPuJfA-z9w">0.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" sign="-" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_jS3Lo46FaUWhBg_0OuV7cw">0.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" sign="-" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_tzQu6u9z50KabqolBS2DIQ">0.11</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" sign="-" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden__3sT1TpM4E2IfKH_4VPYoQ">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_KyqYSEAD7EWap14es3Ir9w">46589976</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_XKJX1D8fhE6MN_XAdnWN5g">42744426</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_z64eekF3002XLUC4QaU8BA">47327952</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_KyDfQ9XtUU6N_OsRMdXKyA">45436907</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityCentralIndexKey" id="Tc_MUQbn6lbn0ijFL6A5WOGVg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:CurrentFiscalYearEndDate" id="Tc_AYurxoM6UUyXJ1m6MZu3ug_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentFiscalYearFocus" id="Tc_AL1YmwQSqkKdIWSR1hoajQ_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentFiscalPeriodFocus" id="Tc_oe6EnY4qWkG-pZkGdxbr2Q_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:AmendmentFlag" id="Tc_K4n9laBg-U-ms91tgfGn2w_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ytcHJNRtMkC-kFhR6Y_Q9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4nVZjnZPfESVPBgjGtf3hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_Z-8iEsWphUCbjtsaDKdovA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qVPpbQRPfk2TReO-LtDjaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6DLzF6gPCkKUOnMGptPp4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bgf7v6oL7UGhXhJ5Qvr8SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xlM86qUkt0KOAmnTSOyfwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_BpzceNB_akmwpVhtRG9COQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q3iT6tByHUqOnNA_O2SM8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C0_vygBSwUKW1_g7vDXPDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Ri85L_GQ6EGDyqBYwwU7vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_bviBEkzn-kuxLoWbK74QKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_RfgCYQ2Rr0qLtIgXDy8V0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tBqUbsRpXUCkCu7As_K8ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_iGheMtaJu06OflGOGrghmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_VVGBDxGe8UudpDjkca8hHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_EDJO9ESATkWFpOj1QBRDjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_KnmF4l_09EC6bg-2BZ311g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_9vZiZcQD8UufQ_SB8sxlmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_poDnVzcNS0KMFLRSo_6oDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_EiQ41j_NqUGvIIayLqE9OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jEHvpKQm5kCqey2CTt_BcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VaxdqtuNcEisKZVLZWPKvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_y6DZaQueokGuDyxDFuaa_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zC0lIICAa0SqzS0gFlR7dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_La_v2P8SgUu8a-sZ8uaD5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MYQxmrO7BkKHz_LbP4Z5QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGjbifYeakiP_pumhgy_NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c2uW99rnTUyPMniVyn2M0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_KiMXzKBurE62LVrcGB85cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_xZtyvQccUESGBiPReGtrYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_aOpGJG-q1k2lYifBL5VXKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Bmg1y9mhxUahVCDnBjO6ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b7YYEGq7sUq5RS6c9gLCog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_EibuCP6l4kKN_Q30vrA0hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EZfCnohvr0y2B-Q9rWZ-Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_WIAQENglMkea-ygnycr5WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_G8oXr3UKV0i09CNvcOUZpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TvQ-GPYn2EGcujvnvNwsGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Fm5H8d3qkaSZ7TvQIrSFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2OW2E9fYbUuNi7TvwRPypA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_DJJNM8qnaEKUcJ3HHuAssg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_QyKQxoFpHUmwj--qWhm7zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zqsmNVni_02194Rs9tUq7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_D0U9HQw9R0WDe2pBZk3w3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bO8o39pQaEml34krQBBNIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_8fJEcV0nCke4OMdxDI5Wmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_VnH5FcNSOEqo6IyPz5y2QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2022_To_8_15_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_AagOsjXaHk2Tye8hFQUyyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2022_To_8_15_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_zEYSsTSOvkScTP7J-kyj4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IkS-U_42B0qptgPPLXKu_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nhGp8vR41EuQp88YBLlW4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_zXSdyWR7tUO8R8iIafuytA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_QeVKh51xs0SPEU0GH8uOSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_3QlMfOhpR0u7fHcnwWrz2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d-nB_IK66k--GPVQiT88QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_BKeU6ZzYJkq_9CWsGYOCHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2022_cMVR1Q0aFUWivfZLB1FiBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_BJyuho_M3E-RzZ63hj9Iag"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_8VPFZCaFnEGUa7jmFn4qhA"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_TxlQgi6e1UilQwKit50P2Q_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3vv-v5_G20itN1papb-TNQ_32_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yQlY42Huak6lD4nU7LzyUA_27_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GBV05_V7V0udz8OxRZmetA_35_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_deucjwu8MU2X0nDSTJw4Mg_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_34L_v0wCxEuRaiizzFnAWA_23_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MjKT05CwDkW6P3tHv3OVIA_29_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_WHZRU1HR00qNCR9SiWvxow_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AUdvBExCfUSmxApu5-3tOQ_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_hTEWKEnK5k21aSTetjwslQ_37_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_TcCS3W8KE06wqIphZkr7QA_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vqUcB4UXeES_j_LBvQNLjw_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7iDs3mR8VUeuTr2byJbBbA_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kT01q2rPC06oxUaemMWsbg_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_l90QbEkG4kaEJOnguvFNpg_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6EOraGnSpka9y4YLOqWBXg_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_825CnEVwuU-5yyNVwXD5ZA_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_z8EulXXFtUCiFYYOQm1lTg_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_SSBGgak3jUuyZlmDOP1GIg_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_e78HqF1JMEa43P-La_R1JQ_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6Pl25RwX_ki7PiR5JudZYg_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_93340c33_7625_4d4c_8f6f_e18378327f0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentType" id="Narr_ohHONYAruEaG9-mXRO1dDA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentQuarterlyReport" id="Narr_rAaBtIbTlUWbkzqbdFW6Hg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentPeriodEndDate" id="Narr_icJRV2r8Ek6pn_bBZRmHtQ"><b style="font-size:8pt;font-weight:bold;">June&#160;30, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:DocumentTransitionReport" id="Narr__bR0XRb_q0aXbcDFu7qVfw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityFileNumber" id="Narr_jX4e4O376Uyt-6sk1r_gYA"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityRegistrantName" id="Narr_EAX2LlW5g0mPVCyHLgPjzA"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_8EVPKMu_BUKr-dPVjurejQ_1_1"></a><a id="Tc_QHmhf-fByEWJeq-jbPNwOA_2_0"></a><a id="Tc_ogquNArJ-UK-eBj3vQ2-hg_2_1"></a><a id="Tc_MDr71yWeHUm0TIpb3w0g0A_4_0"></a><a id="Tc_Op0Ep24pmkOz4BYD9SS3bw_5_0"></a><a id="Tc_KjE-LEZ0JkWVz21EyaEKDA_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityIncorporationStateCountryCode" id="Tc_OlbKjTCGTECGmyiKKHlNoQ_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityTaxIdentificationNumber" id="Narr_FTUj2Dp4REemYjEIGYQOwg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityAddressAddressLine1" id="Narr_Oqphe-KbjECkJK8rMPS18Q"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityAddressAddressLine2" id="Narr_HR6VHAG1l0OcTc5JFSMXPw"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityAddressCityOrTown" id="Narr_ES65vEodoU2Ej3lAWgZQzw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityAddressStateOrProvince" id="Narr_efiqUbJaGECt5qkidSiI0w"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityAddressPostalZipCode" id="Tc_uxJj6crRsUWQFOgNN83jZQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:CityAreaCode" id="Narr_lYtLLH_-qEmyUGEwFyT4uQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:LocalPhoneNumber" id="Narr_d2Jc3tHjKU6IlyT0itA8IQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_xvW-9YlKmEOthc18hfuQoA_1_0"></a><a id="Tc_qqDVGHyQcUyLqfrW5XyEjQ_1_2"></a><a id="Tc_HCrBb7TKk0CQO9JNGvgclQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:Security12bTitle" id="Tc_eVCSQoV51keguCjV1g9XEg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:TradingSymbol" id="Tc_7iaXWLJ_8UaP-aAISsXhsA_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:SecurityExchangeName" id="Tc_-BGc3460iUG0C_RacFOiZw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityCurrentReportingStatus" id="Narr_P9yMCJEZ2kWm-tfV3G072A"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityInteractiveDataCurrent" id="Narr_VGJjSesSd0y_d3XF7A5i5Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_GOnGkKEutEmPGmfx9vnCSQ_1_0"></a><a id="Tc_QSXzhDzKGkG4xCaFDWiepg_1_1"></a><a id="Tc_9Z3S7XDxgk-au_qQNNqLCw_1_2"></a><a id="Tc_4-A_aI8_3Eua7jFUU-lgnQ_1_3"></a><a id="Tc_EsiXtGBoFEKxH40A6au7Bg_2_1"></a><a id="Tc_XJLjj3ZkakObTzMNam9eRQ_2_2"></a><a id="Tc_S47j31MZDUCN85p_8G2jvw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityFilerCategory" id="Tc_Xugtcr_yfUiPN-pfhMsRxQ_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntitySmallBusiness" id="Tc_MM9HUy8-q0q8i8rzfIKWEA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityEmergingGrowthCompany" id="Tc_9tUdHmlWckSwkbWZDdtIoQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="dei:EntityShellCompany" id="Narr_Be4f_Vj2k0eu5UYG8-1uMg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On August&#160;12, 2022, approximately <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_12_2022_cMVR1Q0aFUWivfZLB1FiBw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr__3hDsLK0pkOiBNR2g82iJg">49,753,409</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9944cb5a_dfb1_4dbb_bd8e_22e46e05caf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of June&#160;30, 2022 and December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Six Months ended June&#160;30, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f275c393_200f_4cab_af06_1e5a9312cf62"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_onNCjpbyY0epqDVuPCjZPQ_1_2"></a><a id="Tc_XAjBQW3BVkWQAXEPtCJilg_1_5"></a><a id="Tc_R-_nWBoIRUG_IGMI77iUHA_3_0"></a><a id="Tc_Avwd7xQnz0-bfYwPN25GYQ_5_0"></a><a id="Tc_-F5L_3myi0uJ1ugFfEjSXw_6_0"></a><a id="Tc_6JQbpBO92UicLGxVCDalmQ_6_2"></a><a id="Tc_j9n-KtdVbkW4gq8siuD35A_6_5"></a><a id="Tc_sW_tUb0-JUyfwb_lfS7hIw_7_0"></a><a id="Tc_UmMXp19Er0uJ6oVicgKwiw_7_6"></a><a id="Tc_goCIkx-CGkCTPw8hwf9fnw_8_0"></a><a id="Tc_5pMsI1dZ50y3Nyo2TjIJcg_9_0"></a><a id="Tc_JzHzaM7nokG9JKqWu2ryzg_10_0"></a><a id="Tc_zdnBDoWPPU6YFUhyPdgM1Q_11_0"></a><a id="Tc_dD4xuJWgm0CXiJdAukHh_A_11_2"></a><a id="Tc_Y7B6nvxS0EClojjK4gibNg_11_5"></a><a id="Tc_leFmTaFERE2UFE1yr40SWw_13_0"></a><a id="Tc_Q6846Zncb0e0QudV6IjhJA_14_0"></a><a id="Tc_KdxSMs_vjkmy_x8IMMCZ1w_14_2"></a><a id="Tc_N3g9v2QkEUGVMYQ15aAQwg_14_5"></a><a id="Tc_S1PVzq7PNkmeisjIuDuyxg_15_0"></a><a id="Tc_WTD1hp8dyU613h7RIi5sRA_16_0"></a><a id="Tc_p4FgYRdWVEeKQhCzBLs5TQ_17_0"></a><a id="Tc_nPAjqzxjTUeW4JdMUQcKjQ_17_2"></a><a id="Tc_uvP1Mpujy0WSuva7N6cq5w_17_5"></a><a id="Tc_yxt02jc4d0SaoCY-nDsgaA_19_0"></a><a id="Tc_QFnb2UZzk02LaELmIxaeXg_21_0"></a><a id="Tc_OktMMLveB0u8QNBU5ZrKVg_22_0"></a><a id="Tc_ytkweZT3GECP6gnT9iD5KQ_23_0"></a><a id="Tc_SqkQAvnev02YGtLrQ1Uh2w_23_2"></a><a id="Tc__I1XQQKf_ECG0is39HutTQ_23_5"></a><a id="Tc_bn1sH9bT_kG58hZicNnMGw_24_0"></a><a id="Tc_FZUkn_gQW0u1uzNCTKwKKg_25_0"></a><a id="Tc_a3A6JirzpU6woVt2Q64NhQ_26_0"></a><a id="Tc_KZ3Scb6I9kS9r9DcWFrYsA_27_0"></a><a id="Tc_Wsg8JTbzA0uk1f88YXZiHA_27_2"></a><a id="Tc_PMaJcpSp_EaF34a6Q4SQ4A_27_5"></a><a id="Tc_957Vc9xftEWgKv8o-8Gh_Q_29_0"></a><a id="Tc_NOlsZzh7U0-k_igTwM6eeA_30_0"></a><a id="Tc_NIksI9SLm0KKOwLnZGKnrQ_30_2"></a><a id="Tc_ImEX6_tXNkmQJSIfgwY0NA_30_5"></a><a id="Tc_WiE9vlLZGEqLQ_jD4G10Mg_31_0"></a><a id="Tc_-PFHtmz3kkOm-damKaTjOw_32_0"></a><a id="Tc_NhJwOHh6skqOpv5cTjcMUw_33_0"></a><a id="Tc_22vRu1cOA0W8Esk0pBJUkA_34_0"></a><a id="Tc_Vrx_4Ydxb0CG8_7agzqMxA_34_2"></a><a id="Tc_G3vM9ZwD_0eM47n2KxnbRw_34_5"></a><a id="Tc_emUwHeISRU2cemoVtrT-tQ_35_0"></a><a id="Tc_6AQNVaiixUCztbquahJ0Aw_35_2"></a><a id="Tc_42WIRvHjb0OeUUUBGorMog_35_5"></a><a id="Tc_EGBs9EcbeECdzNsTzq42xQ_37_0"></a><a id="Tc_TERdOiUOUU2vZu0mXH4ajg_39_0"></a><a id="Tc_Vf5r92FJqkC-6MjNaaMTzA_40_0"></a><a id="Tc_VjrLRyv5kkC_dx3Hr7KlfA_40_2"></a><a id="Tc_lgPpDD8d0U-Obi9v9jRbfA_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_kvFUHpM6X0efbS_8LnG0gA_6_3">12,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Q-aTJLhYGUGwkRaV71ucXA_6_6">38,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_POy7qDimF0eXlrCWUnLOXg_7_3">16,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Ppn6go0Uf0-vYYM5TET1ZQ_8_3">2,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_RlfiBFA86UurYVKY0YHlGA_8_6">3,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_MZFMGrjGFEioG1NQeG7Mtw_9_3">2,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_X-SQguBeh0mUOiTkf7BM4w_9_6">1,285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_aurkYXl3FEKZ9EgaUBPjXQ_10_3">16,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_RsoaWkJpb0SAw2Dey9cAzg_10_6">17,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_hHvvanoHBk-U9nsTaz-BTw_11_3">49,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_QlzAulaBX0qymfsB9Oiocw_11_6">61,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_RGyrlZccQEif9yNzaGNPEg_14_3">1,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_gOfSHjD81U2mU_-COp34Kg_14_6">2,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_MYwLU8KfPki6r5cpvAQ1Mg_15_3">4,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZD_zetMiM0-PaWI-mrbOnw_15_6">4,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_CPYmyKJhgECk-XGsi2dikw_16_3">4,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_9k2sZhxByEGvxrLpWYw3kQ_16_6">4,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_4ej4UMB-6UC_krEKU3nCtA_17_3">60,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_QZE8leLxgk6O3LkMY8VVQg_17_6">73,665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_TMQPpufJUkO7iIoQtmBrOw_23_3">6,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_CIWluQF8Q0qX7KyOsbuipA_23_6">6,986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc__YBGxgvm1EyhQzj8SLZezQ_24_3">12,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_zR4g2erp0ESGx02XVK9Ktg_24_6">16,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_M8fpIZHSVUaaXZgtPQ9Vaw_25_3">1,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_CWuJIIur_Ua45gX3mA9M7Q_25_6">1,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_o7jihE7_Z0WNsbGV2xLs6g_26_3">10,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_2mGigf_2nk2kOc7aHMu_Ow_26_6">8,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_b9zMMR2JVkafeHZHkZh-ng_27_3">30,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_0Q1cImEa_E6xetTcr8CaCg_27_6">33,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_PTh9LrxbGUKDnQiy8VHGcQ_30_3">28,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_jO5sCtVba0uSj5PwB9OZfw_30_6">27,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_CRRf22RYUk2PhFp36ecDOQ_31_3">5,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_RX5FD8AKJUuE7UiD7aZt0Q_31_6">11,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_y0jiQprHBUWBPIbTYVYvhw_32_3">1,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_ul2XhcgsQ0iCA4vOQ-H2iQ_32_6">2,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_hfvwDMVvuUCpg3KqPomgjg_33_3">3,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_7TSopc0Od0WJ-o6M2gzzeA_33_6">4,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_8NifI4pDpE246b-v1g1BFw_34_3">39,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_6Jv2x7hf2kW6Kdvf4qmUqQ_34_6">46,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_16eVPaRo3U-h5lgClzT7ZQ_35_3">70,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_C9LgfhljSEmuAjs1LqYp4g_35_6">79,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1sR_QauZU0Ga5AG8sGM-jA_39_3">9,889</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5lRYPQOw6E2CMImkLpGVGg_39_6">6,036</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_dXqfiJ2gu06LDEBOS-8Fmw_40_3">60,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_PTb99vaZDUe4363WKTfWGw_40_6">73,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8488e67_cd30_41d6_985c_7b2b2667ccf1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_BkodCdGo10OsvXTDH2uIUw_1_2"></a><a id="Tc_s5DM7Z5DF0S2qPJazu5bnQ_1_8"></a><a id="Tc_sNFvwETSg0iUi-h2weKyVQ_2_2"></a><a id="Tc_dqju2wAvokuqg_6wfdA3Fw_2_5"></a><a id="Tc_Pjz1KHSJh0S0IJIPHOlBNQ_2_8"></a><a id="Tc_Rx5c3QEWSkGOmVEMTf_TwA_2_11"></a><a id="Tc_YMc2G22ZFUGDZpAh1gSmVQ_3_0"></a><a id="Tc_etdOzYt8HEma4jHgR-Ft_w_3_2"></a><a id="Tc_9SN8R30C7UOfpN31c8AxNg_3_5"></a><a id="Tc_iwiS6CjjR0GW3FUKl1tFRA_3_8"></a><a id="Tc_kB3w-VMHU0WerUlzbDtjdQ_3_11"></a><a id="Tc_rIXK5bzCI0yDxusoDEddwQ_4_0"></a><a id="Tc_3-TA60ipiEmr-v7cxAxnBg_5_0"></a><a id="Tc_85iNaFvwB06yBrAPqX4ERw_6_0"></a><a id="Tc_531xAuIBe0O41qpZCSD7_g_7_0"></a><a id="Tc_8uTrtNc-ZUymnHQnetzDTQ_8_0"></a><a id="Tc_YO-0HTmp902NPIw_5p9WIQ_9_0"></a><a id="Tc_hJfvfgcxwkaoGOKXURnMKA_10_0"></a><a id="Tc_2cUFhnEY_k22XejrozNcxg_11_0"></a><a id="Tc_VxTjHT3XGESNc5BlvHu8Hg_12_0"></a><a id="Tc_piYUGzxFBUKNm1WERMJduQ_13_0"></a><a id="Tc_eQRg5Z3H0UujHLGfLMynGw_13_3"></a><a id="Tc_tQF0PIglnEG3ib7Soo4kTg_13_9"></a><a id="Tc_TChYYjKnWU2vsc0xWDnUFA_13_12"></a><a id="Tc_zh67tjBYt0i_pCnwY5n7Zg_14_0"></a><a id="Tc_8SQEqEYNZkmllxrExej8nA_14_2"></a><a id="Tc_AZ0TP3KRXEavhUrqVzNXkA_14_5"></a><a id="Tc_wgjqvKJ5HUWgayPn6tiP6A_14_8"></a><a id="Tc_It0eUPftg0yeuAPLnCZUsQ_14_11"></a><a id="Tc_VRXQSK3By02J8Oj5cvw-6g_15_0"></a><a id="Tc_mnoslauNwEWyNaPzMxBX-g_16_0"></a><a id="Tc_ZLOjCmWrMU--RuwHDUDdjA_17_0"></a><a id="Tc_QeMs9FWdPEeWPXvfjooQ3w_18_0"></a><a id="Tc_jZCsExprdEqaKoauRPIHog_18_2"></a><a id="Tc_bGHwnEIXwUePvtXSHjIM4A_18_5"></a><a id="Tc_eb4Vz1Ubm0ycH1RrdLaU1g_18_8"></a><a id="Tc_2am6OWCEgESme8tC8Vf1yg_18_11"></a><a id="Tc_4VadRRRlM0qQdUhTMcki9w_19_0"></a><a id="Tc_UDe4P0LVkUqZIs8WH-y_IQ_19_2"></a><a id="Tc_lAFFc8E5dESBeyQOXhQXXw_19_5"></a><a id="Tc_r4E2RNw22U-oSfVyS_YTHg_19_8"></a><a id="Tc_1_6Dgd3AE02uKKCJdKkdmw_19_11"></a><a id="Tc_MnAAGyLbYEWG4tYRWDnCfA_20_0"></a><a id="Tc_CGMLc578_0qcUZjYPZ54bQ_20_2"></a><a id="Tc_IEkB_s8mckmxoie7TXSa_Q_20_5"></a><a id="Tc_kLxGAB4vm020fspIeem_eQ_20_8"></a><a id="Tc_2qF1NwTtKEy9kAUTlPuq4Q_20_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_SUSlQfKPeUyV40_jBsSpMg_3_3">12,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_boOoddYOrECGY-yvVFdD6w_3_6">7,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GeA4oNa3C0Sd6WqBpTZpwQ_3_9">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_haFeWTbnEEu0kHONdIvQCQ_3_12">3,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ThLqYaRkp0S0XexDbQN_tg_4_3">12,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_f7PmrOAqS02wxUVW-96k1A_4_6">9,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_l0ugRNJCRk2meTJbxXKuTg_4_9">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-dPn5G9fQUGJKBl3KKZ2xQ_4_12">3,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kKP7NvlA_0yXVGhYTP2Aeg_5_3">24,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_RHGTpYcR-U2szHvCB3g9jw_5_6">17,747</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_pIRHyUgWbEOBGhnEPHYXqA_5_9">8,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_x5hj_buL5EW2mrX1tWjBtA_5_12">6,427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_kT01q2rPC06oxUaemMWsbg_6_3">10,121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_vqUcB4UXeES_j_LBvQNLjw_6_6">9,498</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_l90QbEkG4kaEJOnguvFNpg_6_9">4,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_7iDs3mR8VUeuTr2byJbBbA_6_12">4,733</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_825CnEVwuU-5yyNVwXD5ZA_7_3">16,346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_6EOraGnSpka9y4YLOqWBXg_7_6">14,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9">7,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12">7,689</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_e78HqF1JMEa43P-La_R1JQ_8_3">5,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_z8EulXXFtUCiFYYOQm1lTg_8_6">6,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_6Pl25RwX_ki7PiR5JudZYg_8_9">2,611</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_SSBGgak3jUuyZlmDOP1GIg_8_12">3,171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_dRgKqnWhzkWDSluCiiMnsA_9_3">7,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_NNFASd9NyUOmhN4Pj0dnXw_9_6">12,871</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-g-q41u9dEiObzpJhntbfQ_9_9">5,524</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_MyesU8MRHECdg6VG_D4L5A_9_12">9,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_XuDyrBTgM0GSjm_P-LwUGg_10_3">1,242</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_MS1v2UDIL02gbkO1FlI9vA_10_6">4,240</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_MSDORfyHw0u_3h6R2e4BRQ_10_9">623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_XyfsCRQig06u4x9Y36uvYA_10_12">2,203</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_k2If9wihc0OpdTF78Hin-g_11_3">1,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_tlDhmNCTQkGWQIcjiVBmpw_11_6">344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_1fFvYWK2RkqfpqxdwFczhw_11_9">813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_s5szUdhBpkO0EdSdBLA-WA_11_12">128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_FFUcdGeenUCVisLWmhslKg_12_3">226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_f2wiLBMPRkaUPfm5UlGeyA_12_6">3,896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_3QaVWfgWaEqGPKwW3d2cfg_12_9">190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_PSKITsEd2UWnV8CTSTh1NA_12_12">2,075</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_BQ-dzHkJgUiwiRx10Bf1Rw_13_6">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ljNGLrC6y0aiOp7HAywZ8g_14_3">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_LgpVy10NZEKxtZ-oLEH42g_14_6">16,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XcJ9k3jsU06Ye8dCpFSdvg_14_9">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qyppUWEnXk6uXwXjLKKTZA_14_12">11,241</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_K1UiCHy9GUyJUPuJfA-z9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_QjI3tsSOPkyzoUoiGHyTYg_15_3">0.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_jS3Lo46FaUWhBg_0OuV7cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_SQsqDoyTGEqZa5jSa1YMTg_15_6">0.39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tzQu6u9z50KabqolBS2DIQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ZZ4w2ASh-UWolP957O-PNg_15_9">0.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__3sT1TpM4E2IfKH_4VPYoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NfIkjamsQkOT-WfjKls9IA_15_12">0.25</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JDJAf8uZ_Uay_pAWVNhgjQ_17_3">46,589,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3uoiLM-LR0-7vMBwrGD_3Q_17_6">42,744,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4d1M-xVByU-4t8G9bcdYUA_17_9">47,327,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wlIBNFuaWESgkPFPjlJwHw_17_12">45,436,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_WIAQENglMkea-ygnycr5WA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iJPJ9ulWs0Svu3ro3Cip3Q_18_3">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_QyKQxoFpHUmwj--qWhm7zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ceZ9506VCEqGYIBBo9ZIYA_18_6">152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BJKqbOOO00SJxddM8A_efA_18_9">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Fm5H8d3qkaSZ7TvQIrSFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YotCW43CckiSh-Ybs5anyw_18_12">43</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EZfCnohvr0y2B-Q9rWZ-Mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GqYHBKwSAUWUAGXIICn5pg_19_3">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_DJJNM8qnaEKUcJ3HHuAssg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_W_8s2ojXU0qz7tDq4oI03A_19_6">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b7YYEGq7sUq5RS6c9gLCog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tX5qgQzqQEqr0WkolV7oRg_19_9">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TvQ-GPYn2EGcujvnvNwsGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XbXpZ2ZuJkCTcnUbMhOxIQ_19_12">160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_EibuCP6l4kKN_Q30vrA0hw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rc49tdbP_k2zWOycuHk8yQ_20_3">941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2OW2E9fYbUuNi7TvwRPypA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__1ehhqzJwEOVuftssvx6Bw_20_6">872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Bmg1y9mhxUahVCDnBjO6ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GAIvXq0FzESK5ASo_niG8Q_20_9">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_G8oXr3UKV0i09CNvcOUZpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_y_vKUo7hX0mjmoiI0doiUQ_20_12">375</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89eec5e_357a_4111_86ce_812eb43d3102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_I2FZSoUN8kSo49OUDEsUPg_1_7"></a><a id="Tc_cUo9cCYGhkeYLU-XUOCwWQ_2_2"></a><a id="Tc_fNp0drSVeEil-30ILe6SyA_2_4"></a><a id="Tc_DYnU4rPwS0GQpZpTF3zy2g_2_7"></a><a id="Tc_ZrgZB-p7t06Gzg4fz4EImw_2_10"></a><a id="Tc_qIZ__QeFzEGMmUDjp-HFBg_3_2"></a><a id="Tc_h5CjV_i67U-N5qcBjDFJHQ_3_4"></a><a id="Tc_RdtHkyG5Qka9G2tEWjSt9w_3_7"></a><a id="Tc_vkSyQ4wr-kCYbsO5VoGEDg_3_10"></a><a id="Tc_VYCmfs0sxUytorPkSBaKvg_3_13"></a><a id="Tc_0IihTdBhI0e-hvaNrjwxPQ_4_2"></a><a id="Tc_x0mmCDI2jk28W_fAvegd6A_5_2"></a><a id="Tc_w5pm_nPP2Ein3LjSFR67cA_5_4"></a><a id="Tc_HNByZj6Q3UKzS6Fz7KZgDQ_6_0"></a><a id="Tc_ut62JNkgS0-cPY1YvD3mCA_6_4"></a><a id="Tc_IezF6jZIcEOIoPPCPRYdYw_6_7"></a><a id="Tc_qk9oLPvT8EqLzuyobC6GCw_6_10"></a><a id="Tc_ySjpfbStg0OPKEDszbMc8A_6_13"></a><a id="Tc_bfWmJOYf_kKwW0CukmfDHw_7_0"></a><a id="Tc_T1a1_dCIqEWaJF8Zt1UEdA_8_0"></a><a id="Tc_TZewckjl5UOxvZXS10LNxA_9_0"></a><a id="Tc_50pLpUNeOUete4jgVQDZWg_10_0"></a><a id="Tc_NQ2Af-SNOUeUk6lBPtMX8Q_11_0"></a><a id="Tc_8zCwyC8GVES1mtX09zZC2w_12_0"></a><a id="Tc_2pVLIHiTa02RC1esMIcKjQ_12_5"></a><a id="Tc_XAKZpGSNLUej8NfVMfOlvA_12_14"></a><a id="Tc_d94gALCVD0uL866yiysVcA_13_0"></a><a id="Tc_O4cS9YsoAUCy0KZx5RPlhw_14_0"></a><a id="Tc_cx9Rg6WWU0W5j1MLPLY3Ig_14_4"></a><a id="Tc_9a4QOEpKzkCckULAmRyTkQ_14_7"></a><a id="Tc_yha3mpXcbEuWPVHIRPvp6Q_14_10"></a><a id="Tc_hRl2srNS-Ei8YwZbE0DMkA_14_13"></a><a id="Tc_s1WjhmEMBEa2mXduE5c2Pg_15_0"></a><a id="Tc_vxO2xQMLkkGpjhUkYXvBzw_15_4"></a><a id="Tc_GMNfauwzi0SjnSk71-UNNw_15_7"></a><a id="Tc_Nz4TJUwklkKqQuR87oHc3Q_15_10"></a><a id="Tc_mMxCQCO-vEi14z_BL8iWJQ_15_13"></a><a id="Tc_cl4OXvQvK0-JoQ1oUdp0GA_16_0"></a><a id="Tc_geexT7xTbUmRY-ATC1uEQQ_17_0"></a><a id="Tc_AN80FyNL0kStlQr3QlF4nQ_18_0"></a><a id="Tc_QJLosw6NI0SE9UyhfwB7CA_19_0"></a><a id="Tc_IZ9c5aPIhEygX_asSVDyug_19_5"></a><a id="Tc_711XTGtW8kCxHpsZzEIREA_20_0"></a><a id="Tc_7twRGBsYGUSJ4b2nHR3UwA_20_5"></a><a id="Tc_lDWzuHysHkGT2-fws_XzKA_21_0"></a><a id="Tc_SwVz3Cm_ik2F0bJHQWe4Ig_22_0"></a><a id="Tc_JYIlj1Tzd0an7sj-H_DLDA_22_4"></a><a id="Tc_h6_w6j3OTk6UylhYjjPRiA_22_7"></a><a id="Tc_9LG7_8I8i0mmnAgCmm4IFw_22_10"></a><a id="Tc_Cf9YZGaDkkyg6l8fu0UJDQ_22_13"></a><a id="Tc_3mp9sBVGBkeCWvwz-UEqFA_23_0"></a><a id="Tc_ICVK6JiLUE-R-0b4jW4YpQ_23_4"></a><a id="Tc_zaSklsfY1EWfUgYKKePUYg_23_7"></a><a id="Tc_4ojIvBtvlkiFMUoHed59fA_23_10"></a><a id="Tc_02-HsANI3EGOADMLR_eOng_23_13"></a><a id="Tc_p25ClS4F2EOtIgv6BquMWw_24_0"></a><a id="Tc_FWpbLt4jwUWFeUMaT_65LA_25_0"></a><a id="Tc_da5Tv7Z9g0W_9u91p-Pi0A_26_0"></a><a id="Tc_ke30d1JfrECtICwCcO_mbQ_27_0"></a><a id="Tc_fKiqmmvOzkikDy9uMbe3oA_27_5"></a><a id="Tc_NdQwqwfmpUi3vl5mJLVfBQ_27_14"></a><a id="Tc_EDAeSqhtaUawbgPNcYO9Ww_28_0"></a><a id="Tc_7o51sz5On0-Z64rB1hIXOQ_29_0"></a><a id="Tc_lffSPI7lhkuuth46e9KeWw_29_4"></a><a id="Tc_86JOw0Csd0ivEpi8vv2nlw_29_7"></a><a id="Tc_1sn7YePxD0-JqcOQJR7yEQ_29_10"></a><a id="Tc_TsjYff9qskq8YUtKxnk2Rg_29_13"></a><a id="Tc_4CFLtnZQR0ez2gYfnKpBHA_30_0"></a><a id="Tc_lsMb19yoRU-my5_wjvAj6A_30_4"></a><a id="Tc_mgt7Q43KTEyyHQjYtn1p9g_30_7"></a><a id="Tc_XUIYj8BSCUifuZJJBIa0sg_30_10"></a><a id="Tc_jOW4Yh7asEGxKJc_3vDePA_30_13"></a><a id="Tc_L5-X0i-hpU6in7hRaGIprg_31_0"></a><a id="Tc_4NGCDTA4oE2RJmYLav5icQ_32_0"></a><a id="Tc_0_6EhVj50kCe3uo8aGLo6g_33_0"></a><a id="Tc_TOas62MBmEar57NfTXP0aw_34_0"></a><a id="Tc_HOYib23tdEiJhK2BGYXmRA_35_0"></a><a id="Tc_IOra2NWLxUOgwvJ0cj5qlQ_35_5"></a><a id="Tc_MXK9DqjIe0STOC_sO6MQ6Q_36_0"></a><a id="Tc_KrUlGSv6-0WIQJFSyB_UUg_37_0"></a><a id="Tc_SryFis_CGUGukNdg8OOicQ_37_4"></a><a id="Tc_iesu20zdkUGiHXpwnRUGYQ_37_7"></a><a id="Tc_fPs8TGzB_0GLJXh55yoB5g_37_10"></a><a id="Tc_kQk7B8ccck6bSL6I_7zt4g_37_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_deucjwu8MU2X0nDSTJw4Mg_6_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8GqTrJdmj02YByS92zQKvA_6_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C0_vygBSwUKW1_g7vDXPDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qIXjEyPDn06fmm7jHN63uw_6_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q3iT6tByHUqOnNA_O2SM8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EKGjUjDlX0Oo4sShUFTfCg_6_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nWlTK8PFCE23Kll0x9sHUg_6_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_TcCS3W8KE06wqIphZkr7QA_8_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_cErdvYpp_0SH-kONDPe6Wg_8_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_eHBjeuWrVUum59RtqClN7Q_8_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Xu0B8af-ek6zpdxUrDz8Tw_8_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_3dGfUZW4gUaV_7r61l0EcA_9_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_e8-NBcjkhk-lYv3Vb2by7w_9_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_HzUt86alUUCXo7INEWB5wA_9_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_j1UruiRTj0GHD3NcO6jo5Q_10_8">832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_t-EkJ8dav0WfpYS8sJFouQ_10_14">832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_5dvcmVTyh0mRJ5VpE1nssg_11_8">562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_PyauEcHBC0Cf9abHEmWOgw_11_14">562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_La_v2P8SgUu8a-sZ8uaD5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YSsIzshzAEqMwZ4_X6lsIg_13_11">16,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Dg1XLi0o7k2mw16W0JTv7w_13_14">16,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WHZRU1HR00qNCR9SiWvxow_14_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_O4d_ZSXgi0eQHYfE-zNC0A_14_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6H-XOzfgD0a4XkjivfXQBA_14_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_M0QKXqW8n0-zwO5J3y1VaA_14_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_O-IUVmQ-_0Oa0VPqrWJV9A_14_14">3,841</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_AUdvBExCfUSmxApu5-3tOQ_15_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hoYJo8twlkSn8-vWiDj32w_15_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6DLzF6gPCkKUOnMGptPp4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jqpVure3DkaazLClZ046rg_15_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qVPpbQRPfk2TReO-LtDjaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_plfcTydHikWpDDrKvDmPaw_15_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Li6KIjJ_bUagnao4oVaatw_15_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_TxlQgi6e1UilQwKit50P2Q_17_2">2,395,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_dPNPYaYGQEye9C3TyT0x6g_17_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_9KZB-5Zx00W97Izk6o1Ycw_17_8">2,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_S_TJOIFMN0uigpm3YIDM3Q_17_14">2,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_y2i-DEf8vUKYxC0hCBR9Aw_18_8">293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UYe8pB4WiUO91VbRW83kYw_18_14">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_LhNrwbhZVU6G0iKHHuWKpA_19_8">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_EF68SGL5T0q_JZHgULuNLA_19_14">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_cpiW-DvhPkG3E-C85f7Hjg_20_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_m7D7_aNc80OV8tJKtuXrUg_20_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_y6DZaQueokGuDyxDFuaa_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JI034VPflUSSS12ucXqBnA_21_11">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FpU2MYTwSkGve5MDnlfQKA_21_14">7,620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Nf7gcdyI70W0M045OQKLDQ_22_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8AdmiiS4X0CXA98NEH02Xg_22_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EdxLWPPljEmRxchGZi0aiQ_22_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JJrfjquDtEqR2r6EvRfwgg_22_14">9,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_34L_v0wCxEuRaiizzFnAWA_23_2">45,382,831</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RhZ2_KxZjEmO_lOETmBYhQ_23_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xlM86qUkt0KOAmnTSOyfwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Nkva8J1cs0yygrOYUuZIGQ_23_8">367,285</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bgf7v6oL7UGhXhJ5Qvr8SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jtPBn9OEnUO38IgR88xO9A_23_11">352,827</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2021_BpzceNB_akmwpVhtRG9COQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5tR_CvgXz0Wja7lL8LNhhA_23_14">14,504</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0LyJ6njy9ki91gTeKSZmUg_25_8">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc__5Ky9RzMBUOHm8e82MQlcQ_25_14">322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_OMxXvYVIZEmZiLVNi0aXtA_26_8">256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_h984psDS50qGArFws-H4bA_26_14">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bO8o39pQaEml34krQBBNIg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_yQlY42Huak6lD4nU7LzyUA_27_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zC0lIICAa0SqzS0gFlR7dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qOeoFZeBYkKECxmpLGvSNw_28_11">11,241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Oav2mJqns0u5zwSGAS3Z_w_28_14">11,241</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MjKT05CwDkW6P3tHv3OVIA_29_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nUQIwpeJUk-38Ba_AImgZw_29_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-Rkz47t7ik6eZti93_IijQ_29_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tdwq3wcykEWdd4MVgCj-Zg_29_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aPcJd15j2USf-af8PYv1sA_29_14">3,841</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2">46,316,129</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GbUgAqQt_kyD7nCbYnpHig_30_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4nVZjnZPfESVPBgjGtf3hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ddnoSI3xtUurDOePbDiN1g_30_8">369,688</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ytcHJNRtMkC-kFhR6Y_Q9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Lc2sG0tc_kqASxPYnq1hZg_30_11">377,220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_3_31_2022_Z-8iEsWphUCbjtsaDKdovA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ucd_zd_o8U-Xz_n5QrXl9w_30_14">7,486</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_3vv-v5_G20itN1papb-TNQ_32_2">2,395,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_BtWHgUr7YEOrohMU6RvYFg_32_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_n7-FUVWFV0igcFhelf4gXw_32_8">2,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_PSp7e55R2UO6a3hHEtitBw_32_14">2,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ePvwZgTAAUiN0D6XcTfPBA_33_8">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FTXjXIGJOUmuIa5aBHdG8A_33_14">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_L3LPka23HUmnmdeqYHCdoQ_34_8">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_xzGZXGfdaEWe1xR6f2RKAQ_34_14">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_GBV05_V7V0udz8OxRZmetA_35_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_C3rOvNMwG0-UdVMwwFy6DQ_35_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_sjcMvytRX0yoXKR6kHuecA_35_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VaxdqtuNcEisKZVLZWPKvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rgswRpXpu0-CS9dlvaYQQg_36_11">5,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Wa6ZgqUyeUeCx5EpIXaibw_36_14">5,334</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_hTEWKEnK5k21aSTetjwslQ_37_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QOPoNcShs0KwVUOOB2sKJw_37_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_02NPHwWvm0S9-XwwNkB8BQ_37_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_klJXROjkCUu0uaSQ7BVyNg_37_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_21hBHjTCF06CUUVZmaLuhA_37_14">9,889</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Represents an amount equal to less than $1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_xirKAx8TiEm-jw1vIIf2MA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZS22zFIBkEiDsGVSEMg_-A">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of June&#160;30, 2022 and 2021 - <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_oFzX5PDpU02Xl1udyj9rBA"><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lL0Fkq-md0GU7sk-GuExyQ">120,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1969ae3b_b04b_4ede_8d7d_86a45b16dd76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_WZFHPE6CbEOa6_DEosqQJg_1_2"></a><a id="Tc_LhXVYtpDzUmz3_ho69MukA_2_2"></a><a id="Tc_O3EqtMQ51kSZsMQaqF14Kg_2_5"></a><a id="Tc_iqMt1t-EMk-i0lsqAmB8nA_3_0"></a><a id="Tc_2uJrUqGQAEWmhSVDYsal2g_4_0"></a><a id="Tc_-O2Y3C0b30aovMK5c-gXUw_4_2"></a><a id="Tc_mQiBw8Hork2jbpzmfXarUA_4_5"></a><a id="Tc_BrhuwHdjkkCyWBzWRdGgcQ_5_0"></a><a id="Tc_qxuYKz2bxk2rKB_A_Y-syg_6_0"></a><a id="Tc_xAakr9aYpkmy8WeFGoIFAQ_7_0"></a><a id="Tc_Z-h2a3J4eU26VGxZx79wDg_8_0"></a><a id="Tc_X81xURvVVky2WMVbMLkthA_9_0"></a><a id="Tc_HkRmHLeTDEiY-4Y_FRDKbQ_10_0"></a><a id="Tc_9R782gNqLkuISGABscpuZw_11_0"></a><a id="Tc_GFuqD0Z4bUWTg8FKvxLAUA_11_3"></a><a id="Tc_d_84U-gmtkKP0OcJwhRk1A_12_0"></a><a id="Tc_5sjU8jq41E28ZMgpQvOkzw_13_0"></a><a id="Tc_08eGOLG1x0-bu552iEok7w_14_0"></a><a id="Tc_0oTCX915TU-gLGTe7VlJCQ_15_0"></a><a id="Tc_sPVhe9mJ8kiHlce2oqe24Q_16_0"></a><a id="Tc_tVIPgptgE0u4hDAs855JnQ_17_0"></a><a id="Tc_lWvtT__tJUCGa57MnZDJqA_18_0"></a><a id="Tc_Kf0jQit2kEChl1LRR1HN5g_19_0"></a><a id="Tc_SsbPaEBC1kOgscs1nPRBdQ_19_3"></a><a id="Tc_EYdoh2o0LEaW--jdUowK6g_20_0"></a><a id="Tc_xCVUNj2RS0udWFNgQEelew_20_2"></a><a id="Tc_S_1UstyY8kKm5jUezP9AYg_20_5"></a><a id="Tc_zjVwz8tSeUWCdqYkXz8HKg_22_0"></a><a id="Tc_q_Ujsud5WUysupQ26Ar72g_23_0"></a><a id="Tc_VfFGoD7_6UqKjXt7dTtxHQ_23_2"></a><a id="Tc_K48Gz5eo9ECmWzqS3TB7gw_23_5"></a><a id="Tc_0dSy6fRvMkyr6OW7369DQg_24_0"></a><a id="Tc_T1eNuLNmtUOdncK74M9eWw_24_3"></a><a id="Tc_4g_8c62K3E-zV-BjBIQvdQ_25_0"></a><a id="Tc_w-dF6zRWLUeHIBPHk9iqiw_26_0"></a><a id="Tc_exihtf2oTkCyo0H2CwBF0g_26_3"></a><a id="Tc_kwMz9lnFxkmvp-T_UyXfWg_27_0"></a><a id="Tc_a2F9xeSrb0mjRceyjXRO_Q_27_3"></a><a id="Tc_qpNv727zaEOIj3-NaU8tVg_28_0"></a><a id="Tc_r8hrw6iYJESyVGt3huY5VA_29_0"></a><a id="Tc_vanWvZuTjkKS2ytIrLQ1Zw_29_2"></a><a id="Tc_j5Mu3oM67km507-LSvpr3A_29_5"></a><a id="Tc_22McPR6u4USXO4AnaQZZjw_31_0"></a><a id="Tc_gFFg0km3y0ONpLab10jntg_32_0"></a><a id="Tc_PiSLc5mccEO42CShoVhLVQ_32_3"></a><a id="Tc_aui4b8a1IkmDvZOLjJQ87g_32_5"></a><a id="Tc_6hk2RcW6jk-RTWt4BYDDXw_33_0"></a><a id="Tc_5GbXoQA-PU-YpZe8Jy5kkQ_33_3"></a><a id="Tc_iMhhpWAWOEO9t-gY6ODZjw_34_0"></a><a id="Tc_vySbAaq4jkOpS3cC1SsDlg_34_2"></a><a id="Tc_lVksTR0A7UuNytOaEc0YxQ_35_0"></a><a id="Tc_GB0YExuow0qKT1WWcOnenw_35_6"></a><a id="Tc_TBJlRrTEa0KEy7t9BD6J2w_36_0"></a><a id="Tc_4fa8ulJHDEOhSJNzEEvmIw_36_2"></a><a id="Tc_RfoXDkONREecR-1pz46CEA_36_5"></a><a id="Tc_Djs9l6MmyUukjQ-c9w3gug_37_0"></a><a id="Tc_f2q28ogOpkOWkzZ95jWa2Q_37_2"></a><a id="Tc_XD4o2qYkq0imWDDLSck2wA_37_5"></a><a id="Tc_JI4rkFiySkmLRGGOnDpMwA_38_0"></a><a id="Tc_Xv-Vs9nP6UasC2XDPA0-HA_39_0"></a><a id="Tc_amO8_RGVyE2HgouLWPYxfQ_40_0"></a><a id="Tc_mGqXrElhAUio6D3Ztfl-2Q_40_2"></a><a id="Tc_M7Q2YWj3OUuxXDxIFNH7Gw_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_5r7490orxU6IVSbg4qEF8g_4_3">7,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_y7-ycFlkkUCzjaRg2d_B7g_4_6">16,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_OmWhaqV0Y0iQVoFU-Iebag_6_3">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_TGvQLofvVU2Na13upFLeAQ_6_6">1,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_ZEaP20XvSUeEQmPMJHgzhQ_7_3">538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_lyIHJwOxV0ez61Y-aqakaw_7_6">574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_7oj04OHUe0yYlRj0Tq0yNQ_8_3">952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_LSHw2Z_nnkmj57rBBoctrA_8_6">121</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_B_CATt_iyU6VI43R81XTfA_9_3">449</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_JnvW9VROuEyOjZdqgxd12g_9_6">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_YivofNGL10K9VQppeHBktg_10_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_UcDBA2x8vUCxOLSd9aTUiA_10_6">56</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_4zYTHnAMi02piP2uV8eSQA_11_6">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_JYfFqWdZmUaedmKfA7EVTw_12_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_a9YxXX2MgUKyvFqdCmEjig_12_6">1,928</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_yYZwqiUrc0amo-T8ScG08w_14_3">2,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_B2-L9zUdoEeGi8hrvUNjRw_14_6">12,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_K_0Hao4bOE26htZOFqC4-w_15_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_iQy3g3it9kuiHXVO319U7w_15_6">1,587</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_zTWih1hYAEiyk5OK8Ay0RQ_16_3">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_iiSYiVA_OUCR_Psc9ITYqg_16_6">94</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_EsGvNX1bv0qAG4QOvf2VPw_17_3">1,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_N44_DJaCBkqbfXwks0FVGQ_17_6">558</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_-NFJ9Dn_jEOcL88s7f0RCQ_18_3">4,864</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_68gZPs3Zk02NqxcREtdGPg_18_6">544</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_4rIuzqCbLkmgNdK7x9QlMg_19_6">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_XkJKKHBO0kanAXToVfOH3A_20_3">13,185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_25E4_nt9-0OyxNgcssTtRQ_20_6">3,318</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_0n-3ZBAxdUObbOEUm4Njjw_23_3">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_pjUa428LI02k4QNbysm33Q_23_6">37,835</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_5VJLGGJHiEWNxKYq4A8voQ_24_6">15,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_XTzoudM7akizrtzYSYrltw_25_3">357</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_oAxRWQbLeEuaO-yor3qsNg_25_6">667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_WVmIOHUdZEuVTbSxvfBPCw_26_6">53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_nc8ef4XY5kG83Icl-q7v2Q_27_6">359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts paid (funded) in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_PwT5lQft00GB1B2iyA4oGw_28_3">457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_PhD3JZMEHEesIScvnFySqQ_28_6">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_3kr13bwqHEaZy0DFEr_uMQ_29_3">15,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_qm8yopad-0G2CIC3zGmVng_29_6">23,144</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_guga0WSHCU2bFnx0U6D--Q_32_6">4,086</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_lsJYEZSvTE6qUDxYLZVTnQ_33_6">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ZnmWmMKwy0CHogVpRUcniA_34_3">2,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_sV75h77aWU2scwFl2dPxiA_34_6">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_TVSY2Y71c0K8a1GTgRaP_w_35_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_29sroHXQhEimJzXG7WsqBA_36_3">2,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_8xVbeG3VZUWkGqaUsmAGHw_36_6">42,114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_yXGAeiMWfEqpNCLnoJpqAQ_37_3">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_lIBAPuPgV0agpMug-gZlOw_37_6">35</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_H6PCHwOBYE-HOPmMP5Hi8g_38_3">26,493</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_rIJQgwvdSkabCO1iRYlIgw_38_6">15,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_7GybjLFuBUexBR74h6_m3w_39_3">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZqwoRRR9106l-giHopSeMg_39_6">18,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_D8GNWmDGAECRc9-s21infw_40_3">12,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Cp7BtwaRy02GOIMUhoLGhQ_40_6">33,882</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_XZBiaWCc6k6mR7mdHKQQNg_1_2"></a><a id="Tc_09Rzv6kZAkmWw9tD4JH0CA_2_2"></a><a id="Tc_FdwEhXLqQkGX0VwMrT4leA_2_5"></a><a id="Tc_pLndOsv2TEm3pocEibOIuw_3_0"></a><a id="Tc_Ek6omqj8CEyCx_uscQjbuQ_4_0"></a><a id="Tc_YDbGl-kGB0690dWiSahabg_4_2"></a><a id="Tc_zdoqdq28k0KE2zncvmwtgw_4_5"></a><a id="Tc_2jKX1PVGv0iMQlmeNFkdfg_5_0"></a><a id="Tc_cGwYtTWuQEyfojDhj-ra6Q_5_2"></a><a id="Tc_c2UAgsjPFke1sRif8SC9DQ_5_5"></a><a id="Tc_joozOWEEZU2c9SoRUTA8WQ_7_0"></a><a id="Tc_xqRoC0xjmUibtJG0dGEmCQ_8_0"></a><a id="Tc_68z7PcvY-k6RWOS2GWDtug_8_2"></a><a id="Tc_RpF5-OWv_0OO-hbzs6RFCg_8_5"></a><a id="Tc_Z-ffgVsJ5EKSiD0LorAZcg_9_0"></a><a id="Tc_AklIgwln4kWD43lbdPgwhA_9_2"></a><a id="Tc_xwMd9Ir5Kky2seFUTYHi8w_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_yAsc-6uW50KbHtO9rC1xLA_4_3">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_Xeeujn3dV02Cdr-vuNTeig_4_6">372</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_G6uFsWpvbEe779ilhjycRQ_5_3">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_IdpvyyxpdEOu_g6s5JKlFQ_5_6">232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_k84ZgViP60u4RfPQOJNCFQ_8_3">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_RinCMcp4Ek-aETFyYaaDfQ_8_6">2,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_emYTKI_dHU6W-NneIWPoBw_9_3">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_mRGsOf8yjEef5GUAudeE6A_9_6">307</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_yEgAuHaSzUCb5fnmhwypTg" continuedAt="Tb_yEgAuHaSzUCb5fnmhwypTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_LzbvI_8D-0KBh5Eg4eY0yg" continuedAt="Tb_LzbvI_8D-0KBh5Eg4eY0yg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yEgAuHaSzUCb5fnmhwypTg_cont1" continuedAt="Tb_yEgAuHaSzUCb5fnmhwypTg_cont2"><ix:continuation id="Tb_LzbvI_8D-0KBh5Eg4eY0yg_cont1" continuedAt="Tb_LzbvI_8D-0KBh5Eg4eY0yg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_aOpGJG-q1k2lYifBL5VXKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7G_BpTNvNEeanj9wh7znjQ">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_opvL3KvbiUiiovcEqeHY3Q">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_2gM5KpkXIUCahXcYZctUAg">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_in-C_eGnvU2GOXyF7sSNdA">13.8</ix:nonFraction>&#160;million. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_8fJEcV0nCke4OMdxDI5Wmg" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_1xTUZAu0802sCl-ph7K5Hw">17.2</ix:nonFraction>&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_D0U9HQw9R0WDe2pBZk3w3w" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_MtU3GYKvzkK5EMP5OFWe2A"><ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zqsmNVni_02194Rs9tUq7w" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_opVePBSWkkKRkdaTgsfx7Q">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_6fTapv-KNUq9cilP4Oy8CA">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_1M6OHOeGKUyh0MspghqPOA">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_bfOI2ZAt4UKKc7bfvUUHMQ">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_r2i-FKkvhEy4041CLWITlA">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_HSn_7O-8SkKHR83bb7Ieeg">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_lCDgWnIVF0ipPsFxXTXzgw">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_zXSdyWR7tUO8R8iIafuytA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_JX1tlZEfLUywDtY4YQerMg">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_QeVKh51xs0SPEU0GH8uOSQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_WTGj81pqBk2_4BsiB92B-w">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IkS-U_42B0qptgPPLXKu_A" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_G0wqK5830Ei7V-9pI96bFw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nhGp8vR41EuQp88YBLlW4w" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_fBbDCxgCZEq5zTfbFp1nDQ">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yEgAuHaSzUCb5fnmhwypTg_cont2" continuedAt="Tb_yEgAuHaSzUCb5fnmhwypTg_cont3"><ix:continuation id="Tb_LzbvI_8D-0KBh5Eg4eY0yg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_BKeU6ZzYJkq_9CWsGYOCHQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_FgUq7XfrnkKFgpJPQdrYdQ">10.0</ix:nonFraction>&#160;million payment to the Company in the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d-nB_IK66k--GPVQiT88QA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr__zTx4_JEuEubifg7M9BLpA">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_3QlMfOhpR0u7fHcnwWrz2Q" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_mC2z5XuPjEKm17o1RFPBsg">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_mv2ElYzMFU6LmVGX0LoE5Q">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_v0Vz9-2oOkSEI6oO3e9P-w">7.5</ix:nonFraction></span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_k_r-wDp0aE-poMuYjpm2pw" continuedAt="Tb_k_r-wDp0aE-poMuYjpm2pw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yEgAuHaSzUCb5fnmhwypTg_cont3" continuedAt="Tb_yEgAuHaSzUCb5fnmhwypTg_cont4"><ix:continuation id="Tb_k_r-wDp0aE-poMuYjpm2pw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_yZVEwyBl-kKUvTGcHaOMMw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_j0eZe7fUFkOLH-fkHLHa_A">32,960,732</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_RiNOSB4hxUisypQ4AjgNAQ">32,982,043</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2022, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_dBMMh_BMYki0yZwZKah35g">25,874,641</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_YtkqT1myXEquSZLXbaii0g">26,322,164</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_a6G7dpI_8EC54jA0HEsMsA"><ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Vl_mnu4BNEqv14pgOXiWvw">7.50</ix:nonFraction></ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_JJn9iO9-d0eG48SGV4812g" continuedAt="Tb_JJn9iO9-d0eG48SGV4812g_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_BJyuho_M3E-RzZ63hj9Iag" contextRef="As_Of_6_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_VnH5FcNSOEqo6IyPz5y2QA" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_CohABiEfL0mdsyhguGuQEw">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yEgAuHaSzUCb5fnmhwypTg_cont4"><ix:continuation id="Tb_JJn9iO9-d0eG48SGV4812g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_mbUSxoWsyEyVL6vAUOLiKw_1_2"></a><a id="Tc_rHV5UrMuqUq9DvJWDU-3ig_1_5"></a><a id="Tc_By1cwCjpA06HtDAtZD_13Q_2_0"></a><a id="Tc_m7Y1BBpfOE-DmxqyVv5XYg_2_2"></a><a id="Tc_khSIuQk_eEK1ekca9kw1kw_2_5"></a><a id="Tc_1ltUL-31f0utlU4jFiW-dA_3_0"></a><a id="Tc_dgxiJRjC40yaY3QAhzO6xg_3_2"></a><a id="Tc_aDsYChUzW0-DPp1KHMWiOg_3_5"></a><a id="Tc_x3MhGjQJj0y4VW-l-T0vLQ_4_0"></a><a id="Tc_IbJSsNoXqU6rZ1Bd5l3Ozg_5_0"></a><a id="Tc_-eERLiyKF0e01wVorWh9gQ_6_0"></a><a id="Tc_b2zWfN_znE-vLCgfVGH8Gg_6_2"></a><a id="Tc_zbtIftPqOUa9ynKiLaBWqA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_dke8JGEG2Eu4oAsZeGe1gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_yh21nZUbKkOEwM02CNohQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_2aXimOxF602cwLIxvTP8Yw_3_3">3,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_QAOA0dELq0yNwC8GjxqQfw_3_6">3,166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_FIvTom1EmkilUMqLck5_Dg_4_3">3,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_gvNlwsGlNkaTI_MVuhcWLg_4_6">3,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_FjRKR6pVlEqTUS8cceJEjg_5_3">9,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_7-TuwZRfYE6z-wzIogJrFw_5_6">11,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_e9NLFwEW3EyGN3mEz5OmWw_6_3">16,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_-PjobJA0iUqBI-Yle99eWg_6_6">17,954</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_i2SI9vt2kEeznNIJtG1zFA" continuedAt="Tb_i2SI9vt2kEeznNIJtG1zFA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of June&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_dFiF4P0aFkm_OU9H0ktIRA_1_5"></a><a id="Tc_60UaAx6_mk6nw1CfWe_7vw_2_0"></a><a id="Tc_qlkqY0WaWkeF_YS_RzfH0Q_3_0"></a><a id="Tc_9Syb-y0op0KzpdzifT8fPQ_4_0"></a><a id="Tc_Y96KlJHYXkiDrpE_6cKxTg_4_6"></a><a id="Tc_ZtDPjDzh6kqeKIKPUIMlFg_5_0"></a><a id="Tc_6FSZ0D5yMUyK_5NHsjEHlg_5_6"></a><a id="Tc_D2LTbjW9Eki8byxMjCMRFA_6_0"></a><a id="Tc_tkU8odQ4GUuaXT3jc60Bpw_6_6"></a><ix:continuation id="Tb_i2SI9vt2kEeznNIJtG1zFA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of June&#160;30, 2022, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_KCkiLF8mZUencwhfy0soJg">28.75</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_NfZUc-tdu02rvxOMaMHAUw">32.3</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_dUo-EveflkGMD8C_OG0aJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_lQSJbf8j3UWq4t_txkOkvA_2_5">1.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_8VPFZCaFnEGUa7jmFn4qhA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c2uW99rnTUyPMniVyn2M0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_pYNbEik1pkSly1PlTOP7TQ_3_5">2.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MYQxmrO7BkKHz_LbP4Z5QQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_p_3OMdge70ucy-vmNpquwQ_4_5">2.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGjbifYeakiP_pumhgy_NQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_jtmECkhI8Uiqm4rMCP5H2w_5_5">75.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_KiMXzKBurE62LVrcGB85cA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_aKKRXTFf00SeLsTm_EpcSQ_6_5">13.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_PTO6SwBmUUy-SFzXoWar2A_1_2"></a><a id="Tc_o1YozHacxke77aCnl0r4XQ_1_8"></a><a id="Tc_RoPedY1HY0SQU4E26wXIAQ_2_0"></a><a id="Tc_0YDryB25x0WEj59LkgsXwA_2_2"></a><a id="Tc_Xvz1fIkKrk-q3yIApXlP1g_2_5"></a><a id="Tc_cjFkIzAgIEaG5pKzIZLwBA_2_8"></a><a id="Tc_YCNB7D9EMEWtPjdIaTyMow_2_11"></a><a id="Tc_dXJSMsFYZEePP24joVs6Zw_3_0"></a><a id="Tc_15srxO1yN0unQ2spaJj__Q_3_2"></a><a id="Tc_ZwtmQdciIkiK6GLmz3E65w_3_5"></a><a id="Tc_an6G6UPIq0Waw8s5n3fL5g_3_8"></a><a id="Tc_KF8H1CTiQkmHZkRZIBnevw_3_11"></a><a id="Tc_jfG0oD9-B061GBAroCP5sw_4_0"></a><a id="Tc_wJamTNuthk6-D78hvQuZ9Q_4_2"></a><a id="Tc_1L-v8Sl3AkWnccWtoDgi4g_4_3"></a><a id="Tc_nl_Gb0JvmkOJcMcYvidbpw_4_5"></a><a id="Tc_sajZ1F2gBEW2mmXCTw7Zxg_4_8"></a><a id="Tc_y7pZ2j1tiEmMvWQWBLBX9Q_4_11"></a><a id="Tc_F7duCcnv6EyvuVOsn-Ixvw_5_0"></a><a id="Tc_H8VCojCFLk2p_vulK4fYUQ_5_2"></a><a id="Tc_1RenOeBqzE2Ga643x9zbOg_5_3"></a><a id="Tc_oaiCu9JK202qfARWjG84Mg_5_5"></a><a id="Tc_R5oIeurjHkSeBGR4kXcP8Q_5_8"></a><a id="Tc_bu6TrAOHcUKxwQIfV4NChw_5_11"></a><a id="Tc_vuqH_DkzXkqxi9soxlHY2w_6_0"></a><a id="Tc_lcU_6833nUebyZV9qmdmfg_6_2"></a><a id="Tc_l3kW0Dr7a0yx1QlyMbPOYg_6_5"></a><a id="Tc_xtQLWwR-Ok6bfy0-Mx1vEA_6_8"></a><a id="Tc_O8zZmdYy0keD1j7CdmMjdw_6_11"></a><a id="Tc_k62t3THWukqet6JQ8aGYJA_7_0"></a><a id="Tc_2GflE7nFDEWd4wwUGt5MaQ_7_2"></a><a id="Tc_FrMpOHAouUyENRLr7CdFeA_7_5"></a><a id="Tc_2eiV4TAn7U6qz7V8tsY4gA_7_8"></a><a id="Tc_Ny4dJRKjhEK_UP4GPM61WA_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="plx:RevenueDisclosureTextBlock" id="Tb__xRs-cRHkEqZx9Zpd0fT5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_jnZDVWexS0-IqPUcTJo9zA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_RfgCYQ2Rr0qLtIgXDy8V0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_SrrsBl9_Sk-1ibqi607azQ_3_3">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_EDJO9ESATkWFpOj1QBRDjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5ikna_wF3kKoK3gnPUqv_w_3_6">2,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tBqUbsRpXUCkCu7As_K8ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_edtRck6clkuquueo4Oyarw_3_9">6,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_poDnVzcNS0KMFLRSo_6oDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ELe6DdIrh0WeOdBnYtcoMg_3_12">6,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_9vZiZcQD8UufQ_SB8sxlmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_YM9JFY7sEEKuddYTowaPPw_4_6">988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_VVGBDxGe8UudpDjkca8hHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tb6mhqGRckGJk4tXI1qJzw_4_9">5,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jEHvpKQm5kCqey2CTt_BcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_X7CImZJqgES1Tg5mjnacRA_4_12">988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_KnmF4l_09EC6bg-2BZ311g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_95BWho3s1U-pL3N6Nf1plw_5_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_iGheMtaJu06OflGOGrghmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_A7fw_fTzV06Xjf6dthsy7w_5_9">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_EiQ41j_NqUGvIIayLqE9OA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ut8J2sV80kKtdoxRgfx-5A_5_12">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_nVna7Ni_10m8Dt4lPXUAkA_6_3">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_QYGi0V_5QUKM1YLVaQDrIQ_6_6">3,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_NRTdgJFwYkCixZ9Y234D8g_6_9">12,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_lLq3eFBZS0W04LChuFe66g_6_12">7,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5T1it_JgwEKlfdk_D8Re7A_7_3">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9bbHXsa-bUSqu4ngAgRAXw_7_6">3,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9oKWEWcNJ0Cb33G9ZZ_7IQ_7_9">12,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rixTXuMMgEKMkAhCit7-zQ_7_12">9,993</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_vgOe9QSfdk2k2NZiyXACag" continuedAt="Tb_vgOe9QSfdk2k2NZiyXACag_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; SHARE CAPITAL</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_iX2Z28_h_EuP6AyudtbwHA">120,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_8_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_xZtyvQccUESGBiPReGtrYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JtPeyIoLSUK-e46EvJqC8Q">144,000,000</ix:nonFraction> (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Stock based compensation</b></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_stNA1XL37U-J5lbTlROItA">637,531</ix:nonFraction> shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_-ZhSJP0eLUW2KlqTHr7WzA">523,000</ix:nonFraction>.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_TrhAAzTQyEujl_jAy4m9gg">121,951</ix:nonFraction> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_X2R3nVEn4kCG6P1bnWAAgw">100,000</ix:nonFraction>.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On June&#160;30, 2022, the Company granted <ix:nonNumeric contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_MJ3seZHRXkiU83BAHDXMhQ">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uJiuVysWlke_Ei5zazbZww">40,000</ix:nonFraction> shares of Common Stock to a new director serving on the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_j2nckBrxnkyBN4wI2qgQdw">1.09</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_olLxe8ZFME65s769aXgAmQ">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_eDwVNz9ntE2qKMFt5GY09w">16</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and </p></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vgOe9QSfdk2k2NZiyXACag_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_2TgHMRWnaUitu_QcopL1Kg">32,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_zFgLxM7lbEiulIPwRtiWQg">1.09</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_yMRsgtslQkmxgW4gedK7hA">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_cbT2kuHFeU2FX430ICeq2g">85.95</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_OyvXyRLCGkmzcQcTKQogzw">3.025</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_c6ePRJZPiUm8rCMxK8vv2A">six years</ix:nonNumeric>.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">At the Annual Meeting, the Company&#8217;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_bviBEkzn-kuxLoWbK74QKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Qhya5MOA8kSxHeK-1BH9xA">5,725,171</ix:nonFraction> shares to <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Ri85L_GQ6EGDyqBYwwU7vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_1i7mWJzCyEOkpaTQxZ3CBQ">8,475,171</ix:nonFraction> shares and to amend certain other terms of the Plan.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the quarter ended June&#160;30, 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_TJCzjb9wu0uHBdiW-LygPA">2,395,823</ix:nonFraction> shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ" decimals="-5" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="6" id="Narr_mqL3hPBW00KVJmv0HLzWug">2.8</ix:nonFraction>&#160;million in connection with such sales.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_5UP2ymHO9UuJw2Vlywr7uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;1, 2022, the Company granted <ix:nonNumeric contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_XNaja0sxhkKuIv_oegU3KQ">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_cNEk97DMH0GeEXaUql2yrg">160,000</ix:nonFraction> shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_FfV1S9-zgU6v3_FDGsTI_A">1.06</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_yEKn5u9pBkmYzusiyHeIaA">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ" contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_HmPZCQDy1EO-u3Q0InR71A">16</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_ZlV2DIZsfUG6BEVueKhQMA">124,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g" contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_V8OdU-4hi02e_NFNlY2XTA">1.06</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_VU7PPegvzUemLW_Ha_CxSA">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_S8ahHBFSDkCme74NumoXVQ">85.95</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA" contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_XNydszste0Ww9cr0VrrGfQ">2.65</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_3WgmXOPOwUOJzzIaih1yUA">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During July and August 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig" contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_iv4mFFJJG0mGRs6LEgsOnw">1,040,457</ix:nonFraction> shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="0" id="Narr_g8SN16hi00in18gq7qgHBw">1,152,650</ix:nonFraction> in connection with such sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;17, 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_8_15_2022_To_8_15_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_AagOsjXaHk2Tye8hFQUyyw" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_uXeCvm49ukS-LsTbQYM1Kg">1.1</ix:nonFraction>&#160;million from sales to Pfizer. On July&#160;18, 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg" contextRef="Duration_8_15_2022_To_8_15_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_zEYSsTSOvkScTP7J-kyj4w" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_iylGe_flHE2EPUhJUJSIwA">1.1</ix:nonFraction>&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d30392ac_01a9_43ad_9a1c_c82bad98e7fb"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2021. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing and progress of the preparation of a BLA resubmission for PRX-102 addressing the CRL;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the FDA and the EMA of a resubmitted BLA and of an MAA, respectively, for PRX-102, and, if approved, whether the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the COVID-19 outbreak and variants which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to maintain and manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents; </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies and institutions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug product to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;30, 2022, we held our Annual Meeting at which our stockholders: (1)&#160;elected the six persons nominated by our Board of Directors to serve as directors of our Company; (2)&#160;approved, on a non-binding, advisory basis, the compensation of our named executive officers; (3)&#160;adopted the amendments to the Plan to increase the number of shares of common stock available under the plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of the Plan; (4)&#160;approved the Charter Amendment; and (5)&#160;ratified the appointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2022. The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;30, 2022, Shmuel &#8220;Muli&#8221; Ben&#160;Zvi, Ph.D. joined our Board of Directors. Dr.&#160;Ben&#160;Zvi is the new Chairman of the Audit Committee and is also serving on the Compensation Committee.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make adjustments again in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three of the clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic and its variants on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our extension trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20220630x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220630x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220630x10q007.jpg" alt="Graphic" style="display:inline-block;height:116.18pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease was approximately $1.9&#160;billion in 2021, and forecasted to be approximately $2.1&#160;billion in 2022, and is forecasted to grow at a CAGR of approximately 10% from 2020-2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential treatment of Fabry disease in adults. The submission is supported by the 12&#8211;month interim data analysis generated from our phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was released in June 2021. Data generated from the completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial, the phase&#160;I/II clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the filing. In addition, the MAA includes data from the completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial of adult patients treated with the 2&#160;mg/kg every 4&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The initial BLA submitted on May&#160;27, 2020 included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our <i style="font-style:italic;">BRIDGE</i> study and safety data from our on-going clinical studies of PRX-102 in adult patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta, a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021 to discuss the FDA&#8217;s requirements for a BLA resubmission. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the clinical data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. We intend to continue to work collaboratively with the FDA resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our clinical development program is designed to show that PRX-102 has a potential clinical benefit in adult Fabry patient populations when compared to currently marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs. Providing a meaningful improvement in the health and quality of life for Fabry patients being treated with PRX-102 represents a significant potential market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102, which was a dose range study in ERT-na&#239;ve adult Fabry patients. In the phase&#160;III clinical program, we are studying two potential dosing regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety, offering an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and provide a better quality of life for Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients that completed the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Currently, 126 subjects that participated in the our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term extension studies; 10 subjects that completed an extension study from the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial, 18 subjects that completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects that completed the <i style="font-style:italic;">BALANCE</i> study; and 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study. Of the 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study that enrolled in a long-term extension study, 26 of them are being treated with 2&#160;mg/kg of PRX-102 every 4 weeks, with a total exposure of more than 100 patient years in the aggregate, and two are being treated with 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The pivotal </span><i style="font-style:italic;">BALANCE</i> s<span style="background:#ffffff;">tudy was a 24</span>-<span style="background:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background:#ffffff;">102 in adult Fabry patients with deteriorating renal function that was </span>designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta (Fabrazyme)<span style="background:#ffffff;">. The study</span> was completed in October 2021, and topline results from the study were announced in April 2022. The clinical study report (CSR) for the <i style="font-style:italic;">BALANCE</i> study was since completed and the final analysis confirmed the positive topline results and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for at least one year with an estimated glomerular filtration rate (eGFR) slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. <span style="background:#ffffff;">Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between the agalsidase beta and PRX-102 treatment arms. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the September 2021 Type A End-of-Review meeting, the FDA, in principle, agreed that <span style="letter-spacing:-0.1pt;background:#ffffff;">the proposed analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study demonstrating non-inferiority to agalsidase beta to be included in the data package for the PRX-102 BLA resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. Given the changed regulatory landscape in </span>the United States with the full approval of agalsidase beta in March 2021 based on clinical endpoints<span style="letter-spacing:-0.1pt;background:#ffffff;">, the primary analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study was changed from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. </span>The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study compared the eGFR annualized changes (slope) between the two treatment arms in the intent-to-treat (ITT) analysis set (77 patients). The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The median (95% confidence interval) of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.788, -1.240) and -2.155 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). The prespecified non-inferiority margin was met. Topline results in the PP&#160;analysis set (72 patients) are consistent with the ITT results, with difference in medians (95% confidence interval) of -0.118 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.450, 2.213).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>approximately six years. At baseline, mean (SD) eGFR was 73.69&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (20.32) and median eGFR was 74.51&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.10&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year&#160;(5.92) and median eGFR slope was -7.25&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (4<span style="direction:rtl;">0</span>.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assessment of anti-PRX-102 antibodies or anti-agalsidase beta antibodies, respectively, in the study indicated that, for the PRX-102 arm, 18 (34.6%) patients were ADA-positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA-positive at baseline, of which seven (87.5%) had neutralizing antibody activity. At the end of the two-year study, 11 (23.4%) patients receiving PRX-102 were ADA-positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment-related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 have opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every other week in a long-term open-label extension study (NCT03566017).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa (Replagal; marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc)) for at least two years and on a stable dose for at least six months. The trial was completed in December 2019. Patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE </i>study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">et</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">al</span>., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 18 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every other week in a long-term open-label extension study (NCT03566017).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIGHT</i> study was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four&#160;weeks for 52 weeks (a total of 14 infusions). The trial, which was completed in June 2020, enrolled 30&#160;adult patients (24&#160;males and 6&#160;females) with mean (SD) age of 40.5&#160;(11.3)&#160;years, ranging from 19 to 58&#160;years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30&#160;patients received at least one dose of pegunigalsidase alfa, and 29&#160;patients completed the one-year study. Of these 29&#160;patients, 28 received the intended regimen of 2&#160;mg/kg every 4&#160;weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg pegunigalsidase alfa every two weeks per protocol at the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Overall, 33 of 183 total treatment-emergent adverse events (TEAEs) reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs lead to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36&#160;nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05)&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every 2&#160;weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every 4&#160;weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (NCT03614234) of the 2&#160;mg/kg PRX-102 every 4&#160;weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three studies. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45 million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $1.5&#160;billion and $1.6&#160;billion in 2021 and 2022, respectively, and to grow at a CAGR of approximately 8.6% from 2020-2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;">, currently the only commercially available DNase therapy), even more so in the presence of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">actin. We are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is he presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or imaging disease elements of gout. An estimated approximately 2% of the gout population is considered to have chronic refractory disease, and we believe the frequency of severe gout is even higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. However, we believe that new effective, safe therapies are needed to treat severe gout and chronic refractory gout regardless of treatment history. One treatment option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients that have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. In addition, a recent phase IV study demonstrates that co-treatment with Krystexxa and methotrexate increases efficacy and tolerability in patients with uncontrolled gout. Krystexxa is no longer marketed in the European Union for commercial reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of severe gout which we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity supporting the potential of PRX-115 to be a safe and effective treatment for severe gout. We initiated toxicity studies of PRX-115 in the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of June&#160;30, 2022, we hold a broad portfolio of over 80 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The five poster presentations listed below were available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities. The program was supported by Kidneys for Life, a Registered UK Charitable Organization (Manchester, UK), and took place May&#160;29, 2022 through May&#160;31, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="letter-spacing:-0.1pt;">&#8220;</span>Safety and Efficacy of Pegunigalsidase Alfa vs Agalsidase Beta on Renal Function in Fabry Disease: 24-Month Results from the Phase III Randomized, Double-blind, BALANCE Study<span style="letter-spacing:-0.1pt;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="letter-spacing:-0.1pt;">&#8220;</span>Long-term Safety and Efficacy of Pegunigalsidase Alfa: A Multicenter Extension Study in Adult Patients with Fabry Disease<span style="letter-spacing:-0.1pt;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="letter-spacing:-0.1pt;">&#8220;</span>Tolerability and Infusion Duration of Pegunigalsidase Alfa in Patients with Fabry Disease: Data from 5 Completed Clinical Trials<span style="letter-spacing:-0.1pt;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 36pt;"><span style="letter-spacing:-0.1pt;">&#8220;</span>Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease: 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study<span style="letter-spacing:-0.1pt;">&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="letter-spacing:-0.1pt;background:#ffffff;">&#8220;Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4 Weeks in Patients with Fabry Disease: Results from the Phase 3, Open-label, BRIGHT Study&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended June&#160;30, 2022 compared to the three months ended June&#160;30, 2021 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $3.4&#160;million during the three months ended June&#160;30, 2022, an increase of $0.2&#160;million, or 6%, compared to revenues of $3.2&#160;million for the three months ended June&#160;30, 2021. The increase of $1.1&#160;million in sales to Pfizer, resulting from timing differences, was partially offset by a decrease of $1.0&#160;million in sales to Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $5.4&#160;million for the three months ended June&#160;30, 2022, an increase of $2.2&#160;million, or 69%, compared to revenues of $3.2&#160;million for the three months ended June&#160;30, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $4.1&#160;million for the three months ended June&#160;30, 2022, a decrease of $0.6&#160;million, or 13%, from cost of goods sold of $4.7&#160;million for the three months ended June&#160;30, 2021. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of decreased manufacturing costs due to higher yields and lower wastage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended June&#160;30, 2022, our total research and development expenses were approximately $7.6&#160;million comprised of approximately $4.4&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.7&#160;million of materials-related expenses and approximately $0.9&#160;million of other expenses. For the three months ended June&#160;30, 2021, our total research and development expenses were approximately $7.7&#160;million comprised of approximately $5.<span style="direction:rtl;">1</span>&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.<span style="direction:rtl;">8</span>&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $0.1&#160;million, or 1%, from the three months ended June&#160;30, 2022 compared to the three months ended June&#160;30, 2021<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.6&#160;million for the three months ended June&#160;30, 2022, a decrease of $0.6&#160;million, or 19%, compared to $3.2&#160;million for the three months ended June&#160;30, 2021. The decrease was primarily due to a decrease in salary-related and selling costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net were $0.2&#160;million for the three months ended June&#160;30, 2022, compared to financial expenses, net of $2.1&#160;million for the three months ended June&#160;30, 2021. <span style="background:#ffffff;">The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92&#160;million of 2021 Notes to an aggregate principal amount of $28.</span>75&#160;million<span style="background:#ffffff;"> of 2024 Notes, and an increase in the exchange rate of New Israeli Shekels for U.S.&#160;Dollars over the period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Six months ended June&#160;30, 2022 compared to the six months ended June&#160;30, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $12.4&#160;million during the six months ended June&#160;30, 2022, an increase of $4.6&#160;million, or 59%, compared to revenues of $7.8&#160;million for the six months ended June&#160;30, 2021. The increase resulted primarily from an increase of $4.5&#160;million in sales to Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $<span style="direction:rtl;">12.4</span>&#160;million for the six months ended June&#160;30, 2022, an increase of $2.4&#160;million, or 24%, compared to revenues of $10.0&#160;million for the six months ended June&#160;30, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $10.1&#160;million for the six months ended June&#160;30, 2022, an increase of $0.6&#160;million, or 6%, from cost of goods sold of $9.5&#160;million for the six months ended June&#160;30, 2021. <span style="background:#ffffff;">The increase in cost of goods sold was due primarily to an increase in sales of goods which was partially offset by higher production yields.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 0pt 0pt;">For the six months ended June&#160;30, 2022, our total research and development expenses were approximately $16.3&#160;million comprised of approximately $10.2&#160;million in subcontractor-related expenses, approximately $3.7&#160;million of salary and related expenses, approximately $0.9&#160;million of materials-related expenses and approximately $1.5&#160;million of other expenses. For the six </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">months ended June&#160;30, 2021, our total research and development expenses were approximately $14.8&#160;million comprised of approximately $9.4&#160;million in subcontractor-related expenses, approximately $3.6&#160;million of salary and related expenses, approximately $0.4&#160;million of materials-related expenses and approximately $1.4&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">The increase in research and developments expenses of $1.5&#160;million, or 10%, from the six months ended June&#160;30, 2022 compared to the six months ended June&#160;30, 2021 resulted primarily from a $0.8 million increase in subcontractor-related expenses in connection with regulatory submissions for PRX-102, and a $0.5 million increase in materials-related expenses<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $5.8&#160;million for the six months ended June&#160;30, 2022, a decrease of $0.5&#160;million, or 8%, compared to $6.3&#160;million for the six months ended June&#160;30, 2021. The decrease resulted primarily from a decrease in salary-related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $0.2&#160;million for the six months ended June&#160;30, 2022, a decrease of $3.7&#160;million, or 95%, compared to $3.9&#160;million for the six months ended June&#160;30, 2021. <span style="background:#ffffff;">The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92&#160;million of 2021 Notes to an aggregate principal amount of $28.</span>75&#160;million<span style="background:#ffffff;"> of 2024 Notes, and an increase in the exchange rate of New Israeli Shekels for U.S.&#160;Dollars over the period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity include our cash balances and bank deposits. At June&#160;30, 2022, we had $28.6&#160;million in cash and cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60. During the six months ended June&#160;30, 2022, we raised gross proceeds equal to approximately $2.8&#160;million from sales of common stock under our ATM program through the sale of 2,395,823 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of June&#160;30, 2022, we were in compliance with all covenants.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $13.2&#160;million for the six months ended June&#160;30, 2022. The net loss for the six months ended June&#160;30, 2022 of $7.6&#160;million was increased by a $2.6&#160;million decrease in contracts liability, a $4.9&#160;million decrease in accounts payable and accruals and $1.0 million financial income, net (mainly exchange differences), and was partially offset by a $1.4&#160;million decrease in inventories and a $1.1&#160;million in share-based compensation. Net cash used in investing activities for the six months ended June&#160;30, 2022 was $15.9&#160;million and consisted primarily of investment in bank deposits. Net cash provided by financing activities was $2.6&#160;million resulting mainly from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $3.3&#160;million for the six months ended June&#160;30, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the six months ended June&#160;30, 2021 of $16.7&#160;million was increased by a $1.6&#160;million increase in accounts receivable and other assets, and was partially offset by a $12.3&#160;million increase in contracts liability, a $1.9&#160;million of amortization of debt issuance costs and debt discount and $1.4&#160;million in share-based compensation. Net cash used in investing activities for the six months ended June&#160;30, 2021 was $23.1&#160;million and consisted primarily of a net increase in bank deposits. Net cash provided by financing activities was $42.1&#160;million resulting from the sale of common stock under our former ATM program and from our public offering of common stock, net of the promissory note payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160;payment of interest on our outstanding 2024 Notes. We believe that our cash and cash equivalents and short term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program, as amended on May 2, 2022, pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $17.2&#160;million remain available to be sold under the Sales Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the six months ended June&#160;30, 2022 and June&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of June&#160;30, 2022 and June&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9b4c0d00_75a4_4f05_9aa8_2e415e016c80"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and approximately 65% of our expenses and capital expenditures, as well as the repayment of our 2021 Notes in 2021, are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 31% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.230</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.110</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a32759e_5a74_480e_8c2b_45fce53eb63c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June&#160;30, 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b630537_1066_49ba_916f_ffdd013d7a89"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d06ddd6e_f9f5_47bb_a0a1_6ec9d55b2394"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt 18pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_f9ad971f_2b7a_4e22_a819_fe4e9ed02dfb"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eec34dc_1253_475d_a1be_0c42559aa930"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966e3751_9a3a_4eca_8883_8a8569ef5519"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_456f122b_a221_47f7_9a57_c06b953e1e11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_11a4c9d6_778c_4de5_9fb0_1794b2af99ac"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465922079877/tm2221015d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">S-8</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">s</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;14, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb42ea3a_7937_40ba_a34c_13018e511030"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>plx-20220630xex3d5.htm
<DESCRIPTION>EX-3.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/14/2022 09:21:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title>Submission Proof - 22-12755-1</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;3.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOURTH CERTIFICATE OF AMENDMENT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION OF</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Pursuant to Section&#160;242 of the<br>General Corporation Law of the State of Delaware)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Protalix BioTherapeutics,&#160;Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The name of the corporation is Protalix BioTherapeutics,&#160;Inc. (the &#8220;Corporation&#8221;). The Certificate of Incorporation of the Corporation was filed with the Secretary of the State of Delaware on March&#160;30, 2016, as amended by that Certificate of Amendment dated August&#160;16, 2016, that Second Certificate of Amendment dated January&#160;15, 2019 and that Third Certificate of Amendment dated December&#160;16, 2019 (the &#8220;Certificate of Incorporation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Certificate of Amendment to Certificate of Incorporation of the Corporation was duly adopted by the Board of Directors of the Corporation pursuant to a resolution setting forth the proposed amendment of the Certificate of Incorporation and declaring said amendment to be advisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Article&#160;III of the Certificate of Incorporation, as amended, is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">&#8220;The Corporation is authorized to issue the following shares of capital stock: (a)&#160;144,000,000 shares of common stock, par value $.001 per share (the &#8220;Common Stock&#8221;); and (b)&#160;100,000,000 shares of preferred stock, par value $.0001 per share (the &#8220;Preferred Stock&#8221;). The voting rights, the rights of redemption and other relative rights and preferences of the Preferred Stock shall be established by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">The Board of Directors may authorize the issuance of such stock to such persons upon such terms and for such consideration in cash, property or services as the Board of Directors may determine and as may be allowed by law. The just valuation of such property or services shall be fixed by the Board of Directors. All such stock when issued shall be fully paid and exempt from assessment.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The aforesaid amendment was duly adopted in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Remainder of this page&#160;intentionally left blank.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to Certificate of Incorporation to be signed by its duly authorized President and Chief Executive Officer this 26th day of July, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:49.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:49.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>plx-20220630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/14/2022 09:21:55 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>plx-20220630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/14/2022 09:22:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>plx-20220630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/14/2022 09:22:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>plx-20220630xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/14/2022 09:22:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;15, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20220630x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220630x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
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MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
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M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
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MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
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M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
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MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
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MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
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MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
M)?"VLZ[XCMI=/L?$M[;KX4U#36NM7LC:()V1=D2QE4V\@\[0IX )Q7IU]:WF
MM_LZ75E!IUZFH/H+VHL9[9XY_-$10KY; '.1QQSP1D$4I:1D^O\ P9?Y)E1M
M)Q7?_P"U_P V=./BIX0;2CJ0\1Z<;#S?(^T"<;#)@':#W."#QZU?U#QMH&E:
M/!JUWJ]G;Z;/CRKIY1LDSTVGO^%>9#1[OPCKW@+7KG1[Z[TBQT"339K>QM'N
M);2X;RBK^2@+X(1D) ..,X!)K!\,^%=:\'7WA3Q'J>CWTNE07>L3-IEK;FXG
MT];J4/;MY* L2%5E(4$KYGIFJ:2=K]_P?Z[KU)B[I/\ K:_X;'L=_P#$;POI
M=C97MWKUA!:WH=K:5YU"S!1EMOK@=<4FF?$CPMK6H6MC8:_I]W=W2>9!##.K
M-(N,Y7'7H:\<\,>!M:C\>>#=4N-&N;?3I-<UK4E@EA_X\89H0(A(!PA8@G'8
MMCK2Z5X'U6P\+^ H8M%N()[7QI+>W*) 5:.%GN/WK<<*0R\].126K2?6WRO9
M?A?\ ;LG;I?YVO\ G;\3U;QG\4=&\#>(O#&C:C*$NM>N7MX"6 $>V-GW-GL2
MH48[L*TX/'/A^ZUY]%BUFSDU9,AK-9@9 0,D8]?:N3^*]A>R>*?AYJ5O975U
M:Z?JTS73VD+3-"LEI-$KE5R=N]U!..,Y.!7EOAWP#X@B30_#M])XFFO]/UP7
M\D8M+>"Q15E+F<7GD$N"IQY8<NV[:<#)"CJ[>?\ E^6_^0Y::KM_G^=OZZ^W
M)\6O!DER;=?$^F&<!SL%RN?D)#=^HP<CVJ>3XF>%(M*L]3?Q#IZ6%Y(T5O<-
M.H25U4LRJ>Y 5CCKP:\7T'P!J:>'/AQ#<:#.)+/QK<7]TCVQS%$5NMLK\<*2
MT?)]5K$UVVG\)>,/#=UJVB7MQ;/\0+RY@MH[4R221FQFVRQIU< _-\N2=O )
MII7T?]?#_P#)?A]SE[MVO/\ ]N_^1_'[_HY/&V@2>'VUQ=8LSHZ_>O?.'ECG
M&,^N>U59_B3X5M=%@U>;Q!I\6F3R^1'=-.H1Y,$[ ?[V%)Q[5XIXD\#^(M7!
M\265MJFFZ7_PE*:L;"VM4:\%N+=HO.%O*I!;S")/+*EL#@;L57E\!ZOJ>K:)
MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
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M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
MB#IGG[ISCTKZ1\ S+'!'MB X .!7AOPOTZ&_DCU$ " R- D97!V@\$GN>O-?
M2WA6QMXH56)!FO64>AYU^IW-K=DP+A><5Y5K'@>%_%&N:FTUQ.;^+RG@FD+1
M*.,[5Z#I7K"XB@&1C KF]1D0RN<=>M6KK8B6I5\+Z0FCZ!!;VP\F&,86-3P!
M7)>.=(_M198I1OC<88'H:[RWN5%J%' %<[K<B.3WK"2&F?(GQ'\)W'A2>YE"
MO/!>%81*G/DIZ-D\^V*X2:]DMO#]^TD,D1C>(0(!_>)4,?1<<U]7>+M%MM3M
M98I8]R2*58@\@5\N^/\ 2)=!9-#MI97:>=&:61,>9$@9@H/?'!_"B.S3'J>T
M_ :XD_LK5K,R":.T(575<+R"<>_UK9OW)\KY2#]B1L^O2N/_ &;;\SP^,8FY
M,%R$SG/&S-=IJ)#01$=1;1+GVVBLE'E@TS23YI71YL(X+CXFV:7,<<T(EC=E
M.00%RQ.1["I?B?X@L-2;0H+67$@L#=&!F^<;P&+'OU)I]M;*WB7Q'=]9K>Q9
M8@.N]EV#_P!"KB/''E6/QE$+QB6./1O("@XSMPHY_P" UY=E/#U;];GHQTJ0
M\CL_AQK>HZ9XHMH[&Y,*3W%O%*HZ,IX(_*OI+X+?#O3O"$/B#Q4;B&YUGQ#(
M%F(/,<:X 3'U7/XU\V> #I=WXOTX0&ZMIEGB>2.10Z$JA/##! X[UU?PH\=Z
MQK7QZU[3)]3_ .)-I=LZ6]C@C:657W'CD\FM<K7LZ5GKJ+'OFJ:::%3XK.]S
MXP,C-\S;L<]MS8KS;4!ML8 PSMG&/^^#7?\ Q!D,GB:W8L&W6P<D>IW&N O<
M26T0/_/53_XZU?'Y@_\ ::GS_)'TN!_@P^1[WX5^$WA/Q!X=T)=2@+W)M]TD
MD?4M(=V?P4H/^ U:_;-^QZ;X5\(Z=#&9 L[1PRL>45$ Q^.?TK!^&_BGS=/T
MR+>RR(?()';R]H'_ ([M_7TJY^V=-_HG@J(GDO/*?Q _QKZ=.F\$Y4U;1'C1
MY_KD5-WU9\S0=+X'_GXMO_09JTK)]E_<-G&(8S_Y&CK+@.3?$\#[1;_^@S5<
MBEP][QT@3G_MJE?.1^->A[<E>+]3J/&,-LQDU&V;_7OY$R8QME3(/YJ4;_@5
M<K?MMTRWY_Y8R$?]]M6WJ-V7TG7(&&0FHPNI]-T<@;\]B_E6#J>/[*M0.]N_
M_H;?XUW2?-)-=D<"5HM,I?&Z(P?!'PX"P_X_(>/^V<M/L+S^S=%\"/C"MF-C
MZ@H@_K3/CP,?!SP\!SF[B Y[^7)5#796'AWP;$@.](]WL/ECKZ>3M"_H>%&S
M:7J5]9MFL]1N;3!_=C8H]LG%?M;^R C1_LR_#I6&UAI2 @]N6K\9O'UW%;^)
M;]H 1/M0LY[':.E?LO\ L=G=^S%\.2>3_92?^A-7+A%:O41O7;=*!ZY)TK&U
M+[C?0ULR=*QM2^XWT->P>>:FD?\ (-@^A_F:N53TC_D&P?0_S-7* /._'OP4
MTGX@^//"/BN]O]0MKWPW,9K>"VFVQ2D]G'^&,CCI7HE%%"T5@>KN>4?%+P5_
MPE_Q,\!?:=.N;S2K?[8UQ+"9$2(F,!=SH1MR>F3S7 _$WX7W&FWGCB'P]H>H
M2VUWHU@D7EB:X\V5;LLRJ6+$D+@D \#FOI6BA:-/L#UO\OP/ESXF[O#/@GXC
M:3J^BZAJE]JNL1WMI>PV32P&)O($8:8 K&T6TIL8AC@%0<U>U;P1JLWA7XU-
M'H=V][J6KVLMD5M6,ERB6]J T?&6 8/R.A!]*]NN?AGX9O-<?5YM)B>^DD$S
MMO<(\@QAVCSL9A@?,1G@5T]$=%YVM]W+_P#(@][^=_S_ ,SYKNO#6K:+:?$[
MQ*VGW%M>Z7XAM]:T]YXRGVE([&W60(3C<& D3(XR"*]?^$VCW&F_#^RDO4V:
MIJ7F:E> ]?/G8R,/PW!1[**Z/7?#NG>);:.WU.V%U!'()1&SL%+#ID C(]CD
M5HJH4    < "C>/+Y)?<DOQLON%U3]?SO^%W]Y\Y>#-/U+P]:^ -4U/0M8>R
M\._VE8ZA:IILTLT$\C*8YTB52TR;0R[X@WW^/XL4-1^'_B;48-!:RTR]T];W
MQ%J]];1&(J=/@FM)5B,@'^JW,<X.,%\=>*^G:*'KO_6MW^/X:%7_ *^37ZGS
M3X.\):U=W7A2VF7Q&]SX>LKF.YCN]+CLK>W+0-&8UE$0^U!VP0(V(^4,Q! !
MM6>@ZKX?^%_PKAET?4;*&QG,FH3V6F275[8MY4@0K JLWS,Q4L$)4-GC.1]&
M44V[W?I^K_4E*VGR/ECPCX+UR3Q+X8FNM!UC[)%XZO-0+:E:DLD#64NR9^,*
M"Y'/9B!P>*V;WPWK&FQZE=G1=1>UM?B#!J9CM[221S:C :6.-06=<G)V ]SV
M-?1U%"T::Z6_#E_^10W[R:?6_P"/-_\ ),\U^*EA=GQ!X%\1+I]UJFCZ-?2S
MWUI:P--,@>!TCF$(!9RC$?*H+#=D XKSJ\\+:UJ?B'2=:M=%U"WTN\\=6NHQ
M6TEJZ20VZV\B//)&1NB#-S\X!Y&0":^CZ*(OEDGV=_Q3_3^M!-737=-?>FOU
M_K6_GGQBTJTO+31;V=-=AN-/NS-;:CH%H;N6S<QLF]H5#,ZD,5^5&QGG YK@
M?#VD>(M8\:?#O4-5T60V]E>ZHXO/[--J3&T2B*::+ \EW.[A@ISV'2OH&BE'
MW7<;U/G72?!.IZ?IWA$0:'=6\L7CR[O9]EJRE(&>XQ*W'"$%?F/!!%88T;7[
MO4/"D+:/X@BU"R\7?;;ZSATQXK"SB:63,BS%<3!@P)96;&X[MO0?4U%$?=MY
M6_"W^02]Z_G?\>;_ .2/G+X1^$M;TOQKX9N+S1[ZU@AEU\R236[HJ"2\+1Y)
M'&Y>1ZCD5V'B%9/#'Q7UG5]6T/4=>T?5=(AL[5+#37O<2([EX6"@A ^Y3N?:
MG'+#%>NT4=(KM_P?\PW;??\ SN?/'B?P=J&H1?&Z>+P[=QR:GHUI%81&UR\I
M6U8>5'MR&*M@80D BL/XCZ+K]YIGC2P;2-?^V7VAVL%A!I.FO(M_MMQN,UQM
M*HR.67RV93CH&+5]1T4GK_7J-.S3[?\  _R/GQ?"&IW.I?$"XFT6ZD:[\%V-
MG;R2VK$RRB*??$I(Y8$KE1SDC-8TT-SX*\+^)I/$6B:GJJZKX2LK>W6*Q>?[
M.T5NZRP3$ ^3\QW[I-JG)YR,5].5S6N_#?PWXEU3^T=2TN.XO"@C>3S'02J.
MBN%(#@9/# ]:)^_==_\ @_YA#W;/M_\ :_\ R)\\Z?X9US3HUOICKHTW6O"N
MG65I'I6DI?@LD3B2V?,;F#)<-O;:AW<G*UN:OX6O/"$,!TZV\2)XHDT:TLY$
MDTO^U+#4S$&V13.B%8RI<@L_E#G(S@U]&QQI#&L:*$10%55& !Z"G5<G=M]W
M_G_F1%623Z+_ "_R7]6/+OC+I6JZY\-])ABTZ2;4!J.G2S6MG&9/+VSQL^ N
M?E7!Y[ 5Y_/X*U9?A9K,$>AW8U&3QM]N2-;5O-:+[<I$P&,E=F3NZ;?:OI&B
MDG9W\[_C%_\ MH[:)?ULU^IY'^T==6]CHW@V>ZL9=2@C\46#-:PQ>:[_ '_N
MI_$>^!R<5QGB/PMJ?BC61K=IH=^FCZAXPTB[BM)[*2*41PH5EN9(64-&I./O
M@'"@GK7O^L:!I^OBS&H6J70L[E+R#?G]W,F=KCW&36A2A[NO]Z__ *3_ /(C
MEK]UO_2O\SPCQ%IUWHTOQ+TF[\/:EJ]YXF;=IDUI8O/#,IA"+&\J@I#L8$_O
M2HYR"36-K>AZMX0\.^.=)UK0M4\4W^M:)#!92V%@]VD[I:B-H6=01'AP6!D*
M@[N"3Q7TA14VO%Q[JWR12=I*79W^>G^1\QVNFZSX0T;Q5!<>'-:N[G7/"5I;
M6$=EI\LP:>.T:-XI&52(F!(_UA7/;)XK8\$V5UX$NFE\1^&M6U>UU3P]IUK;
MP6NE279#QQ;9+:0 $1?,<YEV)R<L,''T)16CE=M]_P#@_P"9FE9)=O\ @?Y'
MS7\1/#^L7>M>)+>W\/ZIF]UC0+ZW$5D\D8ABN(O-^= 4!3!R-W !/3FK&I^'
M-7?PKK7@M=$U%O$][XC_ +0M]66S<VJQ&Z65;DW.-BE(QMV%M_& I%?1E%"=
MK>O_ ,C_ /(K\1M7_KU_S9\W:CX*U?\ X07Q0D6AW?V^;QY#?1!+5O->$7<)
M\Y>,E0H8[AQ@&O3?C9H]_J6BZ'=6=K-J$&F:Q;7]Y96\?FR30(QW;4ZN5R&V
MC).W@$X%>B45*TC%+I9_<DO_ &T;U;;ZW_%O_,\6UZ]34O%OAWQ?9^%]930=
M/NI_MF[1Y([F61XPJW(MMOGMM(*Y,8;G(!'-<W;>#=6O_%.D:O\ V%>0:1?>
M,I-4@LYK8AK:#[+L\Z6/'[K?(I?#8(W#(#$BOHVBFO==UT_S3_0'JK?ULU^I
M\YIX:UC1?'>OZY-HVH3:':>+S?O;6]F\K31-91)Y\48&Z0+)G.P$Y!X)%8WA
M?PWJVH?$V75[?PMJNE:9<>,YKY/M-B\.83IZ)YY!'RJ[@]<<G!P<@?4M%3%6
M279)?^D__(H;=[^=_P ;_P#R1\JV'@SQ)K?A;P-H]II6IZ=J6G:7K&FW,EU:
M2PI!.T>$^=EVE6R-KJ2IYP>#6_KVF7_B_2?#EGH_AO5=,N- TF\AO_M.GR6X
M7=:M&+:)F4"?<Y!S$67Y<YSC/T713E[R:?7_ (/^;_K=IV:?;_@?Y'SV?!%W
M]C^$=O)X?OGM;31+VUU&"U@\MX@]HH\MB=H0LP( 8CYJT/AU?WGAK7@R1:S=
M>$M.TF43W.NZ#);7FG[&0I!&_EAKA2-Y.P.!L!W<C/NE175K%>VTMO.@EAE4
MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
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M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
M:\#$Q?UB[VU_]*1Z-+^ K>1Z#X#@EN+V-I@/^/2X4E>G"X%><OXPA^'/B7_A
M'Y8@USK @D7!)V OC''?BO<OAO%_;?@^75C;"$7&F2+D# 5N5_I7AWBWPM<Z
MK\<?"$?]GF8)8VLCW6W.P*,GG\*^PA1C>,I;GS?M79Q07PT"R^*]_);1W<FH
MVGF@VTN#$"R#)/?!]*V_@S%>^.Y5?4].GCEMVD\MS:F**.($;57(_E3[KX>:
MKXO^).H:G8316L'VGS9)YU)\QL *H [ "OJ/PCI7D:9 DP1IE4!V5=H8^PK9
MRYMC-=R?P9X?:)$+J0  !FO6-&L2B*. /:N<T>V ('2NVTZ$+&!CBFE83=R&
MZA X!.:QI+4>;D\FN@NP,D;<$BLN2+G^M5<13G7]V1P,5E36JN>.E;4T7R^_
MK58P9S6;0T8K6 'ICWJ"2P!4Y K>>V![57DMQSZU+07.;O\ 2(-2TR>RF7<K
MJ1GZBO(-:^#TUOY@@U&]=\C:6D)^6O=IK?CC@UCW=O('R>E0T4CY$\0Z%J'A
MSQUX=>!9);BTNA* [X).Y>??I73:]IW@6V\57WB2_OIY8[6U8O8^7L985R6W
M>@SGIZ5Z-<?"Z:X\<'Q!<:G),D3EHK9UR%''&?3(S7S7\2-3FT[Q9X_V,J/'
MHGF)N&0<.1S[4G!3CRM%*3B[H]%GO=1\3ZKI&JF-+BQDOH3;M:L'BC@'W  .
M0,8ZT_X/6\1^-'Q1GDX+&&%?J<'^E>,? GQ-+8>(='LC*\B:C*)$C;=\G[S&
M5]N#@>U>U>$]=FT#Q!XWNDD202^(["T.$!P) P(YZ=*YZ=%TI-ON=,JJFK6\
MB#XD1#_A)4R?^6:+GV*M_C7"+8-=HD$:&222>-451R20P _,UZ%\18R/$X1L
M_P (_0UJ?##0K31M+OO&6KK_ *+IC_Z'&_2>XP=H'J!D5\AB*3JXJ4>FOZ'T
MM"?L\/%K>R,CXM7,GP\\+:#\.(BGVB<KJFK2(V<RL<)&/8!1^0]:B_:8NI[6
M_P#!TMO*T4R12LCH<$'"<BN#\6ZK>>)/%<6IWS^9=W3>;(Q]3*_ ] ,8_"NW
M_:4;??>$5SR+>8_^@UZ*J)T*O)LDK>AAR<M:DI;MML\AT^:<0_:UE=+K^T78
M2JQW!EC0YS]374:#-]EN;YY+AGU"2ZMQ<2DY^]YAV_7@Y/O6!HJ#^R()<X/]
MI7'/TB@_QI]D9(=/UN1@5D6]M&#>^V<C^5>?";C)2\CJJ14ERE;4+96N-9P"
M0;I""1CC$E9^JIMMH@.GV;G_ +ZK9U*Y%S<:E<A01/+$YQVR'_Q-96M ?9UV
M?,!;@9_X$*UO[VGD8RVMZC_VA+,0^#/""@$;G?(_[9K_ (U:N=+^U?$KP]&1
M\D%BLK?\!)(_4"G_ !X26\\.^#(T7?F608R.!LBK>OH!9^.[ZZ.$2ST-F#-P
M,\FOJ+727H> MOO//;[4C<ZEJ,Z2DF2Z\P+CJ3TK]IOV1F9OV;? )?[W]G#.
M?]]J_$>/ L&F"Y(;?NS["OVW_9%.?V;/ )_ZA_\ [.U<&"=ZU1G7BE:$3UB3
MI6-J7W&^AK9DZ5C:E]QOH:]L\PU-(_Y!L'T/\S5RJ>D?\@V#Z'^9JY0 4444
M %%<YXD^(?A[PCK.BZ5J^I)97^LRF"PA>-SYSCMD @?\"(J?5?&^B:)XCTG0
M;V_2#5]5#FSM2C%I0@RQR 0,>Y%&X;&Y6-XI\+VWB[3/[/O)[F*S9@9HK>0(
M)U[H_!RI[@8K8)P,U7T[4(M4LHKJ%9DBD!*BX@>%QSCE' 8=.X% $T4201)'
M&H5$ 55'0 =!3ZIS:Q96^J6VFR7427]RCRPVY;YW1,;F ]!N&3[BK,L@BC=V
M#%5!8[5+'\ .3]!1YA;H/HJ"RO(]0M(;F)95CE4,HFB>)P#ZHX#*?8@&IZ "
MBBB@ HI"<#-9OA[Q)IOBK3OM^E7(N[3S'A\P*R_.C%6&& /!!% &G115&XUR
MQM=16PDN4^W- ]RMLN6D:-2 S!1R1D@?4T 7J*@LKN._M(;F(2K'*@=1-$T3
M@'^\C@,I]B 14] !1110 4444 (1D$=*I:)H]MX?TFUTZS4I;6Z!$#')/J2>
MY)R2?>KU% !115/2=8LM=L5O-/N8[RU9G19HFW*2K%6 /LRD?A0!<HHHH **
M** "BBJ5QK-C::G9Z=-=11W]XLCV]NS?/(J8WD#T&Y<GW'K0!2M_".GVOB^\
M\2H)/[3N[2*RD)?Y/+C9F7 ]<N>:VJ*0D $DX H#K<6BJ>E:O9:Y9)>:?<QW
MEJY95FB;<I*DJ<'V((_"KE !116=XB\0Z?X3T*_UG5KD6>F6$+7%S<%681QJ
M,LV%!)P/04!OHC1HJI<ZI;VNEOJ#>;+;+%YW^CP/*[+C/RH@+,<=@"?:K*.)
M$5AD!AD;@0?R/2@5[ZCJ*S-/\2:;JFKZGI=K="6_TTQB[A"L#$77<G)&#D<\
M$UIT#"BBB@ HHHH Q+GPCI]UXPLO$KB3^T[.SEL8B'^3RY&1FR.YRB\UMUF:
MOXDTW0KO3+:^NA;SZE<?9;1"K'S9=I;;P#CA2<G XK3HZ6_KO^H=?Z]/T"BF
MR.(T9SDA1D[02?R')K&TGQEI.M:O-I5K<2?VE!;17DMK-;R0R)%(65&8.HQD
MHW'7CD4 ;=%8FO\ C/2?"\%W/JL\MG;6B1R2W#VTIB =]B@.%*L=W5021D$@
M BI9/%6EP2PQ3W!M9)[O[#"MU$\)GFVEML>\#?PK'*Y& >>#0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
M-UNZ;5+SQ2;68/=,99U66;=$_.6  4%3[5[O#X \+V^M2:Q%X;TB+5I)1.]^
MEC$)VD (#F0+N+8)&<YY-"_#_P +IK$NK+X;TA=5EE6>2^%A$)WD7[KE]NXL
M,G!SD4[Z_-/\M/P!K3Y6_/7\3RKX?2Q:MX33Q9J_B34;3Q)<7%[;O;2:JR0O
M*ID46ZVY;8"H4$;5#_+DGK7G?POM[7Q1XCO;W7/$FHVU_'X*L+D21ZG)!+(1
M+=$S.RL&?9\O!)7Y^0>*^GD\$^'8]=GUM= TM=9N$,4VHBSC%Q(A&"K2;=Q&
M .":J77PS\(7P@%SX4T2X$ C$0ETZ%O+V;MFW*\;=[8QTW''4U/]>FC6GWW_
M *N-Z_UYI_I;^K'S)XH\4:YX@\->)1J]W<N6\,Z+<&WD<[/,:]D!D"= S*JY
M('/%:NK6W_"5>*M(75K_ %"5(/B++:0[=1GB\J,V4I"KM<8Y48QTR0.&(/TO
M>^%M%U*2XDN](L+J2XC2&9Y[9',J(VY%8D<A6)(!X!.145YX,\/ZA:7%K=:'
MIMS;7$XNIH9K.-TDF!!$C*1@N"!\QYX%5=<U_P"OB3_)6#HU_7P\OYZGD?@W
M6]8U'QWIO@.?4+QIO#-W<7^HW#3,7N;;!%HKMG+!C+NP>OD<U[K7->&?!G]A
MZYK.LW5V+_4]3**\PA$02%,B., $\#)Y)Y)/2NEI7T2Z]?475_U_6MPHHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y]?\ C]G_ .NC
M44+_ ,?L_P#UT:B@#PC_ (*#:9<:K^S_ .5;1"25-6MI,LZHJ +)\Q)(Z9K\
MR_A-X?DTGXHP7$ES#<;Y=N8&W ''][N:_1;_ (*=7'V;]F8-@-G6[0;2>#\L
ME?FO\%+F:X\<Z?(S?N%D 4+]W/<BN*44\0I=3J4K47'N>R?%_P ;W'@I;JYT
M^")[]T$8VQ ELCJ['D =J\=_9\OM1U'XO6EYKDT][J%V7'G3,2 -O0'OZ5TW
M[2,^OQ^(R-.T][K35A1KAT8* >@R37/_  :CO(?'_AS4W1'2/?OBCD#&/(X#
M8/%>C"/+T\SSG)WL?1GP8TEKWP@R%B/L^I3.">V)6KW*VT[=>)(J_*RAB<>U
M>._!>Z$NCW4-I"UQYFHRHX3CR\N22?85]":;8GR(>,84"K:LP006G3BM2VM0
M&'&:FM[3&.,FM&WM\D8%"%<6WM@2.U:(M\+4EO#M SS5AHR1[50FKF=Y&?K2
M?9B>WY5>6+ Y)SFG+'AN!4W HK <<C '>I$@W'!!JX(J>L63G&,4@*?V7&?2
MHI+7 QBM3R.*8\61TH R'M,C %5+FQ)0\5OM#436H(.:0(XR\L1* ",,O>L#
M5M%2Y5BR#<!^E=_>:?N)*C!K+N+3>A!&#[TO(M'SEX[\$/%K5AJT(Y@<;PW0
MIGG\NM>(>";)H/&OQ+U=;MG6..Y46[$;5W.%W8_&OJOXQ0:O8>'C+I5@EZ&<
M)-P2Z*>Z@5\P_#7PEXK/C37]0GT:2PM&DD1UO(CY=Y"YY!^G6L[-/0#!_:8T
MY+76M&\0_8EN[C[,;<LPR!M;*_H:X[X;?$Z71EN!DZ;:P1 QQPMC8Y;"@=MN
M3^N*]2^+FI>'_$FLVFEZE=_V+':@R^8TF!*6W#: 1VV?K7DKQ^#?"::J+:X'
MB SH1]EV[A&H&200/7GVJG0=6-I;=!JHZ<KH[6/XC6GB#Q+8G5='M3<B6.$7
MEF#!(ZEPRE@ORM\S,<D9^:N]_:%L=(D\3:')J&HOISQV3>41#YB-ESG=@Y'0
M5XII9L-<\0:3>:1&\6G_ &JW58KC*E 77*D^QY!KTO\ :X5QXA\/")7D9K1E
MPHSC+G'ZC'XUY$\/*%.I!ZGK4\0I5826AS%I;Z9+9VL"^(+-Q&\\@_=.N=Y0
M=_\ KG56/2+!D-O%K%M.OFE]J(QSA<?SS^5<-K.K?8H(='00L+90K7"#+,Y^
M9CGVW;?P]ZB@OY[9XD@8)<N,0Q$X9CC->34PK;?)&[>AZ"Q*23E+8[^_TZ+3
MM"#2WJRDRJJHG!/WL*,_C7A?Q"^)-U?W4&GZ?:O9Z>)$$NPE6E(. 7[X'I7K
MBQZ=J.F?9YI&N;U'$LRR$J\4F/ER.W4G\:\FU_PS=6&L1O)&UU \JGS0/5N]
M>UA,*J"4I;GC5\0ZM^78]E^.FF&74OA@$+C9*)&5?N_\LQR/S_.MGQ)=Q6WA
MJ_8$+-_:,+1R&/>5=4)! '3IC/N:R?C?>75CXK^'L2.AB<$.C+GC<H!'N,5I
MWD O_#E\^_R7M[Y9 ^_;N.Q@/YUZF^C.+JF0>+=8T;XEVL;Z]H:6U[Y87^T]
M+<QR/CNZ$8;GUYK]6?V0K;['^S5\/X \L@CTT('F^^P#M@FOQ[2/4X;@SW'B
MHP(3D0Q-D 5^Q'[)4_VG]G#P%)]H:[W:</W[]7^=N31S/D4;C7Q-GJLG2L;4
MON-]#6S)TK&U+[C?0U!H:FD?\@V#Z'^9JY5/2/\ D&P?0_S-7* "BO./B!K_
M ,0M,^('@ZS\+Z%9ZCX8NIF76KV=\26R=BO([<]#D\<=:]'H6JN#T=BM/J5I
M:W5O;374,-S<DB&&20*\I R=H)R<#GBK->1_%R9[;XD_#Z:-MLD?]H.K8Z$6
MY(KDO GQ \6V^B_"O6]4U^?7#XHLF-[8O:PQQJPMS(&CV(&#$C!RQ!SP!TH6
MJ;[?\'_(;6J7]?UJ?0%UJ5I826\=S=0V\EP_E0K+(%,KXSM4$\G / JS7S-?
MZCK>OV_PB\8:CKLMX-5U)+TZ1Y,2Q0%H)&6.(JH?*C@[V;)!Z=*T? WQ3\8:
MT/"FNS1:M);Z[<JEQ9W<%I#I\$3[MOD2 B5G7 ^\6W<_*.U<KU3W3L2W;7RO
M^9]$45\^^&O&OBVV\%Z'XOOO$LFJ&[UN33I-*^RP+"T)NY(5P50/YBA1SNQ@
M?=SR:WASXK^,-7BTKQ$(-7,-]JAMI+">"TBTV.W,S1C9*2)3*  >2<G(VBI6
MO]>G^8WI=_UU_P CZ+JM?:E::8D;WEU#:))(L2-/($#.QPJC)Y)/ '>OGW1?
M'WB^'POX?\577B.>]^U>)9-(ETQK6!8&@-U)$#D('W@ ?,&QP,KU)H^+M0UO
MQ=X1\(^*;W79U@NO%-JO]B-!$L,2+<E552%\S>-H))8@\\"FM6O5+[[?Y@]+
M^2;^Z_\ D?3-%?.FD?%?QAJ26WB&.#5S%-J_V-M/F@M(]-6W\_RN)21+YH'.
M2<$\;>:++QWXOB\,V'BF;Q+/<;_%7]C/IIM8%@:W:[,/)";]Z@@A@V.!E3S0
ME>WG_P #_-!+W;^7_!_R9]$1S1S;O+=7VL5;:<X(Z@^]/KRC]GK39[#1_%#3
M:G=Z@'U^] 6Y$0"8E.2-B+U[YS[8K:^+4WBR"QTIO#(NC;"Y)U,Z:(3>B#RV
MV^0)E:,G?LSD'C..>0GHD^]OQ#JUVO\ @=[17SW+\5]7UG4/#_A_2]0UZ[$E
MM=SWM_8:=;IJ(>&1$$31RYC4C?\ .P4YXP!G-/T#QGXT\9^*/"VAW&LS^'!/
M;ZG]L>"&V>XG\B2)8GY$B1OA_F'(^]QTPTK[>?X7_P A-VW/H&BO!HOB-XBU
M>TTO0X]3NFU4ZC>V<MQI5M%]JN8K<@"5?,5HD ++N)4\\*!GC#\,_$'QIXOU
M7PGH4OB"YTAYM6U6PO;J"&V>XECMU4QY)C:,/DX)5<=>/02OMZ_(;TW_ *W_
M ,CZ5IB31R.Z*ZLZ'#*#DK]?2OG7Q/\ $WQ7I=U_;%AJ=]>:9;>(K;2&7R+>
M.QEB:=(9 <IYK2 LV65E7/0$"J$^OZWX&\1^,UTW4=5OI]8\60Z?F.&WD>W5
MK99"\2E%!? V+O)' )!.<I:J_P#7V?\ Y)#M:Z[?\'_(^D[[4K33(TDO+J&T
MCDD6)&GD"!G8X502>23P!WJS7S/XL\2ZYJ>EC2M72_>&P\3:,UK<ZLMO'>.K
MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
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M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
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MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
M^NL#^TU]?TI1J8]?TH W_-'K^M.60&L%-1!/7]*M07@8CG]* -A6XI<U5CF#
M#K4F\#O0!(6P:8T@]:K33A>]4IKX*>OZ4 :GFCU_6D\\?Y-8;:D!W_2F_P!I
MKZ_I0!O>>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::
M^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFO
MK^E &_YX_P FCSQ_DU@?VFOK^E']IKZ_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ
M_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ_I0!O\ GC_)H\\?Y-8']IKZ_I1_::^O
MZ4 ;_GC_ "://'^36!_::^OZ4?VFOK^E &_YX_R://'^36!_::^OZ4?VFOK^
ME &_YX_R://'^36!_::^OZ4?VFOK^E &_P">/\FCSQ_DU@?VFOK^E']IKZ_I
M0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4
M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
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M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
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M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
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MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
M>N1GC'4UIZEJ-MH^GW-]>3+;VEM&TTLK]$11DD_0"DMY()(PT+(T>!@H<C':
MIY8H[B%XI466)P59'&58'J"#U%9.]M#9>9A^!O'N@?$KPY;Z]X:U%-5TF=F2
M.YC1D!*L58;6 (P1W%:.N7<EAHM_=18\V&WDD3(R,A21_*G:3HUAH%A'8Z98
MVVG64>=EM:0K%&N3DX50 ,DDT_4K)=2TZZM&8HL\31%AU 8$9_6B>J?*.&C7
M,>=6?Q'OU^ EKXRO"&U!M-2[D\A  6.,X!R*P$_:)U"66U^S^#9;BUNM:?P_
M;W!U!$:2Z568$KL^6,[#ELDC^Z:V+/X+:E#X'_X1"X\72W.@BT^QI$-/C215
M'W3O!Y(^G-6K'X'6%C;Z7$NIW+"P\1-XB4E%^:0JZ^6?]G]X>>O%:.SFWT_X
M*_2Y.J@EUU_+3\;'GWBG]HW6;G2;^30=-6UU*VL3)-;7,RF.&1+Y;>3#A,MU
MXX P<]:W)/VJO#MGXA_LZ[;3HXH[Y=,F$>KPO>).2%+"UP':(,<;^N.=N.:N
M/^S5IC)K 76;Q7U&WG@W>6G[HR70N=P]<, ,'J*WM%^$MWH5W.EIXGNX=(N[
MHWMUIT=O&!+(W^L <Y*HYY*CU."*A;*^_7[_ /('O*VW3TM_F<YI'QGU_P 2
M_$/P+:V^B#3?"NOQW\L=W+*LLEPL48:,X 'E$\G&6R#U'-+J_P 9]9\,_$7Q
M'I-WI,=]:K/86&CV]O<!9)KF=6(#DKA5PK,6R=H7@'-:_ASX'_\ "/\ BCPW
MJ7_"1WMUI_AY+F+3M,DA0)&DR[2&8<MM'0^E3>+/@G;>*/$UYK:ZQ<V%U+):
MW4/E1JWV>ZM\B.4$]1M9E*G@AC3TO'MU^_\ .WR!7M+OT]?\K[];&EH_Q.-]
MHGBB>^TI[#5/#HD^VV F$BDK'YBE),#<&7H2!]*XR#]I>.UTNWNM9\,W&GRW
M^FV^HZ9:P72SO=":5(HXS\JA&+R(.21@YSVKMM&^&,6G:)XEM;K4Y]0U#Q )
M/MVH.BH26C\L;4'"A5Z"N<U7]G;2-9M-)@N-2O!_9FCP:3;R1A596AECECGS
M_>#Q*<=*2WUVT_)WM\[6N/IIOK^:M^%RKJ/Q\U'2_$]CX5G\(./%-W<K EFN
MH*8-K1/(LGG;.5^1@1MR,< UUWA?XI6&N>"=2\17T)TI-*>ZBOX'<2>2]N6$
MNU@!N'RD@X&?2L.T^!L;>-=,\6:IKUUJFNV=R)S,T*1HZB%XEC"#A0/,9LCD
MFI[?X$^%K;1=9@OM&LO$5S>7%[=I-?6T?G1FX9F:-)-I*#+8!'UI2NHNV]OQ
MTM^HU;F5]M/UO^APGCC]H[Q!I7AMY8O"[:)=7>FQZKI]U<7*W"F%IXDVR( -
MK[9,D9('J:ZC4OVC-+T7PY-J5_ID\-S9WEY:7U@L@:2W^S EGZ?,&7RR.F?,
M'-<!I/P-\2>.KR*S\12:MI6BV>C)ID/V]K9Y5*S1NH3RF8. (@"[;2?[HKL_
M^%)6GB[X@>/M4U:PN['2M9L5TP0R2I^];!62YC",VW<HC )P3MY JW;IY_GI
M^'YW)C_>\ORUM\]?E8V)/BWKUK-INGW?@F2VUO57 T^W.I1M!*GE[W9Y NY"
M@X(V'GH3UK$D_:6ADO;+3;;00FM227,%Q8:CJ45GMF@D$<D,+N-LSDG<H!4%
M2"2*WI/@]J=S+IU[<^,[^XUC2V'V"[:UB"0KLV,&C ^<L.I)Z@8Q5&^_9^CN
M_#4^B+XBN7M+][B74UO+2&X%W-,VZ24!A^[?G"E>% ''%+KY?U;_ (/GMH-;
M*^^G_!_2WD0ZY\?&M_"6ORP:1+9^)-/O;G33ITTBL8W2(RI,2!AD,>Q^/7&>
M*J7OQ_O?"_A+P_JVKZ-;2V]W:6,DUR^IPP2323JN3!!RS ,V""5/!P#UI+?X
M'0:E\1M9OC:WNF:6F@)H<4D\B/\ :9/+:/[2JAB<K$0F7 )],"F7/[+=E);7
M=K!XBNH+>[BLDG)M(GE8VT:1IMD(RJ$1@E!QDD]Z%;KY?A=/[]_PZ"?^?XV:
M^[5?+S,S1?VE+G1O#D,OBB/2+75=0UG4;2R%YJ\=G;>3;S,I+RN@"E<!1@$L
M<'C/#]5_:>F\2^"]:U'P)HAU:?3=+-]>7#W*>7:.7D157 (F.8G;@@;0#GG%
M=7:? C^R9+>YTWQ'<V=_9ZA=WUE<_9D<PK<L6GB8'AU+'(S@C ]*9XB^ \VN
MPZF8_%VI6EWK&GIIVJW(AB=KM$9RC8P C 2,N1_#@=LTGJOZ[?U\_(I:2U[_
M *_Y&UXM^**>!OASI?B._@CGDNA;1L9)A;P(\N!NDD((C0$\L0<5QWB/]H6Y
M\-/9W-WH;D2Z3/??8K:]AGCE*W4$*LDRY!!\[(Z<=0#7IFJ^$[B[\*VNCV&K
MS:9);I&BW*PI+O5 !M=&!!4@<CBO-/\ AE?1O)=1JUQ%)+'<++Y%O''&6EN8
M9V98QP@S H"CCDGK5:.>NUW^6GXDK2"OOI^>I8;]H._LKO4X]2\(/96^D:A;
M:?J4ZZBL@B:XV>4T8" R<.NX?+C/&ZLW6?VD=0MO"4VLOX8ETFPNY;NPT[49
M+E9LW42R%-\04$(_E-ALGD8(&<UV&M_!*QUJ/Q0KZE<1_P!O:C9ZC+M1?W36
MXCVJOJ#Y0SGU-<+X/_9[U+7?!J:;XNU6\@MH;Z^NK;2PL3"&25I520NI.X!)
M"0IZ$\]*AZQMU_X"O\][?CH7&RU?];_\"Y):_M9Z'9):Q:A+IKO!':QZ@6U2
M&&[,TJ(6,-H?FD52XSR#UP#BO0O&_P 2;_PWXLT/P[I'AYM>O]5M;F[5C=K;
MQPI"8]Q<E6//F # ZX'?(S_#WP8F\(3LFA>)[W3-/N# ]W:I!&QEDC14+JY!
MV;PJ[@ ?PJO\1? OB+Q)\6?"&JZ/>S:39V.G7\%SJ$2QR!&D,.Q#&QRVX*QR
M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
MB2,*=[;TV_> Y!S4'Q#^.?B?0[*.PA\.Q:3XA^W:63%/>B6)[6XNDA.'"<-D
ME",?+G(+8P>AT?\ 9R\/Z3I'B73#=W=Q::]9Q6MP'(#JR;CYH8?Q%F+>F0*3
M5/@(/$$-U-JWB6\OM9D-EY&H&!%\A;:=9XP(QP<NN6)Z^U"LI*^UU?[]?Z[%
M/9V_K;_@[=3#?]JWP_)K,NG1O88>YFT^'R-5AEO!<(K<M:CYUC+(5#GOC( -
M,TG]IB9]$.I3^')I=)L(=.;4=2-VBNGVI8RK+$$^;!D&1D<=,]*Z_2OA!<Z,
MEW8VGBB\AT*YDGF;34MXP-\H.\;R"=FYBVWU[UDV_P"SAIEOX+UGPX-8NS!J
M<>GQO,8UW)]E$87 Z?-Y8S]31"WVO+_@BEY>?_ -7P5\9!XW\7ZCI%GI40MK
M*YGM9IAJ,1N87C.,RVQPZ*W\)&[(P2 #7I5>=Q_"$3>.[#Q+J6M2ZE+ITTLU
MFDEK$DL7F*5*-*H#.@!.%/MG.*]$J5\*[C?Q/L%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 9.N??M_J:*-<^_;_4T4 +X=_X\W_WZU:RO
M#O\ QYO_ +]:M !1110 A.*X[QIKWE.MA#(59AND8'&!Z?C757DQBMI''!52
M17EUG ]UJTS7!+-)ECO&<\UR8BHX)16[.BE%-W9XGXP^&*^(OBQHGCV>]DM7
MTJSEMTM$QY<A9C\S'UQM'N !7-S>()KC7I8?,DC</U(SM'7KZ=:^B-9\/12J
M^T!=H.$/>OFW1-'U>7XK:A:S6]PUHL@VHT!555>A+8P02!7E2GRV3/4IT^=-
MKIJ/\*?!-=+^-D_Q)M=0N9;FYLVM9K L/)/RJJD?]\YQ7U_\/]<>^T]8)C^\
MC''/;TKSW3?#$4%P9/-&'P3'^'M7;:1;G3[F">*,!0-I4'J*Z*,VIHY*RBXG
M>#!Z4M,B.5S3Z]@\X***XCXD^&O&/B&Y\//X4\4Q^&XK2]6;44DM5F^V0<9C
M!/W>_(]>M'5(#MZR_$?B;2_"6EOJ.KWL=C9JRQ^9)G+.QPJ*!DLQ) "@$D]!
M6I7G'Q;L+V/6/!/B"#3[C5K'0]3>XO+6T0R2A'MY(A*B#ERA<' R<9P":.P=
MSJ/"_CG1?&+72:7=2/<6A"W%K=6TMM<0Y&1OBE574'L2,'M4?BWXB>'? B@Z
M[J2V -M/>?-&[_N85#2M\JG[H(..I[9KQSXP7FH_$+1KR;P]X7OX=.CNK)=2
MU*?2I$NK^T$A,T*V[A)98U!!*'AAN !S7EWCCX<ZG_8VK#0+#6M1TZ?1M92"
MUC\/R6$$,CVZ*$@M^60.P.%(7)S@&C=-^OY7_$:2NEWM^9]IV]Q'=V\4\3;X
MI5#HV,9!&0:DKR'XMZ->7_@3P?%+I]UJ.C6]_9OK6G00M*\MJ$(96B4%I%#;
M2R '(!&#TKS/7M-@T5O%;^'?"'B"TT35_"EUIFEVJ:9<,3/ND.T1X)@0[LJK
MA !P .E$_=YK=+_@K_CL*G[ZC?2]OQ=OPW/H5OB/X>&OMHHU -J:7:V+6XC?
M*S-%YH4G&/N<YSC\:Z6OCG0_AS=-KFFWNK^$[J=(-1TT++<:6\K1?\2I(]P&
MPD!90 6'"L.<8K*UK0=>U+X6^%/#\/AC7O[2T3PI?:=>JVF3*JW&U%"(VW#Y
MVD@H2".AJY1LVENO\K_UZHF#YU%[77Z_U]Q]MT5\G>,/A+'IGBZ\LTTNXTK1
M7TNV&BMH_AUKUK>XY\YHW4@6\Y;:QD;;N[MP:V])\,3Z'\9(KVWT>_UO49]4
M!N;W5=)FAN+>,Q!6=+U"8WAX&(F;@D_+FI2N[!?W;_UM<^EJ*^=OB9\.=0\1
M_$GX@ZMI^CM+J\7AFSCT;49("=DX>?>(7. )-I R""-PZ9KB[7X>NMO;7&GV
M>KR: &L_[>T.#PU)IT%S&KY<M$3NN)1_$54[EX);@4HZ[Z?\.U^A;TO_ %T3
M_7\#Z]JLE_$^H2606;SHXUE9C XCVL2!B3&TGY3E0<C@D $9^1OAQ!::-X[G
MUW1= U2#PSIGC#48VM;;3IGFMEETZW6/]PJET0MP!M&T$9P*Y_1?AOK>K065
MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
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MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
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MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
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M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
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DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20220630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
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MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
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M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
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M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
MQ6WX;\(Z1X0AO8M'LDL8[V[DOKA49CYD\AR[G)/)/IQ6KE=OS3^]M/\ !71#
M6UNC7W6E^;:?R/B+4?B?XSNM"\0?$[_A9MWIVM:9K#V5OX(#K]EDC63:(VA/
M+,P[U4UWQOXNU_Q+\9]1?XL:OX3D\+W$-YIVA+=*$<F!6,95N2F[(VKQG-?7
MUW^S[\.K_P <IXQN/".GR^)%;>+YE;.[^\5SM)]R,UYOX?\ V0]!U'XD^.O$
MGCK2-(\0PZMJT>HZ4 TAEMU6)5(DX4=5SMRPK*/1;:/Y.\=N[T;U-)M-\R77
M\/>T\DM%H>(^!3K7B'X]7?BK4?%NK6&I7/@Y-3-CYX1'=EQY(7^X#\P [U6\
M.>(_'GQ"E^%NC6_Q"U_05OO!%QJ5Y<65R=\TJ3R ,<Y&[  W=<"OLO6?@MX)
M\0>);'Q!?^'K6?6+& VMO=@NC1Q$8*X4@$8XY%-T?X)>"- NM+N-/T"&VFTO
M3WTNS=99#Y-JS%FC&6Y!))R<GWJG9JR5M[?^3V_]*C]Q*NFF]=%_[9_\B_O/
MD;P!X\^(R+\)?%NH^/M3U*/6=<.@W6DR[1;/""1YC #YI#C[QJ+6_'NH7'P4
MUG4-1^(_B;0M;B\7ZK8Z7!H]Z(YKT^?MCA);HB #Z U]?6GP4\$V.G:+80:!
M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
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MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
MM?"WAFXT6^E\/ZG;:E?V]BT9AFDLB$-PX7Y3O;C?SGI0KV=UM?[_ '__ )%?
M>59.UG_5H-_^E/[CZLLOCEX!U*]U>SL_%>F75YI,;2WL$4P9X57J2/;VKC?"
MO[6'@_QSH=AJ>A75M<Q76M1Z,T=Q=K Z,^[8P!!W%MA(4<D5\E_LZ?!3Q2OQ
M#TBPURT\5V-UHJ3"YAN?"EG#IT@((:,WPG#SJWJ5;Z5O^%_".K1^!O!N@6_@
M'6M)U+1?B1;W%],=),:30%YRLJLH.Z-%P"QP!N'K5PBG**;WY?QDDW]S,Y-I
M2MTO^$6TOO1]GR_&+P3!XR3PG)XGTU/$C\+IIG'FD^F/7VK8\7^--"\ Z)+K
M'B+5;;1],B(#W5T^Q 3T%?&GAKP_=>%O%6I^$M=^"FI>+O%%UXBDU&V\3%1!
M9^2TA996O5)9"H/W,<]Z]S_:LUS6]"\(:%+I_@L^,=.;4HUU.&WTU-2N;:':
MWSPP/@,V<+D] 365_P!W&2W=OQM\]+V?I\EI;]Y*/17_  O^=KH[:+X[?#Z;
MPS;>(4\7:6VB7,WV:*^$W[MI/[N?6KOAWXO>"_%NCZIJNC^)M.U#3M+8I>W,
M,P*6Y'7<>U?!MI\*=?U3PKJ>G77@O7[2RN_'%O=KIUYIXW):D [B(5\L#UV\
M"NX^)?P6UQ_$_P ;]+\(^%IK72;NQTFX@L[6V-O;7_DS;I8HV "EB@(('K[U
M3T7K^'NQD[^EVOD0M[;V_'WG'3[DSZ,\+_M,^%/'/Q1L_!_AN>/7([FP>^&J
MV<ZM"NTX*$8SFNJ\9?&;P/\ #W438>)/$^GZ->"W^U^3=R[6\K=MW_3)Q7S'
M\#HQXA_:9T?7](^%6M_#[18M DM97U#2_LBRS#C)"Y4>@R03UQ4/[1.K6.A?
MMA:#?ZGX'O/']C!X4E:32["TCNIES/@2+$Y ?!(&!R-V>U$M.1=^;\.:WY((
M>]SM].7\>6_YL]]\??M'>&O!$7@R\22/5=(\37GV2'4K>X40PC&?,8GJ*Z2S
M^,_@;4/"%UXJMO%.FS>';5S'/J*S#RHV'4$^M?&>C_!GQ#+X5^$]KJ_A&\&F
M7/C";4)-'EM6E%C:.25690"$&.H/ K6O]*\3_#&X^,"Z'\.)=6\/3>)]/=;!
M=&\]!:F$^=-:P, LK!@H^7@$\]ZIJR??_@P5GZ<S^X;WC;7]?CU7KRK[SZJM
M_C]\.KOPF_B:'QAI<F@),+=M06;]VLA. I/8FJEQ^TK\+K2".:;QSH\44D3S
M([3X#(K[&8<<@-Q7Q'?_  X\1:KX/\>PQ>!O$5A::GXBTV\M],N],57:#<NY
MMD"[!@=0"=O>O<_'WP=LKW]I;2DC\%Q3>&+7P3=QQ!-,S9QW)D)51A=@D.20
M.O.:F6B4N]_PAS?GH.*3;7]?$E^3N?0.F_&7P/K&O6>B6/BG3+K5;R$7%O:1
M3@O)&1D,!4-C\</ .I^,Y/"5KXLTR?Q)&Q1M-2<&4,!DC'J*^0O GPCU#0?"
M?P0O[7P9=6VNVWB"5[^7^SW29(N=OG-MRJ=/O<5G7%KXL\:_$CP=>WGPRUGP
MWJ^D^*V.I7VGZ'#!8B)BXC99$!EFR "TG" DYZC%\JYU'SM^*U_$S;:IN?E=
M?^3:?^2_B?:J_&/P0WC/_A$AXGTT^).G]FB<>;GTQZ^U-O\ XS>!M+\8Q^%+
MOQ3IEOXBDQMTYYP)3GIQ7R9X$\/7?AC7G\&:S\%-2\2>+_[?>_C\5R*(+-8F
MDW+,;U<ME1_RSQSC%8>O^ ]9M+;QE\/+KX4ZKJ_CO6_$$FHZ?XVBM4DM(H'F
M5TD:[)W1E%!'E^WO4QUY?/\ ';;TN]^WK;26CDNS^[?5^3LMN_I?ZV^*_P"T
M/X,^$EEJ*ZGJ]G+K=K:/>1Z,+@+/.JC.%SW-:O@3XP^'?'6D6MS!>PVM^^E0
M:O<:=)(#+:P2IO5G[8P#R/2OC'XE^#M7\'7_ ,4-&U_X6ZS\0-9\0VJOI'B"
MPL!<Q0!8L%3)G,9!YPH)/85I?%W0M?\ A[X$^%&MZ38W%OJWB#PS#X*OX'!B
MDB>18S&74C.5_? @\BDKN-UJVTEZM2LO_ DDQM*Z6V[^2Y=?N<FCZKNOVD?A
MA8Q>9<>-](A3R1<;GGQF,G 8<<C-:?B/XU^!/"'A[3M=UGQ5INGZ1J(!M+R:
M8!)P1G*^M?-^D? "SMOCW)9:AX5;4M"TSP;';6T]U9&2V,^W!"L5*E^3P.:\
M^\,)XQ\.?!OX;>'-6^&&JZUI<EKJ,#R0Z)'<ZA:W#7,@B3%P ((]I#;V!SD>
ME#^&ZWZ??)??[J^\275[:7^<4_PNTS[-U?XZ?#_0;+3;S4/%NEVEKJ4+3V<T
MDP"SQJ,EE/<"BR^.?P_U*^T:RM?%VE3W6L1^;81)< M<+G&5_(U\;_"GX3:M
M?ZK\&;+Q#X/U&>PL#J8O+?5--9HK<G)02938!G&.Q[4W0/@Q>:=\*='N8?!5
MW;Z]!\2&D61=,=;F.R$SX8?+N6'&#G[O>M(Q3FHO9O\ #F4?UOZ)_*&VHW6]
MOQM)_P#MMOF?8]C\9?#_ /9_B34-5U"PTG3M#NFM;BY>]615('\6 -I_V>37
M0>#?'7A_XAZ*FK^&M7M=:TUV*+<VDF]<CJ/K7Q5XD^'7B<V7B75W\(ZGKFEZ
M;XZ35KS11;'S-1M%')C1\"4=\#.<5]#_ +-<]KJT/B76=,^&-U\--)O[Q7AA
MU F"XO"$"M(]J/E@Z;0 ?FQFHA[T;OLOQ47^-W]WK9R=GIW?X.2_))_/[^IU
M/]H+X<:-K$NE7WC+2K74HKD6;VTL^UUF/1"/6KOB#XT^!O"FOQ:)J_BC3K#5
MI1&T=I-+B1Q(<(0.^X]*^$_$)BO?%_QZT./X8ZEXRUC6M2-EIVKV%E'<+8S-
M&0OF.3NB7/.\#'%>S_#3X-ZC;?'^S7Q1HAU)],\#Z?9)JMW:&6W6\1=K%)&7
M:7!'4'-*'O1C)];/_P E<G;[DOFAU+0E)+II_P"3)7_%_<SZ%_X71X%_X2__
M (17_A*M,_X2'_H'>>/-_+U]J\J;]M/PM>>-?%.@:5#:W<?A]2;B]N=32W20
MJRJVU64G"LV"WJ*^?Y_AWKDNBW7PT'PLU4?$"77?MJ>.?LJ&S2+S@XF^UD[L
MA0?DKH?$OPGOXK+]H^2V\(W#7=W=VXTV:#2R'N%(B,GD$+E@6!)VY&<YHCT;
MVL_G\/\ F_N^Y_:4?-+TW_.WX^C?U!X9^-^F^(?&VO>'Y+;["ND:=!J4U_).
MK0LD@SP?0>M:WACXR^!_&>E:CJ6B>*--U*PTXD7<\$P*P8Z[O2OD[Q=\*_&G
MBJ'XIV&CZ5J%O>7WA/3H;9WA:);AT ,D*NV%+$ @C/?FN7^!OPEO]7L/&5[K
MVF>/;RQ.C#3KK2I/"MEHKW!#!AY!6XQ*RG)RR\YZ]J;Z^2;_ #_R2_4F.J3?
M5I?A'_-OY?=]O>!/BYX-^)S72^%?$EAKK6IQ,MG+N*?45UU?(G[(;:];^/-2
ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
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M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
M,TF[*[&E?0EHKYHT3]HCX@>(K!O%6F^'-)U#PDMY]F;3[5Y9-41=V-Y"Y7'&
M?NUW&O\ [1.CZ#\4-!\*W+):PWT'FSSSK)YD3N/W4>T+U+'&>WM78\+534;:
M]O17.%8RC9R;LM->FKM^?^>QZ_17$V7QI\%:CX@_L.WU^"35O/>W-KL<,)$^
M\#E<#'KT]Z=H_P 9O!6O^)7T#3_$5I<ZNI*_9EW#)'4!B-K'V!-8>RJ?ROOM
MT[F_MJ?\R[;]>QVE%<1XA^-?@?PIX@71-6\16MGJC$#[.P=MI/0,0"%_$BE\
M2_&GP3X/OVL]8\06UC<K;K=;'5SF(G 8$*0<^@R:%3FTFHO78;JTTVG):;Z[
M';45P4?QW\ 2W.F6Z>*+)YM2 -JJECOSTSQ\I]FQ6#J?Q7U>V\>>-=#3^S;>
MST;1/[1M[FY20@29/,I4DE!W"KFJ]C/JK;_AN3[>GI:5]4M//8];HKSVP^,6
M@Z1X5\.7WBC7=.M+O5;59TEMEE%O*=H+%-PR%]-V#6QX>^*7A3Q5H5WK.EZY
M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
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M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
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MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
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MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
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MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
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MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
MP2]+-/NONTO\]ST/1/V@=/U&_P!-CO\ 1[S2+'5=_P#9U[/)&ZW.T%L%5)9"
M0,@,!FKGP^^,S?$&YL7MO#&IVVCZ@CR6FJL4DB=5./G"DM$3V#@9KD/AK\&M
M3\)3Z5;3>!_ -D=-0H=>M[,27=R0,(P41H8FZ9.]ZJ:'\*/$N@^+[3Q+'H&A
M^%FT\7%Q?CPW?3)#K+%3M5K79MCR0"3F1L]Z/=3UV_K^NGHR?>:\_P"OZZ^J
M/<O$FHG1_#^HWP+*;>!Y<JH8C )X!X->.:5^TL;FT2&U\,ZKKL]IH=IK5]=1
MF&%5AFBW[B"V-PP?E&?;->E>9?\ CGX<2F6P_LG4-1LG7[)-)N\IF! !;:/S
MQ^%>6> O@9XB\-6?B.*[EL2VH>$[#1(?*F8@7$-O)&Y/RC"Y88/7':H:<>?N
MK6^Z7ZV+7++E\_\ ./Z7.IO/C]97$]E;^'-!U'Q3=3:>-3E@L-@:" ]"0Q&Y
MB> HR37.Q?M"7.E>/_$=CJEE/)I:7VEV-A;B$13P-=6_F-YN[!X.<CJ.E5/"
M7PD\<?#&[T[5= BT?5=0DT6/2[VVOKIXHHI$.5D1E0EQZKA<^HJKXC^ WC#7
M->\2:[)<Z5)J5S?Z5J=LD;/'#-+;0".5&!#&-22V.6.,9K3W5/RO^'-_\C_7
M;-7<?.VGK9?K?^M^]\3?'S2/#&MZ[I,VGWEQ?::;:.**$*6NY9SMCCC&>N>.
M>*X&X_:"\0P>,O%UCJFF7/AZVTK^RTBLWABFF5YY&5CO#;74@#D'CGO27WP0
M\<>)/%&M^*KXZ/IVL/=6%_I]K#.\T(>W;)CD8JI(;IN [].*37?@[\0/&WB/
MQ/K6K0Z+I[:D=+6UM+>\>41);2L[AG,:Y)W9!P.N.,4H+X>;>^OII_P?N^^Y
M?:M\OZ_KJ=-#^TQ9N+J\E\,ZG!H-GJ8TJYU=WC\N*4N$!VYW%<L.0..]3>)?
MVD+30?[3N[?PSJFJZ%I]^-,FU:V:,1"XWA&4*3N(5B06QC((KG[WX#^([CX3
M^(?#:RV']H7_ (@&IQ,9F\L0^<CX)VY#84\8_&O._'-U?>'O#GB7P1H.H:1J
MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
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M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
MKMM:DG;PI%<0HIMPOVD2J5Y^;Y<9]\UZI10L14244]O\FOR;0?5J3DY6U?KW
M3_-(XWXF?#F/XCV.F6TE\U@+*]CO RQ;]Y4YV]1C/K78D94CU&*6BL7)N/(]
MO\_^&-U"*DY]79?=?_-G!>!_A'9>$/!%_P"&;BZ;5+.]EFDE9XQ&<2,21C)Z
M9ZUR&C_LT+9ZAID>I>+M2UCPWI<XN;'0YXU6.)U.5RX.6 YX(KVRBM57J*3D
MGJ_Z_IF4L/2FDI+:_P"._P GVV/FB/X1^(O%'QA\?7%MJVK^$;:X\M([V&US
M%=)_$HW8!^H/%=QJ7[-^E'PYX=LM%U:\T+5M"+M::O"H>3<_^L+*3@[J]?HJ
MWB*EHI.UK?@K?TMC-86G>3DK\S?XN_\ 3W/)+CX "]^']QX=O/$U_?7=U=QW
MEQJ=TOF,[JV<*F["CV!K>^*/PJ7XD:%I5G'J\^C7VEW4=W:WT$0=DD0$ [21
MGKZUWM%9^VJ73OL[_/3_ "1K["GRN-M&K?(^;?B?X#OOB7\4O"ND'1=69-'*
M_P!H^(+B#R[:ZAZE58'#'/:OH'7-*?5=!OM.MKC[ ]Q;O DZIN\K*XR!D9Q]
M:T:*)U7.$8/97_'<5.BJ<Y5%N[?<MCSSPQ\#_#?A_P $1>'IK&TU%Q"T<E_-
M:)YLC'J^>2#^-<A!^S$=/T;P_%IWB^]T[6=$,L=KJT-NN_R';<8F0M@X).#G
MOTKW*BJ^L54W*^^OY_YLEX:BXJ/+HM/R_P E\]3R_P"'?P,MO UOXGAN=8GU
MU=><O.UW$ PRN#D@_-^E-^'GP!TCP#X&USPT+R:_CU=I//NF7RY A4*J#D_=
M'3ZUZE14RK5)73>]D_EL5&A3BXM+:[7SW^\\(T+]EUM'NO#LTGC*^O4T*[6X
MLK>2U18T0'[F <D_[1/X5UEE\%H;/2/'5B-5=AXIN))W?R /L^Y0N -WS8Q[
M5Z7153Q%2=U)_P!73_-"AAJ5.W*MO7LU^39Y)J'P",J^#Y=/\2W.EZAX=@^S
M)=16ZMY\9^\"I/RY_&N>U7]E"'4!XAM8/%^H6>CZO<F].GI A5)R02S-G+CC
M[O':O?**I8FJG=/\NKO^>OET)>$HM6Y>W?HK?EIY]3Y;^,'A?Q%X4^(.CZGH
M^E^(Y+9;!+.ZU/PU +B6Y"C&QHCPG^]DUK_"SX!S:U\(;S3/$45WHEY=ZQ)J
M]DS$&YM"<"-F_P!K Y!]:^C:*OZU-4^1;]_G?\S+ZG#VG.WIVZ;6_(\IT/X$
MR6VE:S!K?B_6-=O]2B$)O3(8#"H^[L53@$>O>JW@W]GZ30O&5EXCUSQ7>^)[
MO3XS%9+/;I#Y(/!R5)+G'<UZ_167UBI=N^_IZ?+Y&WU6E9)K;S?KKW^84445
MSG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5]0TZUU:
MRFM+VWCNK692LD,RAE8>A!JQ10!\2_M!?\$\;'7VN=;^',R:=?MF1]&N&Q#*
M>O[M_P" ^QXYZBO@KQCX'U[X?ZW-I'B+2KK2-0B)!ANHRA89QN4]&7T(R#7[
MGURGQ!^%OA?XI:0VG>)M&MM4MR#M:9 7C/JK=5/N* /P_HK[B^,/_!-O4-/\
MZ_\ A]JGV^');^S-0;;(!Z*XZ_0\^]?'WC#X>^)/ %^UGXAT6\TF=3C%Q&0#
M]#T- '/4444 %%%% !7=? O_ )+%X/\ ^PE#_P"A5PM=U\"_^2Q>#_\ L)0_
M^A4 ?MC7@G[8/_(C:9_U^?\ LM>]UX)^V#_R(VF?]?G_ ++0!\A4444 %%%%
M !1110 45O>%_ FO>,KI8-(TV>[)/+JI"#W+=*^@_ /[(D4?E77BJ\,IZFQM
M3A?HS=3^&* /GKPCX)UKQSJ0LM%L);V7C>R#Y(QZLW0#ZU]4_"O]F'2_"AAU
M#Q R:MJ:X80@?N8C_P"S&O8M"\/:;X9L$LM+LH;&U3I' @4?7CO6C0 U$6-%
M5%"JHP% P *=110 4444 %%%% !1110 4444 %5=5O3IVF7=V$\PP1-)M)QG
M SBK59GB?_D7-4_Z]I/_ $$U,G:+:+@KR29X-IG[2?C>Z\)0^+[CX<1KX4/S
M27UOJR22*F[:6$> W!]<5[>_CC0[3P]9ZU?ZI::5IUU&DD<U_.L*_,,@98@9
MYKYO^!GP&C\>_"?0KO4_%WB%M)N-S2:%'=8LR Y^7;CH<9K:^*5IX;T'XR>'
M$\;6T9\#VVEM#9B[C,EK',,#YQ@CH!C/>O9KTJ+JNC#1IO:^R6VKU?H>!AJU
M=4%7J.Z:6]MVUKHM%K=W/9O&'CH:-X3AUO1CIVK132QK')+J,4$#JQQN$K':
M?89YJ_J?CGP_X?\ LD>LZYIFDW%RH:.*[O(XR^?[NXC=U[5\F3Q1#X9^,9M&
MBD@\'R^(X&TI&4JFS<,E >BYZ59^-=AH,'CJ^O;S4;".ZDTN.-K'Q%I^^*4;
M>#;2CE6Z],&LUAHW47^6OPIV_$V>+FDY)+[]/B:NON[GUSJNOZ9H6GF^U+4;
M73[(8)N;J98XQGI\S$"BUU[3;W2_[3M]0M9].VE_M<<RM%M'4[P<8_&OC3Q[
M+=ZYX+^%EQ<11^%_#ZP/&_\ :5NU[;0,#@%TDR2I &-V::OA^[@^ _BZ33=6
MDUS1)=5MI)Q8:>;2+RE<>:8E!QM(V] .E/ZDK:RL[V_\FY=>GGN3]?;DK0NN
M6_G\/-I?7RVW/I"[^-FGS?$'PYX?T9['6['5HY&;4+2\618BI(VC;D'IZBI/
MC=\9;3X/Z#;7)B@OM4O)UAMK&6Z6#?D\NS'HH[MT&1FO$M#N? %U\?\ P+)X
M$M[:*W^R.+AK.+RXRWOP,MZFNW_:XT33]0T?P=-<V4%Q,=>MK??)&&/EN3N3
M)_A.!D=\4O8052E!IV;UOONT5'$5)4JTTU>*NK:KX4_Z\ST_2?B+I\7A32-6
M\37VE>'9K^)9!%+J4319(SA)<[7'N*V[_P 5:+I5O:7%[J]C:07;!+>6>Y1%
MF8C("$GYB1Z5\W>*+7P;X>^-&KQ?$"QMH_#R:7!%HD=S!NMHU"X947& V>E<
M2^AOJO@/P)I]]!+_ &#>>-@MC;W(.39MG"X/\)YIQPL*K33LG;TU>WJNI,L7
M.BG%V;BGZZ*]]MGT/LW3=;L-;TT7^F7MOJ-FP.R>UE62-L=<,I(KQ+0OCA\1
M_&/]H3^'?AK:ZGIUK>2V?VEM;CA+,C8/RN ?3\Z]GTO0=.\-:+_9^E64&GV,
M2MLM[= B+GDX X%?-?P-^%5]XMTW6]4@\<>)-!B37;I38:9=>7 V'!R5QU.<
M&L:$:3<W+96M>_?R-L1.LE3C'=WO:W;S/:M%^)5W?_$JY\)7>EI:26^GQWDD
MPGWD,PY3&,<>N:Z?3_&&@ZMJD^FV.M:?>:C!_K;2"Z1Y8_\ >0'(_&O"O%D5
M\?C1XXCTTNU__P (T@B*_>+;?YUXQ\(] BN?%?@<V_B:SCUR&\\R6PLM#"7<
M>"?,6XF!!(*[AEL]:VIX:%:*E>VB[];_ (:&57%SH/EMS:^2V4?35W/MA?&W
MAU[*\O%UW36M+)_+N9Q=Q[(&_NNV<*?8US.M_$Z?3->U2VM[73[S3K70Y-7B
MN$U*,S2E>B^2,OL(_P"6F,=J^=/B'?Z>_P 7[[5;6SNI_ ":A"NN/"?]'ENE
M/WL=P#UKN/&4\%S\:O%,ULRO;R> )VC9/NE2W&/;%9_5THJ7=-^EHW_X*\K&
MRQ+E-P[-+UO*W_ ?G<];^'?Q8TCQOH>C3S7MA8:SJ-NMP-)^UJTP!'93AB/?
M%&@?$AM9^)7B;PO)9);PZ-!#.+OS<F3?G.5QQC'K7R5IQ\&W?PQ\&6GARU2/
MXB&]A8O#"5N3\WSL7QDICISBN]^($.K3>)?C5'I8D;4#I%D"(<[BN?WF/^ [
MJWJX:$9RMHO>W\FM?37\#FI8N<X1OJ_=V\[W3\]#Z;T;Q;H?B.:>'2M9L-3E
M@.V5+.Y25HSZ,%)Q^-<W\7OBC#\*_#UM>FRDU._O;I+*SLXV"^;*V< L>@XZ
MU\U_ +0[9_B;X;N-,\3V-Y<0VQ:XM=+T06VU,?,D\BXRWUS7M?[3=SH:>$=.
MMO$FB7>I:/<7JK)?6<FU]/;!Q-T)Q@M6%3#QI5H0O=/Y=?,VI8J=:A.=K-+3
MKTOT[?TB[\//C/J/B#QC/X3\4^&V\,>(%@^TQ0K<K<1RQXSD.O?':N]B\9Z!
M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
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M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20220630x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220630x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #I!#@# 2(  A$! Q$!_\0
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ML<\WE2!HF8@+N0KN&2>N,5/X=^)WAGQ7>-:Z7J8N)A USAH)(PT2MM+ NH!
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MT?VC;_W_ /QTT 6:*@BO89G"(^6/;!J>@ HHHH **** "BBB@ HHHH ****
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MVC;_ -__ ,=- %FBH8KN*=MJ-DXST-34 %%%% !1110 4444 %%%% !1110
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MJX9?C9X"&/\ BK-*_P# E:?_ ,+M\!?]#;I7_@2M/V<^S#^T\#_S_A_X$O\
M,[:BN)_X7;X"_P"AMTK_ ,"5H_X7;X"_Z&W2O_ E:/9S[,7]IX#_ )_P_P#
MH_YG;45Q/_"[? 7_ $-NE?\ @2M'_"[? 7_0VZ5_X$K1[.?9A_:> _Y_P_\
M H_YG;45Q/\ PNWP%_T-NE?^!*T?\+M\!?\ 0VZ5_P"!*T>SGV8?VG@/^?\
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M1_POCX>?]#EH_P#X%+1[.?9A_:> _P"?\/\ P*/^9WE%<'_POCX>?]#EH_\
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MO/SXY)-=_P#L\ZO=:Q\(]$>[<RS6_G68D;JRQ2O&A_[Y4?E3E323:>UOQO\
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MVV?5*Z[K5&;1116AYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&33]5>WDAVJ 8R2C*R'&?NAAG[U;?_#)7Q"_Y]+'_P #%H_X9*^(7_/I8_\
M@8M"E03NI?CZ?Y()87B645"6'DTG?^&M_>_N].9V[7TV1FS_ !R_MII!KNB?
M;HDU"34+6.TO6MA$7P6B?Y6\R,D X^4Y)YYKS;5]2?6-4N[Z2..%[B5I3'"N
MU%R<X4=@*];_ .&2OB%_SZ6/_@8M'_#)7Q"_Y]+'_P #%IQG0A\+7WG-BLMX
MBQJMB,/.6M_@U^;2N]]+[;(\9HKV;_ADKXA?\^EC_P"!BT?\,E?$+_GTL?\
MP,6M/;TOYD>=_JYG'_0+/_P%GC-%>S?\,E?$+_GTL?\ P,6C_ADKXA?\^EC_
M .!BT>WI?S(/]7,X_P"@6?\ X"SQFBO9O^&2OB%_SZ6/_@8M'_#)7Q"_Y]+'
M_P #%H]O2_F0?ZN9Q_T"S_\  6>,T5[-_P ,E?$+_GTL?_ Q:/\ ADKXA?\
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M_#&_Q)_Y\]/_ / U:/;TOYD'^KF<?] L_P#P%GA]%>X?\,;_ !)_Y\]/_P#
MU:/^&-_B3_SYZ?\ ^!JT>WI?S(/]7,X_Z!9_^ L\/HKW#_AC?XD_\^>G_P#@
M:M'_  QO\2?^?/3_ /P-6CV]+^9!_JYG'_0+/_P%GA]%>X?\,;_$G_GST_\
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MDKXA?\^EC_X&+1_PR5\0O^?2Q_\  Q:/;TOYD'^KF<?] L__  %GC-%>S?\
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M@"W153[%+_S_ -Q^4?\ \31]BE_Y_P"X_*/_ .)H MT54^Q2_P#/_<?E'_\
M$T?8I?\ G_N/RC_^)H MT54^Q2_\_P#<?E'_ /$T?8I?^?\ N/RC_P#B: +=
M%5/L4O\ S_W'Y1__ !-'V*7_ )_[C\H__B: +=%5/L4O_/\ W'Y1_P#Q-'V*
M7_G_ +C\H_\ XF@"W153[%+_ ,_]Q^4?_P 31]BE_P"?^X_*/_XF@"W153[%
M+_S_ -Q^4?\ \31]BE_Y_P"X_*/_ .)H MT54^Q2_P#/_<?E'_\ $T?8I?\
MG_N/RC_^)H MT54^Q2_\_P#<?E'_ /$T?8I?^?\ N/RC_P#B: +=%5/L4O\
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M@)Z?[M:_V*7_ )_[C\H__B: +=%5/L4O_/\ W'Y1_P#Q-'V*7_G_ +C\H_\
MXF@"W153[%+_ ,_]Q^4?_P 31]BE_P"?^X_*/_XF@"W153[%+_S_ -Q^4?\
M\31]BE_Y_P"X_*/_ .)H MT54^Q2_P#/_<?E'_\ $T?8I?\ G_N/RC_^)H M
MT54^Q2_\_P#<?E'_ /$T?8I?^?\ N/RC_P#B: +=%5/L4O\ S_W'Y1__ !-'
MV*7_ )_[C\H__B: +=%5/L4O_/\ W'Y1_P#Q-'V*7_G_ +C\H_\ XF@"W153
M[%+_ ,_]Q^4?_P 31]BE_P"?^X_*/_XF@"W153[%+_S_ -Q^4?\ \31]BE_Y
M_P"X_*/_ .)H MUF:O\ ?B^AJQ]BE_Y_[C\H_P#XFL[5;216CS>3MP>H3_XF
M@""BH/LTG_/U-^2?_$T?9I/^?J;\D_\ B: )Z*@^S2?\_4WY)_\ $T?9I/\
MGZF_)/\ XF@">BH/LTG_ #]3?DG_ ,31]FD_Y^IOR3_XF@">BH/LTG_/U-^2
M?_$T?9I/^?J;\D_^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_ (F@">BH/LTG
M_/U-^2?_ !-'V:3_ )^IOR3_ .)H GHJ#[-)_P _4WY)_P#$T?9I/^?J;\D_
M^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_B: )Z*@^S2?\_4WY)_\31]FD_Y^
MIOR3_P")H T]*_X^3_NG^E:]8&F6LC7! O)E^4\@)_\ $UJ?8I?^?^X_*/\
M^)H MT54^Q2_\_\ <?E'_P#$T?8I?^?^X_*/_P")H MT54^Q2_\ /_<?E'_\
M31]BE_Y_[C\H_P#XF@"W153[%+_S_P!Q^4?_ ,31]BE_Y_[C\H__ (F@"W15
M3[%+_P _]Q^4?_Q-'V*7_G_N/RC_ /B: +=%5/L4O_/_ ''Y1_\ Q-'V*7_G
M_N/RC_\ B: +=%5/L4O_ #_W'Y1__$T?8I?^?^X_*/\ ^)H MT54^Q2_\_\
M<?E'_P#$T?8I?^?^X_*/_P")H MT54^Q2_\ /_<?E'_\31]BE_Y_[C\H_P#X
MF@"W153[%+_S_P!Q^4?_ ,31]BE_Y_[C\H__ (F@"CJ7_'V_T'\JJTNH6LBW
M3 W<S<#DA/3_ ':K_9I/^?J;\D_^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_
M (F@">BH/LTG_/U-^2?_ !-'V:3_ )^IOR3_ .)H GHJ#[-)_P _4WY)_P#$
MT?9I/^?J;\D_^)H GHJ#[-)_S]3?DG_Q-'V:3_GZF_)/_B: )Z*@^S2?\_4W
MY)_\31]FD_Y^IOR3_P")H GHJ#[-)_S]3?DG_P 31]FD_P"?J;\D_P#B: )Z
M*@^S2?\ /U-^2?\ Q-'V:3_GZF_)/_B: )Z*@^S2?\_4WY)_\31]FD_Y^IOR
M3_XF@">BH/LTG_/U-^2?_$T?9I/^?J;\D_\ B: )Z*@^S2?\_4WY)_\ $T?9
MI/\ GZF_)/\ XF@#H=/_ ././\?YT4FF*4L8@6+D9^9L9/)]** +5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X_P#'=L7NC_[DG\Q7#::<%:H_MN>/=3\"CPM+I@@+SF97\]"W P>.
M17S58_M'>+4(PNG_ (P'_P"*K:-*4U='!6QM*A)PG>Y]KZ5T6NKL_NCZ5\1:
M?^TYXQC PNG?^ Y_^*K>M_VJ/&JJ,+IG_@,W_P 56GU>9S/-<.N_W'VA'TJ4
M=*^-E_:M\;@?=TS_ ,!F_P#BJ>/VKO&^/NZ7_P" S?\ Q5/ZM4)_M;#>?W'V
M/17QS_PU=XW_ +NE_P#@,W_Q5'_#5WC?^[I?_@,W_P 51]6J!_:V&\_N/L:B
MOCG_ (:N\;_W=+_\!F_^*H_X:N\;_P!W2_\ P&;_ .*H^K5 _M;#>?W'V-17
MQS_PU=XW_NZ7_P" S?\ Q5'_  U=XW_NZ7_X#-_\51]6J!_:V&\_N/L:BOCG
M_AJ[QO\ W=+_ / 9O_BJ/^&KO&_]W2__  &;_P"*H^K5 _M;#>?W'V-17QS_
M ,-7>-_[NE_^ S?_ !5'_#5WC?\ NZ7_ . S?_%4?5J@?VMAO/[C[&HKXY_X
M:N\;_P!W2_\ P&;_ .*H_P"&KO&_]W2__ 9O_BJ/JU0/[6PWG]Q]C45\:77[
M4_CFY@>-9-/MV;'[R*V^8<]LL1^E9_\ PTEX^_Z"R?\ @.G^%'U68GF^'71_
M=_P3[;HKXD_X:3\??]!:/_P'3_"C_AI3Q]_T%H__  &3_"G]5F+^V*'9_A_F
M?;=%?$G_  TIX^_Z"T?_ (#)_A1_PTIX^_Z"T?\ X#)_A1]5GY"_MBAV?X?Y
MGW)IO_'XGX_RK:KY \.?&CQ7J5A;W8U=E=E^;$4> >A_AK:_X6]XO_Z#+_\
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M_P"/M_H/Y55KF)-=O9G+-.2Q[[1_A2#6+OO,?R'^%'(Q^WCV.HHKFAJUT?\
MEJ?R%/&J7/\ SU/Y"CD8>WB=%17/C4[C_GJ?R%.&I7'_ #T/Y"ER,?MHF]16
M(-1G/_+3]!3AJ$__ #T/Y"CD8>VB;-%9 OIO[_Z"G"]E/\?Z4<C'[5&K168+
MN7^_3Q=2'^+]*.1C]HC0HJD+E_[U/$['O1R,/:(M457$I]:>)#ZT<K#VB):*
M8'IP-+E'SH6BG#'I3P%/:CE8^=$5%6 B'^&E,:;3\O.*.4.9&CI__'G'^/\
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M #_A_P $_.G8W]T_E1L;^Z?RK]%_^$9T?_H$V/\ X#)_A1_PC.C_ /0)L?\
MP&3_  H^MKL']BO^?\/^"?G1L;^Z?RHV-_=/Y5^B_P#PC.C_ /0)L?\ P&3_
M  H_X1G1_P#H$V/_ (#)_A1];78/[%?\_P"'_!/SHV-_=/Y4;&_NG\J_1?\
MX1G1_P#H$V/_ (#)_A1_PC.C_P#0)L?_  &3_"CZVNP?V*_Y_P /^"?G1L;^
MZ?RHV-_=/Y5^B_\ PC.C_P#0)L?_  &3_"C_ (1G1_\ H$V/_@,G^%'UM=@_
ML5_S_A_P3\Z-C?W3^5&QO[I_*OT7_P"$9T?_ *!-C_X#)_A1_P (SH__ $";
M'_P&3_"CZVNP?V*_Y_P_X)^=&QO[I_*C8W]T_E7Z+_\ ",Z/_P! FQ_\!D_P
MH_X1G1_^@38_^ R?X4?6UV#^Q7_/^'_!/SH*,.JG\J3%?HL_A;19%*MI%@RG
MJ#;(1_*H_P#A#= _Z >F_P#@)'_A1];787]BR_G_  /SMQ1BOT2_X0[0/^@'
MIO\ X"1_X4?\(=H'_0#TW_P$C_PH^MKL+^Q9?S_@?G;BC%?HE_PAV@?] /3?
M_ 2/_"C_ (0[0/\ H!Z;_P" D?\ A1];78/[%E_/^!\=>"+'[#I$3$8>8F1O
MZ?I72YKZOTWPQHXNHU_LFQV@'C[,F.GTK8_X1?1O^@18?^ R?X5DZZ;O8[(Y
M9**24CXXIV?6OL7_ (1?1O\ H$6'_@,G^%'_  B^C?\ 0(L?_ 9/\*7MUV*_
MLZ7\Q\=@TH:OL3_A%]&_Z!%C_P" R?X4?\(OHW_0)L?_  &3_"CVZ[!_9TOY
MCX]!Q2AJ^P?^$8T;_H$V/_@,G^%'_",:/_T";'_P&3_"CVZ[#_LZ7\Q\@ TX
M-7U[_P (SH__ $";'_P&3_"C_A&='_Z!-C_X#)_A1[==@_LZ7\Q\AYIP.*^N
MO^$9T?\ Z!5C_P" R?X4O_",Z/\ ] JQ_P# 9/\ "CVZ[!_9\OYCY%!IP;%?
M7'_"-:1_T"K+_P !T_PH_P"$:TC_ *!5E_X#I_A1[9=A_P!GR_F/DD-FG!L5
M]:?\(UI'_0*LO_ =/\*/^$;TC_H%V7_@.G^%+VR[!_9\OYCY-#4M?6/_  C>
MD?\ 0+LO_ =/\*7_ (1O2?\ H%V7_@.G^%'MEV']0E_,?)P-.#5]7_\ ".:3
M_P! NR_\!T_PH_X1S2?^@79?^ Z?X4>V78/J$OYCY2!S3)&((KZP_P"$<TG_
M *!=E_X#I_A6=JOA_2U:/&FV8X/2!/\ "CVR[!]0E_,?+X;-/#5]'?V#IG_0
M.M/^_"_X4?V%IO\ T#[7_ORO^%'MEV']0E_,?.8:G U]%?V'IO\ T#[7_ORO
M^%+_ &'IO_0/M?\ ORO^%+VR[#^HR_F/G8-BG U]#_V'IW_0/M?^_*_X4?V)
MIW_/A:_]^5_PH]LNP?49?S'SR#BGAJ^@_P"Q-._Y\+7_ +\K_A1_8NG?\^%K
M_P!^5_PH]LNP_J4OYCY^!IP:OH#^Q=/_ .?"V_[\K_A1_8NG_P#/A;?]^5_P
MH]JNP?4G_,> AJ>&KWO^Q=/_ .?&V_[\K_A1_8VG_P#/C;?]^5_PH]JNP?4G
M_,>#!J<#7N_]C:?_ ,^-M_WY7_"C^Q[#_GQMO^_*_P"%+VOD/ZD_YCPH-3PU
M>Y_V/8?\^-M_WZ7_  H_L>P_Y\K?_OTO^%/VJ[#^IO\ F/#@<TX'%>W_ -D6
M/_/E;_\ ?I?\*/[(L?\ GRM_^_2_X4O:^0?4W_,>*1-S4P->XZ7H]@UP0;&V
M(VGK$O\ A6K_ &)IW_/A:_\ ?E?\*/:KL'U-_P Q\]A\4\-7T#_8FG?\^%K_
M -^5_P */[%T[_GPMO\ ORO^%'M5V']4?<\ #4X-BO??[%T__GPMO^_*_P"%
M+_8VG_\ /C;?]^5_PI>U\@^J/N>"!J>&KWC^QM/_ .?&V_[\K_A1_8UA_P ^
M-M_WY7_"CVB[#^J/N>$ TX-7NO\ 8]A_SXVW_?I?\*/['L/^?*V_[]+_ (4>
MT\A_57W/#0U/#5[?_8]A_P ^5M_WZ7_"E_LBQ_Y\K?\ []+_ (4>T78/JK[G
MB(:I U>U?V38_P#/E;_]^E_PH_LFQ_Y\[?\ []+_ (4>T\A_57W/%PU.!]*]
MF_LJR_Y\[?\ []+_ (4O]E67_/G;_P#?I?\ "E[1=@^JON>-!J>'KV+^R[+_
M )\X/^_2_P"%']EV?_/I!_WZ7_"CV@_JS[GD :G!L5Z[_9EG_P ^D'_?M?\
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MJL;%_NC\J78OH/RHYP]F^Y"&J16YIVT>@HP/2ES#4&;>G_\ 'G'^/\Z*-/\
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M?]^7_P */ML?]V;_ +\O_A4]% $'VV/^[-_WY?\ PH^VQ_W9O^_+_P"%3T4
M0?;8_P"[-_WY?_"C[;'_ '9O^_+_ .%3T4 0?;8_[LW_ 'Y?_"C[;'_=F_[\
MO_A4]% $'VV/^[-_WY?_  H^VQ_W9O\ OR_^%3T4 0?;8_[LW_?E_P#"C[;'
M_=F_[\O_ (5/10!!]MC_ +LW_?E_\*/ML?\ =F_[\O\ X5/10!!]MC_NS?\
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MU]:\YKII8.A.-W'OU?<XZ^/Q%.?+&71=%V1[]_PTY:?] ";_ ,"1_P#$T?\
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M6$.M/6E[.(^>1N?VQ#_=D_(?XT#5X3_"_P"0_P :QQTI5ZU/(BN=FQ_:T/\
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M6D)JHKHQJ4Y4GRR"BBBM#(**** "BBB@ HHHH ***T- TXZIJ]M;X^5FR_\
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M #%F_P# ?_[*E_X4W'_T%F_\!_\ [*O2**/K=?\ F_(/J=#^7\SS?_A3<?\
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M'.#P<H_Y>C_W[_\ KTX>$5'_ "]'_OW_ /7KH:*/;U.X>PI]C 'A,#_EY/\
MWQ_]>E'A11_R\G_OC_Z];U%+V]3N'L*?8PQX74?\O!_[X_\ KT?\(PH_Y>#_
M -\?_7K<HH]O4[C]C3[&*/#0'_+P?^^/_KTO_".C_GX/_?'_ ->MFBE[:IW'
M[&GV,<>'@/\ EN?^^?\ Z].&@@?\MS_WS_\ 7K6HH]M/N'L8=C+&A@?\MC_W
MS_\ 7I?[$'_/8_\ ?/\ ]>M.BCVL^X_90[&<-' _Y:_^._\ UZ7^R!_SU/\
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M_:A_YYC\Z/[4/_/,?G5&BBX6+W]J'_GF/SI1JI'_ "S'_?54**0R_P#VL?\
MGD/^^J/[6/\ SR'_ 'U5"B@1?_M8_P#/(?\ ?5']K'_GD/\ OJJ%% S1_M<_
M\\A_WU1_:Y_YY#_OJLZB@5C1_M<_\\A_WU39-5+HR^7C((SNJA10,VM/_P"/
M./\ '^=%&G_\><?X_P Z* +-%%% !1110 4444 %%%% !1110 4444 %%%%
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M^=7:* *7]E0^K_G1_94/J_YU=HH I?V5#ZO^=']E0^K_ )U=HH I?V5#ZO\
MG1_94/J_YU=HH I?V5#ZO^=']E0^K_G5VB@"E_94/J_YT?V5#ZO^=7:* *7]
ME0^K_G1_94/J_P"=7:* *7]E0^K_ )T?V5#ZO^=7:* *7]E0^K_G1_94/J_Y
CU=HH I?V5#ZO^=']E0^K_G5VB@!D,0@C"+G ]:*?10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>plx-20220630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2022 9:21:35 PM-->
<!--Modified on: 8/14/2022 9:21:35 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20220630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20220630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_EmployeeMember" name="EmployeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>plx-20220630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2022 9:21:35 PM-->
<!--Modified on: 8/14/2022 9:21:35 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637961088946754247" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637961088946754247" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637961088946754247" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637961088946764285" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637961088946754247" xlink:to="plx_ShortTermBankDeposits_637961088946764285" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637961088946754247" xlink:to="us-gaap_AccountsReceivableNetCurrent_637961088946764285" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637961088946754247" xlink:to="us-gaap_OtherAssetsCurrent_637961088946764285" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637961088946754247" xlink:to="us-gaap_InventoryNet_637961088946764285" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637961088946764285" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637961088946764285" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637961088946764285" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637961088946774331" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637961088946774331" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637961088946774331" xlink:to="us-gaap_LiabilitiesNoncurrent_637961088946774331" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637961088946774331" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637961088946774331" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637961088946774331" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637961088946774331" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637961088946774331" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637961088946774331" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637961088946774331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637961088946774331" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637961088946774331" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637961088946774331" xlink:to="us-gaap_LiabilitiesCurrent_637961088946784249" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637961088946784249" xlink:to="us-gaap_AccountsPayableTradeCurrent_637961088946784249" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637961088946784249" xlink:to="us-gaap_AccountsPayableOtherCurrent_637961088946784249" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637961088946784249" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637961088946784249" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637961088946784249" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637961088946784249" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637961088946784249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637961088946784249" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637961088946794245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637961088946794245" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637961088946794245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637961088946794245" xlink:to="us-gaap_CostOfRevenue_637961088946794245" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637961088946794245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637961088946794245" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637961088946794245" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637961088946794245" xlink:to="us-gaap_Revenues_637961088946804245" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637961088946794245" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637961088946804245" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637961088946804245" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637961088946804245" xlink:to="us-gaap_OtherNonoperatingExpense_637961088946804245" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637961088946804245" xlink:to="us-gaap_OtherNonoperatingIncome_637961088946804245" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_637961088946804245" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_ShareBasedCompensation_637961088946814248" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_Depreciation_637961088946814248" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637961088946814248" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637961088946814248" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637961088946814248" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637961088946814248" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637961088946814248" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637961088946814248" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637961088946814248" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637961088946824289" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637961088946824289" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_IncreaseDecreaseInInventories_637961088946824289" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637961088946824289" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_ProfitLoss_637961088946824289" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088946804245" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637961088946824289" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637961088946824289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="plx_IncreaseDecreaseInBankDeposits_637961088946824289" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637961088946834312" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637961088946834312" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637961088946834312" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637961088946834312" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088946824289" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637961088946834312" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637961088946844249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" xlink:to="us-gaap_RepaymentsOfNotesPayable_637961088946844249" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088946844249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088946844249" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637961088946844249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637961088946844249" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637961088946844249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088946834312" xlink:to="us-gaap_ProceedsFromWarrantExercises_637961088946844249" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637961088946844249" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637961088946844249" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637961088946854247" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637961088946854247" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637961088946854247" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637961088946854247" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637961088946854247" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637961088946854247" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>plx-20220630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2022 9:21:35 PM-->
<!--Modified on: 8/14/2022 9:21:35 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20220630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>plx-20220630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2022 9:21:35 PM-->
<!--Modified on: 8/14/2022 9:21:35 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES) - NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum entitlement of development costs to cover per year</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Performance obligation number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">New director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Option to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Value of restricted stock granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="plx_EmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>plx-20220630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2022 9:21:35 PM-->
<!--Modified on: 8/14/2022 9:21:35 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637961088947324260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637961088947324260" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637961088947324260" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637961088947324260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637961088947324260" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637961088947324260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637961088947324260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637961088947324260" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637961088947334268" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637961088947334268" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637961088947334268" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637961088947334268" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637961088947334268" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637961088947334268" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637961088947334268" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637961088947334268" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637961088947334268" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637961088947334268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637961088947334268" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637961088947344259" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637961088947344259" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637961088947344259" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637961088947344259" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637961088947344259" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637961088947344259" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637961088947344259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637961088947344259" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637961088947354259" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637961088947354259" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637961088947354259" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637961088947354259" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637961088947354259" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637961088947354259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637961088947354259" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637961088947364262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637961088947364262" xlink:to="us-gaap_AssetsCurrentAbstract_637961088947364262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637961088947364262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="plx_ShortTermBankDeposits_637961088947364262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="us-gaap_AccountsReceivableNetCurrent_637961088947364262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="us-gaap_OtherAssetsCurrent_637961088947364262" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="us-gaap_InventoryNet_637961088947364262" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637961088947364262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637961088947364262" xlink:to="us-gaap_AssetsCurrent_637961088947364262" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637961088947374266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637961088947364262" xlink:to="us-gaap_AssetsNoncurrentAbstract_637961088947374266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637961088947374266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637961088947374266" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637961088947374266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637961088947374266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637961088947374266" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637961088947374266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637961088947374266" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637961088947384262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637961088947364262" xlink:to="us-gaap_Assets_637961088947384262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637961088947384262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637961088947384262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_AccountsPayableTradeCurrent_637961088947384262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_AccountsPayableOtherCurrent_637961088947384262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637961088947384262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637961088947384262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637961088947384262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637961088947384262" xlink:to="us-gaap_LiabilitiesCurrent_637961088947394257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637961088947394257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637961088947394257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637961088947394257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637961088947394257" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637961088947394257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_LiabilitiesNoncurrent_637961088947394257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637961088947394257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_Liabilities_637961088947394257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637961088947404252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_CommitmentsAndContingencies_637961088947404252" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637961088947404252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_StockholdersEquity_637961088947404252" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637961088947404252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637961088947384262" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637961088947404252" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637961088947404252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637961088947404252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637961088947404252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947404252" xlink:to="srt_ProductOrServiceAxis_637961088947404252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637961088947404252" xlink:to="srt_ProductsAndServicesDomain_637961088947414265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637961088947414265" xlink:to="us-gaap_ProductMember_637961088947414265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637961088947414265" xlink:to="us-gaap_LicenseAndServiceMember_637961088947414265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947404252" xlink:to="us-gaap_StatementLineItems_637961088947414265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_Revenues_637961088947414265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_CostOfRevenue_637961088947414265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637961088947414265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637961088947414265" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_OperatingIncomeLoss_637961088947414265" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_OtherNonoperatingExpense_637961088947414265" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637961088947414265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_OtherNonoperatingIncome_637961088947414265" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_NonoperatingIncomeExpense_637961088947424258" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_OtherIncome_637961088947424258" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_NetIncomeLoss_637961088947424258" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_EarningsPerShareBasic_637961088947424258" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_EarningsPerShareDiluted_637961088947424258" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637961088947424258" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637961088947424258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947414265" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637961088947424258" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637961088947434273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947434273" xlink:to="us-gaap_IncomeStatementLocationAxis_637961088947434273" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637961088947434273" xlink:to="us-gaap_IncomeStatementLocationDomain_637961088947434273" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637961088947434273" xlink:to="us-gaap_CostOfSalesMember_637961088947434273" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637961088947434273" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637961088947434273" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637961088947434273" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637961088947434273" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947434273" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637961088947434273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637961088947434273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637961088947434273" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637961088947434273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637961088947444263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947444263" xlink:to="us-gaap_StatementEquityComponentsAxis_637961088947444263" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637961088947444263" xlink:to="us-gaap_CommonStockMember_637961088947444263" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637961088947444263" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637961088947444263" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637961088947444263" xlink:to="us-gaap_RetainedEarningsMember_637961088947444263" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637961088947444263" xlink:to="us-gaap_EquityComponentDomain_637961088947444263" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947444263" xlink:to="us-gaap_StatementLineItems_637961088947444263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637961088947444263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_StockholdersEquity_637961088947444263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_SharesOutstanding_637961088947454264" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637961088947454264" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637961088947454264" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088947454264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947454264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947454264" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088947454264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637961088947454264" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637961088947454264" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637961088947454264" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637961088947454264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_637961088947454264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_637961088947454264" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_637961088947454264" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637961088947464257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_NetIncomeLoss_637961088947464257" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_StockholdersEquity_637961088947464257" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947444263" xlink:to="us-gaap_SharesOutstanding_637961088947464257" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637961088947464257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637961088947464257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637961088947464257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_ProfitLoss_637961088947474265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_ShareBasedCompensation_637961088947474265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_Depreciation_637961088947474265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637961088947474265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637961088947474265" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637961088947474265" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637961088947474265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637961088947474265" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637961088947484271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637961088947484271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637961088947484271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637961088947484271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="us-gaap_IncreaseDecreaseInInventories_637961088947484271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637961088947484271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637961088947484271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637961088947484271" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637961088947484271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637961088947474265" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637961088947494260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="plx_IncreaseDecreaseInBankDeposits_637961088947494260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637961088947494260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637961088947494260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637961088947494260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637961088947494260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637961088947494260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637961088947494260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637961088947494260" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637961088947504260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" xlink:to="us-gaap_RepaymentsOfNotesPayable_637961088947504260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637961088947504260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088947504260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637961088947504260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" xlink:to="us-gaap_ProceedsFromWarrantExercises_637961088947504260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088947514256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637961088947504260" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637961088947514256" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637961088947514256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637961088947514256" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637961088947514256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637961088947514256" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637961088947514256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637961088947514256" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6379610889475142561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6379610889475142561" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637961088947514256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637961088947514256" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637961088947524252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637961088947514256" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637961088947524252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637961088947524252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637961088947514256" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637961088947524252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637961088947524252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637961088947524252" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637961088947524252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637961088947524252" xlink:to="us-gaap_InterestPaidNet_637961088947524252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637961088947524252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637961088947524252" xlink:to="plx_InterestReceivedNet_637961088947524252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637961088947534257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637961088947534257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637961088947534257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637961088947534257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637961088947534257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637961088947534257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637961088947544270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637961088947544270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637961088947544270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637961088947544270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637961088947544270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637961088947544270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637961088947544270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637961088947544270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637961088947554265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637961088947554265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637961088947554265" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637961088947554265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637961088947554265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947554265" xlink:to="us-gaap_DebtInstrumentAxis_637961088947554265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637961088947554265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637961088947554265" xlink:to="us-gaap_DebtInstrumentNameDomain_637961088947554265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637961088947554265" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637961088947564263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637961088947564263" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947564263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947554265" xlink:to="us-gaap_StatementLineItems_637961088947564263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947564263" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637961088947564263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637961088947564263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="plx_SignificantAccountingPoliciesTable_637961088947564263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637961088947564263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637961088947564263" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637961088947564263" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947574265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947574265" xlink:to="plx_AtMarketEquityOfferingMember_637961088947574265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="us-gaap_TypeOfArrangementAxis_637961088947574265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637961088947574265" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947574265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947574265" xlink:to="plx_AmendedPfizerAgreementMember_637961088947574265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947574265" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637961088947574265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637961088947574265" xlink:to="plx_ChiesiAgreementsMember_637961088947574265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637961088947574265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637961088947574265" xlink:to="plx_ChiesiUSAgreementMember_637961088947574265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637961088947574265" xlink:to="plx_ChiesiExUSAgreementMember_637961088947584256" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="dei_LegalEntityAxis_637961088947584256" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637961088947584256" xlink:to="dei_EntityDomain_637961088947584256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637961088947584256" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637961088947584256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="srt_StatementGeographicalAxis_637961088947584256" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637961088947584256" xlink:to="srt_SegmentGeographicalDomain_637961088947584256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637961088947584256" xlink:to="country_BR_637961088947584256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="srt_RangeAxis_637961088947584256" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637961088947584256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637961088947584256" xlink:to="srt_RangeMember_637961088947584256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637961088947584256" xlink:to="srt_MinimumMember_637961088947594254" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637961088947584256" xlink:to="srt_MaximumMember_637961088947594254" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="us-gaap_DebtInstrumentAxis_637961088947594254" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637961088947594254" xlink:to="us-gaap_DebtInstrumentNameDomain_637961088947594254" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637961088947594254" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637961088947594254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637961088947594254" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637961088947594254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637961088947594254" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947594254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637961088947594254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637961088947564263" xlink:to="plx_SignificantAccountingPoliciesLineItems_637961088947594254" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637961088947604257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637961088947604257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088947604257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637961088947604257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637961088947604257" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637961088947604257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637961088947604257" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637961088947614254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637961088947614254" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637961088947614254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637961088947614254" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637961088947614254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_PaymentOnNetSalesPercentage_637961088947614254" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637961088947614254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637961088947614254" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637961088947724249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_AgreementAmendmentPaymentReceivable_637961088947724249" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637961088947724249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637961088947724249" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637961088947734284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637961088947734284" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637961088947734284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_MaintainOfMinimumCashBalance_637961088947734284" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637961088947734284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637961088947734284" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637961088947734284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637961088947594254" xlink:to="plx_RevenuePerformanceObligationNumber_637961088947734284" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637961088947744268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637961088947744268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637961088947744268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637961088947744268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" xlink:to="us-gaap_DebtInstrumentAxis_637961088947744268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637961088947744268" xlink:to="us-gaap_DebtInstrumentNameDomain_637961088947744268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637961088947744268" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637961088947744268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637961088947744268" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947744268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947744268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947744268" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947744268" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947754261" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947754261" xlink:to="us-gaap_FairValueInputsLevel3Member_637961088947754261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" xlink:to="us-gaap_MeasurementInputTypeAxis_637961088947754261" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637961088947754261" xlink:to="us-gaap_MeasurementInputTypeDomain_637961088947754261" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637961088947754261" xlink:to="us-gaap_MeasurementInputSharePriceMember_637961088947754261" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637961088947754261" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637961088947754261" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637961088947754261" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637961088947754261" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637961088947754261" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637961088947754261" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637961088947754261" xlink:to="plx_MeasurementInputYieldMember_637961088947754261" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947754261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947744268" xlink:to="us-gaap_StatementLineItems_637961088947754261" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947754261" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637961088947764252" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947764252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947764252" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947764252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637961088947764252" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947764252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637961088947764252" xlink:to="us-gaap_FairValueInputsLevel3Member_637961088947764252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947764252" xlink:to="us-gaap_DebtInstrumentAxis_637961088947764252" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637961088947764252" xlink:to="us-gaap_DebtInstrumentNameDomain_637961088947764252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637961088947764252" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637961088947764252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947764252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637961088947764252" xlink:to="us-gaap_StatementLineItems_637961088947764252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637961088947774261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947764252" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637961088947774261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637961088947774261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947764252" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637961088947774261" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637961088947774261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637961088947774261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637961088947899496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947774261" xlink:to="srt_ProductOrServiceAxis_637961088947899496" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637961088947901495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637961088947899496" xlink:to="srt_ProductsAndServicesDomain_637961088947901495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637961088947902825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637961088947901495" xlink:to="us-gaap_ProductMember_637961088947902825" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637961088947903493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637961088947901495" xlink:to="us-gaap_LicenseAndServiceMember_637961088947903493" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637961088947904820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947774261" xlink:to="srt_StatementGeographicalAxis_637961088947904820" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637961088947906155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637961088947904820" xlink:to="srt_SegmentGeographicalDomain_637961088947906155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637961088947906825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637961088947906155" xlink:to="plx_PfizerMember_637961088947906825" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637961088947906825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637961088947906155" xlink:to="country_BR_637961088947906825" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637961088947906825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637961088947906155" xlink:to="plx_ChiesiMember_637961088947906825" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637961088947906825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637961088947774261" xlink:to="us-gaap_StatementLineItems_637961088947906825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637961088947906825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637961088947906825" xlink:to="us-gaap_Revenues_637961088947906825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="us-gaap_PlanNameAxis_637961088947914265" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637961088947914265" xlink:to="us-gaap_PlanNameDomain_637961088947914265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637961088947914265" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637961088947914265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="srt_TitleOfIndividualAxis_637961088947914265" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637961088947914265" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947914265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947914265" xlink:to="srt_ChiefExecutiveOfficerMember_637961088947914265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947914265" xlink:to="srt_ChiefFinancialOfficerMember_637961088947914265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947914265" xlink:to="srt_DirectorMember_637961088947914265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637961088947914265" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947914265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637961088947914265" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947914265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637961088947914265" xlink:to="plx_AtMarketEquityOfferingMember_637961088947924258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="us-gaap_AwardTypeAxis_637961088947924258" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947924258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947924258" xlink:to="us-gaap_EmployeeStockOptionMember_637961088947924258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="us-gaap_SubsequentEventTypeAxis_637961088947924258" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637961088947924258" xlink:to="us-gaap_SubsequentEventTypeDomain_637961088947924258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637961088947924258" xlink:to="us-gaap_SubsequentEventMember_637961088947924258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637961088947914265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637961088947924258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_CommonStockSharesAuthorized_637961088947924258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637961088947934249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637961088947934249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637961088947934249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637961088947934249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637961088947934249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637961088947934249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637961088947934249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637961088947934249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637961088947944254" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637961088947944254" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637961088947944254" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637961088947944254" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947944254" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088947944254" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637961088947944254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637961088947944254" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637961088947954251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637961088947954251" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637961088947954251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637961088947924258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637961088947954251" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637961088947954251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637961088947954251" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637961088947954251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="us-gaap_SubsequentEventTypeAxis_637961088947954251" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637961088947954251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637961088947954251" xlink:to="us-gaap_SubsequentEventTypeDomain_637961088947954251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637961088947954251" xlink:to="us-gaap_SubsequentEventMember_637961088947964264" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="us-gaap_TypeOfArrangementAxis_637961088947964264" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637961088947964264" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947964264" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947964264" xlink:to="plx_PfizerAgreementMember_637961088947964264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637961088947964264" xlink:to="plx_ChiesiAgreementsMember_637961088947964264" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="srt_ProductOrServiceAxis_637961088947964264" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637961088947964264" xlink:to="srt_ProductsAndServicesDomain_637961088947964264" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637961088947964264" xlink:to="plx_AlfataligliceraseMember_637961088947964264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="us-gaap_AwardTypeAxis_637961088947964264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637961088947964264" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947964264" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637961088947964264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637961088947964264" xlink:to="us-gaap_EmployeeStockOptionMember_637961088947964264" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637961088947974256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="srt_TitleOfIndividualAxis_637961088947974256" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947974256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637961088947974256" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947974256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_637961088947974256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637961088947974256" xlink:to="plx_EmployeeMember_637961088947974256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637961088947974256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="us-gaap_PlanNameAxis_637961088947974256" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637961088947974256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637961088947974256" xlink:to="us-gaap_PlanNameDomain_637961088947974256" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637961088947974256" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637961088947984813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637961088947954251" xlink:to="us-gaap_SubsequentEventLineItems_637961088947984813" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637961088947984813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637961088947984813" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637961088947984813" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637961088947984813" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637961088947984813" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637961088947984813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637961088947984813" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637961088947994260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637961088947994260" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637961088947994260" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637961088947994260" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637961088947994260" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947994260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637961088947994260" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088948004259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637961088948004259" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_637961088948004259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_ProceedsFromExpenseReimbursements_637961088948004259" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220630.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_637961088948004259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="plx_ProceedsFromSaleOfProducts_637961088948004259" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088948004259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637961088947984813" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637961088948004259" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342748272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,753,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342773008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,492<span></span>
</td>
<td class="nump">$ 38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">16,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">16,507<span></span>
</td>
<td class="nump">17,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">49,700<span></span>
</td>
<td class="nump">61,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,769<span></span>
</td>
<td class="nump">4,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">60,640<span></span>
</td>
<td class="nump">73,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,991<span></span>
</td>
<td class="nump">6,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">16,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">10,223<span></span>
</td>
<td class="nump">8,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,960<span></span>
</td>
<td class="nump">33,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">28,033<span></span>
</td>
<td class="nump">27,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">5,895<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,748<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,893<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">39,569<span></span>
</td>
<td class="nump">46,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">70,529<span></span>
</td>
<td class="nump">79,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(9,889)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 60,640<span></span>
</td>
<td class="nump">$ 73,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725343458832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,753<span></span>
</td>
<td class="nump">$ 6,427<span></span>
</td>
<td class="nump">$ 24,838<span></span>
</td>
<td class="nump">$ 17,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,087)<span></span>
</td>
<td class="num">(4,733)<span></span>
</td>
<td class="num">(10,121)<span></span>
</td>
<td class="num">(9,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,579)<span></span>
</td>
<td class="num">(7,689)<span></span>
</td>
<td class="num">(16,346)<span></span>
</td>
<td class="num">(14,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(2,611)<span></span>
</td>
<td class="num">(3,171)<span></span>
</td>
<td class="num">(5,765)<span></span>
</td>
<td class="num">(6,309)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,524)<span></span>
</td>
<td class="num">(9,166)<span></span>
</td>
<td class="num">(7,394)<span></span>
</td>
<td class="num">(12,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(2,203)<span></span>
</td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(4,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">813<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="num">(3,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,334)<span></span>
</td>
<td class="num">$ (11,241)<span></span>
</td>
<td class="num">$ (7,620)<span></span>
</td>
<td class="num">$ (16,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">45,436,907<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
<td class="nump">42,744,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,327,952<span></span>
</td>
<td class="nump">45,436,907<span></span>
</td>
<td class="nump">46,589,976<span></span>
</td>
<td class="nump">42,744,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,382<span></span>
</td>
<td class="nump">$ 3,243<span></span>
</td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 7,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 3,184<span></span>
</td>
<td class="nump">$ 12,428<span></span>
</td>
<td class="nump">$ 9,993<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342640160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725341629936">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 320,280<span></span>
</td>
<td class="num">$ (347,352)<span></span>
</td>
<td class="num">$ (27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,716)<span></span>
</td>
<td class="num">(16,716)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,863<span></span>
</td>
<td class="num">(364,068)<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,285<span></span>
</td>
<td class="num">(352,827)<span></span>
</td>
<td class="nump">14,504<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,382,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,863<span></span>
</td>
<td class="num">(364,068)<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,852<span></span>
</td>
<td class="num">(374,934)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,395,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">372,616<span></span>
</td>
<td class="num">(382,554)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">369,688<span></span>
</td>
<td class="num">(377,220)<span></span>
</td>
<td class="num">(7,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,316,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,395,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 372,616<span></span>
</td>
<td class="num">$ (382,554)<span></span>
</td>
<td class="num">$ (9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of June&#160;30, 2022 and 2021 - 120,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342747952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342809744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,620)<span></span>
</td>
<td class="num">$ (16,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(952)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(449)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="nump">12,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(1,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="num">(558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals</a></td>
<td class="num">(4,864)<span></span>
</td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,185)<span></span>
</td>
<td class="num">(3,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(37,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(357)<span></span>
</td>
<td class="num">(667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="nump">457<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,900)<span></span>
</td>
<td class="num">(23,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,643<span></span>
</td>
<td class="nump">42,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(26,493)<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">38,985<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">12,492<span></span>
</td>
<td class="nump">33,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">2,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725449676736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $17.2&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2022, respectively, and 25,874,641 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344636192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344666160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of June&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of June&#160;30, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $32.3&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344476512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,748</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,754</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,993</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725347100128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; SHARE CAPITAL</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 120,000,000 to 144,000,000 (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Stock based compensation</b></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:108pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On June&#160;30, 2022, the Company granted 10-year options to purchase 40,000 shares of Common Stock to a new director serving on the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $1.09 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $32,000 based on the following weighted average assumptions: share price equal to $1.09; dividend yield of 0% for all years; expected volatility of 85.95%; risk-free interest rate of 3.025%; and expected life of six years.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">At the Annual Meeting, the Company&#8217;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of the Plan.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the quarter ended June&#160;30, 2022, the Company sold, in the aggregate, 2,395,823 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $2.8&#160;million in connection with such sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344671760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;1, 2022, the Company granted 10-year options to purchase 160,000 shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $1.06 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $124,000 based on the following weighted average assumptions: share price equal to $1.06; dividend yield of 0% for all years; expected volatility of 85.95%; risk-free interest rate of 2.65%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During July and August 2022, the Company sold, in the aggregate, 1,040,457 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $1,152,650 in connection with such sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;17, 2022, the Company collected approximately $1.1&#160;million from sales to Pfizer. On July&#160;18, 2022, the Company collected approximately $1.1&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725342801600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies, referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $17.2&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) under the initial Exclusive License and Supply Agreement (the &#8220;Pfizer Agreement&#8221;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2022, respectively, and 25,874,641 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344671760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344555520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725344996208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,748</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,754</p></td></tr><tr><td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,993</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725338032144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,641<span></span>
</td>
<td class="nump">$ 8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,960,732<span></span>
</td>
<td class="nump">25,874,641<span></span>
</td>
<td class="nump">32,982,043<span></span>
</td>
<td class="nump">26,322,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Performance obligation number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725338021280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,304<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,296<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9,907<span></span>
</td>
<td class="nump">11,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,507<span></span>
</td>
<td class="nump">$ 17,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725337990592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">2.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">75.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">13.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725343580496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 32,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725340996560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 8,753<span></span>
</td>
<td class="nump">$ 6,427<span></span>
</td>
<td class="nump">$ 24,838<span></span>
</td>
<td class="nump">$ 17,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
<td class="nump">12,410<span></span>
</td>
<td class="nump">7,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">6,738<span></span>
</td>
<td class="nump">6,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 3,184<span></span>
</td>
<td class="nump">$ 12,428<span></span>
</td>
<td class="nump">$ 9,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725336580096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,152,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="nump">8,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,475,171<span></span>
</td>
<td class="nump">8,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | New director | Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="nump">85.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">3.025%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139725343448736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,152,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Option to purchase shares of common stock | Employee | 2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements | Alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>plx-20220630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20220630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20220630.xsd" xlink:type="simple"/>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ytcHJNRtMkC-kFhR6Y_Q9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4nVZjnZPfESVPBgjGtf3hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_Z-8iEsWphUCbjtsaDKdovA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qVPpbQRPfk2TReO-LtDjaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6DLzF6gPCkKUOnMGptPp4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bgf7v6oL7UGhXhJ5Qvr8SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xlM86qUkt0KOAmnTSOyfwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_BpzceNB_akmwpVhtRG9COQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q3iT6tByHUqOnNA_O2SM8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C0_vygBSwUKW1_g7vDXPDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Ri85L_GQ6EGDyqBYwwU7vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_bviBEkzn-kuxLoWbK74QKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_RfgCYQ2Rr0qLtIgXDy8V0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tBqUbsRpXUCkCu7As_K8ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_iGheMtaJu06OflGOGrghmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_VVGBDxGe8UudpDjkca8hHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_EDJO9ESATkWFpOj1QBRDjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_KnmF4l_09EC6bg-2BZ311g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_9vZiZcQD8UufQ_SB8sxlmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_poDnVzcNS0KMFLRSo_6oDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_EiQ41j_NqUGvIIayLqE9OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jEHvpKQm5kCqey2CTt_BcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VaxdqtuNcEisKZVLZWPKvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_y6DZaQueokGuDyxDFuaa_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zC0lIICAa0SqzS0gFlR7dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_La_v2P8SgUu8a-sZ8uaD5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MYQxmrO7BkKHz_LbP4Z5QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGjbifYeakiP_pumhgy_NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c2uW99rnTUyPMniVyn2M0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_KiMXzKBurE62LVrcGB85cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_xZtyvQccUESGBiPReGtrYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_aOpGJG-q1k2lYifBL5VXKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Bmg1y9mhxUahVCDnBjO6ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b7YYEGq7sUq5RS6c9gLCog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_EibuCP6l4kKN_Q30vrA0hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EZfCnohvr0y2B-Q9rWZ-Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_WIAQENglMkea-ygnycr5WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_G8oXr3UKV0i09CNvcOUZpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TvQ-GPYn2EGcujvnvNwsGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Fm5H8d3qkaSZ7TvQIrSFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2OW2E9fYbUuNi7TvwRPypA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_DJJNM8qnaEKUcJ3HHuAssg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_QyKQxoFpHUmwj--qWhm7zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zqsmNVni_02194Rs9tUq7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_D0U9HQw9R0WDe2pBZk3w3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bO8o39pQaEml34krQBBNIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_8fJEcV0nCke4OMdxDI5Wmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_VnH5FcNSOEqo6IyPz5y2QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_8_15_2022_To_8_15_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_AagOsjXaHk2Tye8hFQUyyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2022_To_8_15_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_zEYSsTSOvkScTP7J-kyj4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IkS-U_42B0qptgPPLXKu_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nhGp8vR41EuQp88YBLlW4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_zXSdyWR7tUO8R8iIafuytA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_QeVKh51xs0SPEU0GH8uOSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_3QlMfOhpR0u7fHcnwWrz2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d-nB_IK66k--GPVQiT88QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_BKeU6ZzYJkq_9CWsGYOCHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2022_cMVR1Q0aFUWivfZLB1FiBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-08-12</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_BJyuho_M3E-RzZ63hj9Iag">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_8VPFZCaFnEGUa7jmFn4qhA">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      id="Hidden_D9pLUZgDkEe5scajs-aR4A"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      id="Hidden_8lY80BgnTUa4R0U4WKYNJg"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="2"
      id="Hidden_K1UiCHy9GUyJUPuJfA-z9w"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="2"
      id="Hidden_jS3Lo46FaUWhBg_0OuV7cw"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="2"
      id="Hidden_tzQu6u9z50KabqolBS2DIQ"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="2"
      id="Hidden__3sT1TpM4E2IfKH_4VPYoQ"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="0"
      id="Hidden_KyqYSEAD7EWap14es3Ir9w"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">46589976</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="0"
      id="Hidden_XKJX1D8fhE6MN_XAdnWN5g"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">42744426</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="0"
      id="Hidden_z64eekF3002XLUC4QaU8BA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">47327952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="0"
      id="Hidden_KyDfQ9XtUU6N_OsRMdXKyA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45436907</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_MUQbn6lbn0ijFL6A5WOGVg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_AYurxoM6UUyXJ1m6MZu3ug_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_AL1YmwQSqkKdIWSR1hoajQ_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_oe6EnY4qWkG-pZkGdxbr2Q_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_K4n9laBg-U-ms91tgfGn2w_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_ohHONYAruEaG9-mXRO1dDA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_rAaBtIbTlUWbkzqbdFW6Hg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_icJRV2r8Ek6pn_bBZRmHtQ">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr__bR0XRb_q0aXbcDFu7qVfw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_jX4e4O376Uyt-6sk1r_gYA">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_EAX2LlW5g0mPVCyHLgPjzA">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_OlbKjTCGTECGmyiKKHlNoQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_FTUj2Dp4REemYjEIGYQOwg">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_Oqphe-KbjECkJK8rMPS18Q">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_HR6VHAG1l0OcTc5JFSMXPw">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_ES65vEodoU2Ej3lAWgZQzw">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_efiqUbJaGECt5qkidSiI0w">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_uxJj6crRsUWQFOgNN83jZQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_lYtLLH_-qEmyUGEwFyT4uQ">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_d2Jc3tHjKU6IlyT0itA8IQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_eVCSQoV51keguCjV1g9XEg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_7iaXWLJ_8UaP-aAISsXhsA_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_-BGc3460iUG0C_RacFOiZw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_P9yMCJEZ2kWm-tfV3G072A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_VGJjSesSd0y_d3XF7A5i5Q">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_Xugtcr_yfUiPN-pfhMsRxQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_MM9HUy8-q0q8i8rzfIKWEA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tc_9tUdHmlWckSwkbWZDdtIoQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Narr_Be4f_Vj2k0eu5UYG8-1uMg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_12_2022_cMVR1Q0aFUWivfZLB1FiBw"
      decimals="INF"
      id="Narr__3hDsLK0pkOiBNR2g82iJg"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">49753409</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_kvFUHpM6X0efbS_8LnG0gA_6_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12492000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_Q-aTJLhYGUGwkRaV71ucXA_6_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">38985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_POy7qDimF0eXlrCWUnLOXg_7_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16082000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_Ppn6go0Uf0-vYYM5TET1ZQ_8_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2022000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_RlfiBFA86UurYVKY0YHlGA_8_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_MZFMGrjGFEioG1NQeG7Mtw_9_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2597000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_X-SQguBeh0mUOiTkf7BM4w_9_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1285000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_aurkYXl3FEKZ9EgaUBPjXQ_10_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16507000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_RsoaWkJpb0SAw2Dey9cAzg_10_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">17954000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_hHvvanoHBk-U9nsTaz-BTw_11_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">49700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_QlzAulaBX0qymfsB9Oiocw_11_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">61666000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_RGyrlZccQEif9yNzaGNPEg_14_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1403000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_gOfSHjD81U2mU_-COp34Kg_14_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2077000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_MYwLU8KfPki6r5cpvAQ1Mg_15_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4768000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_ZD_zetMiM0-PaWI-mrbOnw_15_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_CPYmyKJhgECk-XGsi2dikw_16_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4769000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_9k2sZhxByEGvxrLpWYw3kQ_16_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4960000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_4ej4UMB-6UC_krEKU3nCtA_17_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">60640000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_QZE8leLxgk6O3LkMY8VVQg_17_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">73665000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_TMQPpufJUkO7iIoQtmBrOw_23_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6991000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_CIWluQF8Q0qX7KyOsbuipA_23_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6986000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc__YBGxgvm1EyhQzj8SLZezQ_24_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12663000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_zR4g2erp0ESGx02XVK9Ktg_24_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16433000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_M8fpIZHSVUaaXZgtPQ9Vaw_25_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1083000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_CWuJIIur_Ua45gX3mA9M7Q_25_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1207000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_o7jihE7_Z0WNsbGV2xLs6g_26_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">10223000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_2mGigf_2nk2kOc7aHMu_Ow_26_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">8550000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_b9zMMR2JVkafeHZHkZh-ng_27_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">30960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_0Q1cImEa_E6xetTcr8CaCg_27_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">33176000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_PTh9LrxbGUKDnQiy8VHGcQ_30_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">28033000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_jO5sCtVba0uSj5PwB9OZfw_30_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">27887000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_CRRf22RYUk2PhFp36ecDOQ_31_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">5895000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_RX5FD8AKJUuE7UiD7aZt0Q_31_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">11790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_y0jiQprHBUWBPIbTYVYvhw_32_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1748000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_ul2XhcgsQ0iCA4vOQ-H2iQ_32_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2472000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_hfvwDMVvuUCpg3KqPomgjg_33_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3893000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_7TSopc0Od0WJ-o6M2gzzeA_33_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_8NifI4pDpE246b-v1g1BFw_34_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">39569000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_6Jv2x7hf2kW6Kdvf4qmUqQ_34_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46525000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_16eVPaRo3U-h5lgClzT7ZQ_35_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">70529000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_C9LgfhljSEmuAjs1LqYp4g_35_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">79701000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_1sR_QauZU0Ga5AG8sGM-jA_39_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-9889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_5lRYPQOw6E2CMImkLpGVGg_39_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_dXqfiJ2gu06LDEBOS-8Fmw_40_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">60640000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_PTb99vaZDUe4363WKTfWGw_40_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">73665000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ"
      decimals="-3"
      id="Tc_SUSlQfKPeUyV40_jBsSpMg_3_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12410000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ"
      decimals="-3"
      id="Tc_boOoddYOrECGY-yvVFdD6w_3_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7754000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg"
      decimals="-3"
      id="Tc_GeA4oNa3C0Sd6WqBpTZpwQ_3_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug"
      decimals="-3"
      id="Tc_haFeWTbnEEu0kHONdIvQCQ_3_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3243000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg"
      decimals="-3"
      id="Tc_ThLqYaRkp0S0XexDbQN_tg_4_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew"
      decimals="-3"
      id="Tc_f7PmrOAqS02wxUVW-96k1A_4_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">9993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA"
      decimals="-3"
      id="Tc_l0ugRNJCRk2meTJbxXKuTg_4_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA"
      decimals="-3"
      id="Tc_-dPn5G9fQUGJKBl3KKZ2xQ_4_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3184000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_kKP7NvlA_0yXVGhYTP2Aeg_5_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">24838000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_RHGTpYcR-U2szHvCB3g9jw_5_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">17747000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_pIRHyUgWbEOBGhnEPHYXqA_5_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">8753000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_x5hj_buL5EW2mrX1tWjBtA_5_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6427000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_kT01q2rPC06oxUaemMWsbg_6_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">10121000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_vqUcB4UXeES_j_LBvQNLjw_6_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">9498000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_l90QbEkG4kaEJOnguvFNpg_6_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4087000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_7iDs3mR8VUeuTr2byJbBbA_6_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4733000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_825CnEVwuU-5yyNVwXD5ZA_7_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16346000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_6EOraGnSpka9y4YLOqWBXg_7_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">14811000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7579000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_e78HqF1JMEa43P-La_R1JQ_8_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">5765000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_z8EulXXFtUCiFYYOQm1lTg_8_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6309000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_6Pl25RwX_ki7PiR5JudZYg_8_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2611000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_SSBGgak3jUuyZlmDOP1GIg_8_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3171000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_dRgKqnWhzkWDSluCiiMnsA_9_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7394000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_NNFASd9NyUOmhN4Pj0dnXw_9_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-12871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_-g-q41u9dEiObzpJhntbfQ_9_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-5524000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_MyesU8MRHECdg6VG_D4L5A_9_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-9166000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_XuDyrBTgM0GSjm_P-LwUGg_10_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1242000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_MS1v2UDIL02gbkO1FlI9vA_10_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4240000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_MSDORfyHw0u_3h6R2e4BRQ_10_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">623000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_XyfsCRQig06u4x9Y36uvYA_10_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2203000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_k2If9wihc0OpdTF78Hin-g_11_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1016000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_tlDhmNCTQkGWQIcjiVBmpw_11_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">344000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_1fFvYWK2RkqfpqxdwFczhw_11_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">813000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_s5szUdhBpkO0EdSdBLA-WA_11_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">128000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_FFUcdGeenUCVisLWmhslKg_12_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-226000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_f2wiLBMPRkaUPfm5UlGeyA_12_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-3896000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_3QaVWfgWaEqGPKwW3d2cfg_12_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_PSKITsEd2UWnV8CTSTh1NA_12_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-2075000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_BQ-dzHkJgUiwiRx10Bf1Rw_13_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_ljNGLrC6y0aiOp7HAywZ8g_14_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_LgpVy10NZEKxtZ-oLEH42g_14_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_XcJ9k3jsU06Ye8dCpFSdvg_14_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_qyppUWEnXk6uXwXjLKKTZA_14_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="2"
      id="Tc_QjI3tsSOPkyzoUoiGHyTYg_15_3"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="2"
      id="Tc_SQsqDoyTGEqZa5jSa1YMTg_15_6"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="2"
      id="Tc_ZZ4w2ASh-UWolP957O-PNg_15_9"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="2"
      id="Tc_NfIkjamsQkOT-WfjKls9IA_15_12"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="0"
      id="Tc_JDJAf8uZ_Uay_pAWVNhgjQ_17_3"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">46589976</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="0"
      id="Tc_3uoiLM-LR0-7vMBwrGD_3Q_17_6"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">42744426</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="0"
      id="Tc_4d1M-xVByU-4t8G9bcdYUA_17_9"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">47327952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="0"
      id="Tc_wlIBNFuaWESgkPFPjlJwHw_17_12"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45436907</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_WIAQENglMkea-ygnycr5WA"
      decimals="-3"
      id="Tc_iJPJ9ulWs0Svu3ro3Cip3Q_18_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">22000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_QyKQxoFpHUmwj--qWhm7zg"
      decimals="-3"
      id="Tc_ceZ9506VCEqGYIBBo9ZIYA_18_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA"
      decimals="-3"
      id="Tc_BJKqbOOO00SJxddM8A_efA_18_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Fm5H8d3qkaSZ7TvQIrSFw"
      decimals="-3"
      id="Tc_YotCW43CckiSh-Ybs5anyw_18_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EZfCnohvr0y2B-Q9rWZ-Mg"
      decimals="-3"
      id="Tc_GqYHBKwSAUWUAGXIICn5pg_19_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_DJJNM8qnaEKUcJ3HHuAssg"
      decimals="-3"
      id="Tc_W_8s2ojXU0qz7tDq4oI03A_19_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b7YYEGq7sUq5RS6c9gLCog"
      decimals="-3"
      id="Tc_tX5qgQzqQEqr0WkolV7oRg_19_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TvQ-GPYn2EGcujvnvNwsGQ"
      decimals="-3"
      id="Tc_XbXpZ2ZuJkCTcnUbMhOxIQ_19_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_EibuCP6l4kKN_Q30vrA0hw"
      decimals="-3"
      id="Tc_rc49tdbP_k2zWOycuHk8yQ_20_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2OW2E9fYbUuNi7TvwRPypA"
      decimals="-3"
      id="Tc__1ehhqzJwEOVuftssvx6Bw_20_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Bmg1y9mhxUahVCDnBjO6ow"
      decimals="-3"
      id="Tc_GAIvXq0FzESK5ASo_niG8Q_20_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_G8oXr3UKV0i09CNvcOUZpQ"
      decimals="-3"
      id="Tc_y_vKUo7hX0mjmoiI0doiUQ_20_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q"
      decimals="INF"
      id="Tc_deucjwu8MU2X0nDSTJw4Mg_6_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q"
      decimals="-3"
      id="Tc_8GqTrJdmj02YByS92zQKvA_6_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C0_vygBSwUKW1_g7vDXPDw"
      decimals="-3"
      id="Tc_qIXjEyPDn06fmm7jHN63uw_6_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q3iT6tByHUqOnNA_O2SM8Q"
      decimals="-3"
      id="Tc_EKGjUjDlX0Oo4sShUFTfCg_6_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg"
      decimals="-3"
      id="Tc_nWlTK8PFCE23Kll0x9sHUg_6_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"
      decimals="INF"
      id="Tc_TcCS3W8KE06wqIphZkr7QA_8_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"
      decimals="-3"
      id="Tc_cErdvYpp_0SH-kONDPe6Wg_8_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ"
      decimals="-3"
      id="Tc_eHBjeuWrVUum59RtqClN7Q_8_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_Xu0B8af-ek6zpdxUrDz8Tw_8_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"
      decimals="INF"
      id="Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"
      decimals="-3"
      id="Tc_3dGfUZW4gUaV_7r61l0EcA_9_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ"
      decimals="-3"
      id="Tc_e8-NBcjkhk-lYv3Vb2by7w_9_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_HzUt86alUUCXo7INEWB5wA_9_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ"
      decimals="-3"
      id="Tc_j1UruiRTj0GHD3NcO6jo5Q_10_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_t-EkJ8dav0WfpYS8sJFouQ_10_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_now2ZA_mJ06va-3RH3MkMQ"
      decimals="-3"
      id="Tc_5dvcmVTyh0mRJ5VpE1nssg_11_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">562000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_PyauEcHBC0Cf9abHEmWOgw_11_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">562000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bU6icVZySkW7RC5RUsq5Bg"
      decimals="INF"
      id="Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_La_v2P8SgUu8a-sZ8uaD5A"
      decimals="-3"
      id="Tc_YSsIzshzAEqMwZ4_X6lsIg_13_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_Dg1XLi0o7k2mw16W0JTv7w_13_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w"
      decimals="INF"
      id="Tc_WHZRU1HR00qNCR9SiWvxow_14_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w"
      decimals="-3"
      id="Tc_O4d_ZSXgi0eQHYfE-zNC0A_14_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw"
      decimals="-3"
      id="Tc_6H-XOzfgD0a4XkjivfXQBA_14_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q"
      decimals="-3"
      id="Tc_M0QKXqW8n0-zwO5J3y1VaA_14_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"
      decimals="-3"
      id="Tc_O-IUVmQ-_0Oa0VPqrWJV9A_14_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3841000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw"
      decimals="INF"
      id="Tc_AUdvBExCfUSmxApu5-3tOQ_15_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OW0Cri-lBUCNI8OGeLjcZw"
      decimals="-3"
      id="Tc_hoYJo8twlkSn8-vWiDj32w_15_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6DLzF6gPCkKUOnMGptPp4w"
      decimals="-3"
      id="Tc_jqpVure3DkaazLClZ046rg_15_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qVPpbQRPfk2TReO-LtDjaQ"
      decimals="-3"
      id="Tc_plfcTydHikWpDDrKvDmPaw_15_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_Li6KIjJ_bUagnao4oVaatw_15_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA"
      decimals="INF"
      id="Tc_TxlQgi6e1UilQwKit50P2Q_17_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">2395823</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA"
      decimals="-3"
      id="Tc_dPNPYaYGQEye9C3TyT0x6g_17_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A"
      decimals="-3"
      id="Tc_9KZB-5Zx00W97Izk6o1Ycw_17_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2638000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_S_TJOIFMN0uigpm3YIDM3Q_17_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2641000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A"
      decimals="-3"
      id="Tc_y2i-DEf8vUKYxC0hCBR9Aw_18_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_UYe8pB4WiUO91VbRW83kYw_18_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA"
      decimals="INF"
      id="Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A"
      decimals="-3"
      id="Tc_LhNrwbhZVU6G0iKHHuWKpA_19_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">831000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_EF68SGL5T0q_JZHgULuNLA_19_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">831000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G7m80uXtw0qjSl5kNvlvtA"
      decimals="INF"
      id="Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93Wcq95xT0e8BNAiirQz5A"
      decimals="-3"
      id="Tc_cpiW-DvhPkG3E-C85f7Hjg_20_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_m7D7_aNc80OV8tJKtuXrUg_20_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_y6DZaQueokGuDyxDFuaa_g"
      decimals="-3"
      id="Tc_JI034VPflUSSS12ucXqBnA_21_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_FpU2MYTwSkGve5MDnlfQKA_21_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7620000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA"
      decimals="INF"
      id="Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA"
      decimals="-3"
      id="Tc_Nf7gcdyI70W0M045OQKLDQ_22_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA"
      decimals="-3"
      id="Tc_8AdmiiS4X0CXA98NEH02Xg_22_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA"
      decimals="-3"
      id="Tc_EdxLWPPljEmRxchGZi0aiQ_22_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_JJrfjquDtEqR2r6EvRfwgg_22_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-9889000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA"
      decimals="INF"
      id="Tc_34L_v0wCxEuRaiizzFnAWA_23_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45382831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y1D1_ss0Dk6AqclEvDIYXA"
      decimals="-3"
      id="Tc_RhZ2_KxZjEmO_lOETmBYhQ_23_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xlM86qUkt0KOAmnTSOyfwg"
      decimals="-3"
      id="Tc_Nkva8J1cs0yygrOYUuZIGQ_23_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">367285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bgf7v6oL7UGhXhJ5Qvr8SQ"
      decimals="-3"
      id="Tc_jtPBn9OEnUO38IgR88xO9A_23_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-352827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_BpzceNB_akmwpVhtRG9COQ"
      decimals="-3"
      id="Tc_5tR_CvgXz0Wja7lL8LNhhA_23_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">14504000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ"
      decimals="-3"
      id="Tc_0LyJ6njy9ki91gTeKSZmUg_25_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">322000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc__5Ky9RzMBUOHm8e82MQlcQ_25_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">322000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LTk8RYVC-U2NFEaDxXF0oQ"
      decimals="-3"
      id="Tc_OMxXvYVIZEmZiLVNi0aXtA_26_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">256000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_h984psDS50qGArFws-H4bA_26_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">256000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bO8o39pQaEml34krQBBNIg"
      decimals="INF"
      id="Tc_yQlY42Huak6lD4nU7LzyUA_27_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zC0lIICAa0SqzS0gFlR7dg"
      decimals="-3"
      id="Tc_qOeoFZeBYkKECxmpLGvSNw_28_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="-3"
      id="Tc_Oav2mJqns0u5zwSGAS3Z_w_28_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w"
      decimals="INF"
      id="Tc_MjKT05CwDkW6P3tHv3OVIA_29_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aUXQoSkuM0uD50FVu0pg7w"
      decimals="-3"
      id="Tc_nUQIwpeJUk-38Ba_AImgZw_29_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cV-yjiMQuEisa41RTh6Qdw"
      decimals="-3"
      id="Tc_-Rkz47t7ik6eZti93_IijQ_29_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_njPbkcNHXEumMd5nUqBE_Q"
      decimals="-3"
      id="Tc_tdwq3wcykEWdd4MVgCj-Zg_29_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"
      decimals="-3"
      id="Tc_aPcJd15j2USf-af8PYv1sA_29_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3841000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g"
      decimals="INF"
      id="Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">46316129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZUX6N54a50K1WF9ds4iZ9g"
      decimals="-3"
      id="Tc_GbUgAqQt_kyD7nCbYnpHig_30_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4nVZjnZPfESVPBgjGtf3hQ"
      decimals="-3"
      id="Tc_ddnoSI3xtUurDOePbDiN1g_30_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">369688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ytcHJNRtMkC-kFhR6Y_Q9A"
      decimals="-3"
      id="Tc_Lc2sG0tc_kqASxPYnq1hZg_30_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-377220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_Z-8iEsWphUCbjtsaDKdovA"
      decimals="-3"
      id="Tc_ucd_zd_o8U-Xz_n5QrXl9w_30_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7486000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q"
      decimals="INF"
      id="Tc_3vv-v5_G20itN1papb-TNQ_32_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">2395823</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q"
      decimals="-3"
      id="Tc_BtWHgUr7YEOrohMU6RvYFg_32_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ"
      decimals="-3"
      id="Tc_n7-FUVWFV0igcFhelf4gXw_32_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2638000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_PSp7e55R2UO6a3hHEtitBw_32_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2641000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ"
      decimals="-3"
      id="Tc_ePvwZgTAAUiN0D6XcTfPBA_33_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_FTXjXIGJOUmuIa5aBHdG8A_33_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ"
      decimals="-3"
      id="Tc_L3LPka23HUmnmdeqYHCdoQ_34_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">144000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_xzGZXGfdaEWe1xR6f2RKAQ_34_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">144000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3PfGqCuD0ODsJ4AA33R9Q"
      decimals="INF"
      id="Tc_GBV05_V7V0udz8OxRZmetA_35_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rcCb2OlIDkWLow3LgbzIpQ"
      decimals="-3"
      id="Tc_C3rOvNMwG0-UdVMwwFy6DQ_35_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_sjcMvytRX0yoXKR6kHuecA_35_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VaxdqtuNcEisKZVLZWPKvw"
      decimals="-3"
      id="Tc_rgswRpXpu0-CS9dlvaYQQg_36_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="-3"
      id="Tc_Wa6ZgqUyeUeCx5EpIXaibw_36_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-5334000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA"
      decimals="INF"
      id="Tc_hTEWKEnK5k21aSTetjwslQ_37_2"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIzRP4ihK02BlW_AGA1NkA"
      decimals="-3"
      id="Tc_QOPoNcShs0KwVUOOB2sKJw_37_5"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9RVL1xK04k-Qqu3LKTopJA"
      decimals="-3"
      id="Tc_02NPHwWvm0S9-XwwNkB8BQ_37_8"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zv8C9apaE0e3Yg2zrGoVjA"
      decimals="-3"
      id="Tc_klJXROjkCUu0uaSQ7BVyNg_37_11"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_21hBHjTCF06CUUVZmaLuhA_37_14"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-9889000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"
      decimals="INF"
      id="Narr_xirKAx8TiEm-jw1vIIf2MA"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="INF"
      id="Narr_ZS22zFIBkEiDsGVSEMg_-A"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"
      decimals="INF"
      id="Narr_oFzX5PDpU02Xl1udyj9rBA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="INF"
      id="Narr_lL0Fkq-md0GU7sk-GuExyQ"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_5r7490orxU6IVSbg4qEF8g_4_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-7620000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_y7-ycFlkkUCzjaRg2d_B7g_4_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-16716000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_OmWhaqV0Y0iQVoFU-Iebag_6_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1124000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_TGvQLofvVU2Na13upFLeAQ_6_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1394000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_ZEaP20XvSUeEQmPMJHgzhQ_7_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">538000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_lyIHJwOxV0ez61Y-aqakaw_7_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">574000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_7oj04OHUe0yYlRj0Tq0yNQ_8_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">952000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_LSHw2Z_nnkmj57rBBoctrA_8_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">121000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_B_CATt_iyU6VI43R81XTfA_9_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-449000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_JnvW9VROuEyOjZdqgxd12g_9_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">70000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_YivofNGL10K9VQppeHBktg_10_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-16000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_UcDBA2x8vUCxOLSd9aTUiA_10_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">56000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_4zYTHnAMi02piP2uV8eSQA_11_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_JYfFqWdZmUaedmKfA7EVTw_12_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">146000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_a9YxXX2MgUKyvFqdCmEjig_12_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1928000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_yYZwqiUrc0amo-T8ScG08w_14_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-2644000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_B2-L9zUdoEeGi8hrvUNjRw_14_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12268000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_K_0Hao4bOE26htZOFqC4-w_15_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-76000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_iQy3g3it9kuiHXVO319U7w_15_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1587000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_zTWih1hYAEiyk5OK8Ay0RQ_16_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_iiSYiVA_OUCR_Psc9ITYqg_16_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-94000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_EsGvNX1bv0qAG4QOvf2VPw_17_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-1447000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_N44_DJaCBkqbfXwks0FVGQ_17_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">558000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_-NFJ9Dn_jEOcL88s7f0RCQ_18_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-4864000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_68gZPs3Zk02NqxcREtdGPg_18_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-544000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_4rIuzqCbLkmgNdK7x9QlMg_19_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-13000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_XkJKKHBO0kanAXToVfOH3A_20_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-13185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_25E4_nt9-0OyxNgcssTtRQ_20_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-3318000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_0n-3ZBAxdUObbOEUm4Njjw_23_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_pjUa428LI02k4QNbysm33Q_23_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_5VJLGGJHiEWNxKYq4A8voQ_24_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">15000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_XTzoudM7akizrtzYSYrltw_25_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">357000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_oAxRWQbLeEuaO-yor3qsNg_25_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">667000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_WVmIOHUdZEuVTbSxvfBPCw_26_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_nc8ef4XY5kG83Icl-q7v2Q_27_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-359000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_PwT5lQft00GB1B2iyA4oGw_28_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-457000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_PhD3JZMEHEesIScvnFySqQ_28_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">54000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_3kr13bwqHEaZy0DFEr_uMQ_29_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-15900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_qm8yopad-0G2CIC3zGmVng_29_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-23144000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_guga0WSHCU2bFnx0U6D--Q_32_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_lsJYEZSvTE6qUDxYLZVTnQ_33_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_ZnmWmMKwy0CHogVpRUcniA_34_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2641000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_sV75h77aWU2scwFl2dPxiA_34_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_TVSY2Y71c0K8a1GTgRaP_w_35_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_29sroHXQhEimJzXG7WsqBA_36_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2643000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_8xVbeG3VZUWkGqaUsmAGHw_36_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">42114000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_yXGAeiMWfEqpNCLnoJpqAQ_37_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-51000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_lIBAPuPgV0agpMug-gZlOw_37_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-35000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_H6PCHwOBYE-HOPmMP5Hi8g_38_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">-26493000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_rIJQgwvdSkabCO1iRYlIgw_38_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">15617000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_7GybjLFuBUexBR74h6_m3w_39_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_hCOmMlxKhUiMd5Mighg2tg"
      decimals="-3"
      id="Tc_ZqwoRRR9106l-giHopSeMg_39_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_D8GNWmDGAECRc9-s21infw_40_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_3md2tR5oTkeVZbD7TDClEA"
      decimals="-3"
      id="Tc_Cp7BtwaRy02GOIMUhoLGhQ_40_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">33882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_yAsc-6uW50KbHtO9rC1xLA_4_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">81000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_Xeeujn3dV02Cdr-vuNTeig_4_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">372000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_G6uFsWpvbEe779ilhjycRQ_5_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">99000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_IdpvyyxpdEOu_g6s5JKlFQ_5_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">232000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_k84ZgViP60u4RfPQOJNCFQ_8_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1120000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_RinCMcp4Ek-aETFyYaaDfQ_8_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2172000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="-3"
      id="Tc_emYTKI_dHU6W-NneIWPoBw_9_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">93000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="-3"
      id="Tc_mRGsOf8yjEef5GUAudeE6A_9_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">307000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_yEgAuHaSzUCb5fnmhwypTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies, referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with Chiesi, announced the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $17.2&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) under the initial Exclusive License and Supply Agreement (the &#x201c;Pfizer Agreement&#x201d;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2022, respectively, and 25,874,641 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_LzbvI_8D-0KBh5Eg4eY0yg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil, Uplyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies, referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with Chiesi, announced the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company is continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million. As of June&#160;30, 2022, shares of Common Stock for total gross proceeds of approximately $17.2&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) under the initial Exclusive License and Supply Agreement (the &#x201c;Pfizer Agreement&#x201d;). In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_aOpGJG-q1k2lYifBL5VXKA"
      decimals="INF"
      id="Narr_7G_BpTNvNEeanj9wh7znjQ"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw"
      decimals="-5"
      id="Narr_opvL3KvbiUiiovcEqeHY3Q"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw"
      decimals="INF"
      id="Narr_2gM5KpkXIUCahXcYZctUAg"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_oevBJ4CPRUau2b5bdjAEPw"
      decimals="-5"
      id="Narr_in-C_eGnvU2GOXyF7sSNdA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_8fJEcV0nCke4OMdxDI5Wmg"
      decimals="-5"
      id="Narr_1xTUZAu0802sCl-ph7K5Hw"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">17200000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_D0U9HQw9R0WDe2pBZk3w3w"
      decimals="-5"
      id="Narr_MtU3GYKvzkK5EMP5OFWe2A"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zqsmNVni_02194Rs9tUq7w"
      decimals="-5"
      id="Narr_opVePBSWkkKRkdaTgsfx7Q"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ"
      decimals="-5"
      id="Narr_6fTapv-KNUq9cilP4Oy8CA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ"
      decimals="-5"
      id="Narr_1M6OHOeGKUyh0MspghqPOA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HUhthAbmj0yUzSt-9lwEPQ"
      decimals="-5"
      id="Narr_bfOI2ZAt4UKKc7bfvUUHMQ"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ"
      decimals="-5"
      id="Narr_r2i-FKkvhEy4041CLWITlA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ"
      decimals="-5"
      id="Narr_HSn_7O-8SkKHR83bb7Ieeg"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_bU1LQGuqzkygXrF_p03jQQ"
      decimals="-5"
      id="Narr_lCDgWnIVF0ipPsFxXTXzgw"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_zXSdyWR7tUO8R8iIafuytA"
      decimals="INF"
      id="Narr_JX1tlZEfLUywDtY4YQerMg"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_QeVKh51xs0SPEU0GH8uOSQ"
      decimals="INF"
      id="Narr_WTGj81pqBk2_4BsiB92B-w"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_IkS-U_42B0qptgPPLXKu_A"
      decimals="INF"
      id="Narr_G0wqK5830Ei7V-9pI96bFw"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_nhGp8vR41EuQp88YBLlW4w"
      decimals="INF"
      id="Narr_fBbDCxgCZEq5zTfbFp1nDQ"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_BKeU6ZzYJkq_9CWsGYOCHQ"
      decimals="-5"
      id="Narr_FgUq7XfrnkKFgpJPQdrYdQ"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d-nB_IK66k--GPVQiT88QA"
      decimals="-5"
      id="Narr__zTx4_JEuEubifg7M9BLpA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_3QlMfOhpR0u7fHcnwWrz2Q"
      decimals="2"
      id="Narr_mC2z5XuPjEKm17o1RFPBsg"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ"
      decimals="4"
      id="Narr_mv2ElYzMFU6LmVGX0LoE5Q"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_cYxqifUJ0k2vcX0pnjOvJQ"
      decimals="-5"
      id="Narr_v0Vz9-2oOkSEI6oO3e9P-w"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_k_r-wDp0aE-poMuYjpm2pw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_yZVEwyBl-kKUvTGcHaOMMw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 32,960,732 and 32,982,043 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2022, respectively, and 25,874,641 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three and six months ended June&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ"
      decimals="INF"
      id="Narr_j0eZe7fUFkOLH-fkHLHa_A"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">32960732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      decimals="INF"
      id="Narr_RiNOSB4hxUisypQ4AjgNAQ"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">32982043</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_63T2kwKkMkuk67OB_9oJ-Q"
      decimals="INF"
      id="Narr_dBMMh_BMYki0yZwZKah35g"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">25874641</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_Q2InXGbkvUGki_3g18G19A"
      decimals="INF"
      id="Narr_YtkqT1myXEquSZLXbaii0g"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">26322164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA"
      decimals="4"
      id="Narr_a6G7dpI_8EC54jA0HEsMsA"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_jiZJfvezgUa_d1Msm3mHXA"
      decimals="4"
      id="Narr_Vl_mnu4BNEqv14pgOXiWvw"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_JJn9iO9-d0eG48SGV4812g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_6_30_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_VnH5FcNSOEqo6IyPz5y2QA"
      decimals="INF"
      id="Narr_CohABiEfL0mdsyhguGuQEw"
      unitRef="Unit_Standard_agreement_BJyuho_M3E-RzZ63hj9Iag">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_dke8JGEG2Eu4oAsZeGe1gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2022 and December&#160;31, 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_yh21nZUbKkOEwM02CNohQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2022 and December&#160;31, 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_2aXimOxF602cwLIxvTP8Yw_3_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3304000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_QAOA0dELq0yNwC8GjxqQfw_3_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_FIvTom1EmkilUMqLck5_Dg_4_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3296000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_gvNlwsGlNkaTI_MVuhcWLg_4_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3262000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_FjRKR6pVlEqTUS8cceJEjg_5_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">9907000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_7-TuwZRfYE6z-wzIogJrFw_5_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">11526000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="-3"
      id="Tc_e9NLFwEW3EyGN3mEz5OmWw_6_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">16507000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_Lugf3w0bLUqeu0qmKSnwQA"
      decimals="-3"
      id="Tc_-PjobJA0iUqBI-Yle99eWg_6_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">17954000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_i2SI9vt2kEeznNIJtG1zFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of June&#160;30, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of June&#160;30, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $32.3&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ"
      decimals="-4"
      id="Narr_KCkiLF8mZUencwhfy0soJg"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ"
      decimals="-5"
      id="Narr_NfZUc-tdu02rvxOMaMHAUw"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">32300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA"
      id="Tb_dUo-EveflkGMD8C_OG0aJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A"
      decimals="2"
      id="Tc_lQSJbf8j3UWq4t_txkOkvA_2_5"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">1.09</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c2uW99rnTUyPMniVyn2M0g"
      decimals="2"
      id="Tc_pYNbEik1pkSly1PlTOP7TQ_3_5"
      unitRef="Unit_Standard_Y_8VPFZCaFnEGUa7jmFn4qhA">2.18</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_MYQxmrO7BkKHz_LbP4Z5QQ"
      decimals="2"
      id="Tc_p_3OMdge70ucy-vmNpquwQ_4_5"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">2.94</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGjbifYeakiP_pumhgy_NQ"
      decimals="2"
      id="Tc_jtmECkhI8Uiqm4rMCP5H2w_5_5"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">75.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_KiMXzKBurE62LVrcGB85cA"
      decimals="2"
      id="Tc_aKKRXTFf00SeLsTm_EpcSQ_6_5"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">13.85</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb__xRs-cRHkEqZx9Zpd0fT5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_jnZDVWexS0-IqPUcTJo9zA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_RfgCYQ2Rr0qLtIgXDy8V0Q"
      decimals="-3"
      id="Tc_SrrsBl9_Sk-1ibqi607azQ_3_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_EDJO9ESATkWFpOj1QBRDjg"
      decimals="-3"
      id="Tc_5ikna_wF3kKoK3gnPUqv_w_3_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2237000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tBqUbsRpXUCkCu7As_K8ig"
      decimals="-3"
      id="Tc_edtRck6clkuquueo4Oyarw_3_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6738000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_poDnVzcNS0KMFLRSo_6oDw"
      decimals="-3"
      id="Tc_ELe6DdIrh0WeOdBnYtcoMg_3_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">6748000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_9vZiZcQD8UufQ_SB8sxlmg"
      decimals="-3"
      id="Tc_YM9JFY7sEEKuddYTowaPPw_4_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_VVGBDxGe8UudpDjkca8hHw"
      decimals="-3"
      id="Tc_tb6mhqGRckGJk4tXI1qJzw_4_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">5454000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_jEHvpKQm5kCqey2CTt_BcQ"
      decimals="-3"
      id="Tc_X7CImZJqgES1Tg5mjnacRA_4_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_KnmF4l_09EC6bg-2BZ311g"
      decimals="-3"
      id="Tc_95BWho3s1U-pL3N6Nf1plw_5_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">18000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_iGheMtaJu06OflGOGrghmA"
      decimals="-3"
      id="Tc_A7fw_fTzV06Xjf6dthsy7w_5_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_EiQ41j_NqUGvIIayLqE9OA"
      decimals="-3"
      id="Tc_ut8J2sV80kKtdoxRgfx-5A_5_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">18000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_edyi9UvFpkG4gxc0R_HVVg"
      decimals="-3"
      id="Tc_nVna7Ni_10m8Dt4lPXUAkA_6_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_0YbifMJCwkOhJ3AarF2Gug"
      decimals="-3"
      id="Tc_QYGi0V_5QUKM1YLVaQDrIQ_6_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3243000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I1PewKbwX0-YW_-wyQnwlQ"
      decimals="-3"
      id="Tc_NRTdgJFwYkCixZ9Y234D8g_6_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12410000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_GMwpdP05GU6Z0R2PcaKdGQ"
      decimals="-3"
      id="Tc_lLq3eFBZS0W04LChuFe66g_6_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">7754000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FXIxPjNcD0e7vUhtL3iIBA"
      decimals="-3"
      id="Tc_5T1it_JgwEKlfdk_D8Re7A_7_3"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ghvfczhX1US8YgCtWBXuoA"
      decimals="-3"
      id="Tc_9bbHXsa-bUSqu4ngAgRAXw_7_6"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">3184000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_aehnkaCmiUOni7oYpMhIJg"
      decimals="-3"
      id="Tc_9oKWEWcNJ0Cb33G9ZZ_7IQ_7_9"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">12428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_trspvRUHXEqUgxg133GOew"
      decimals="-3"
      id="Tc_rixTXuMMgEKMkAhCit7-zQ_7_12"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">9993000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_vgOe9QSfdk2k2NZiyXACag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; SHARE CAPITAL&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Authorized Capital&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On June&#160;30, 2022, the Company held its 2022 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 120,000,000 to 144,000,000 (the &#x201c;Charter Amendment&#x201d;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August&#160;2, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Stock based compensation&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On February&#160;25, 2022, the Company granted, with the approval of the Company&#x2019;s compensation committee, the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:108pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:108pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;II.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;On June&#160;30, 2022, the Company granted 10-year options to purchase 40,000 shares of Common Stock to a new director serving on the Company&#x2019;s Board of Directors under the Plan. The options have an exercise price equal to $1.09 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the director is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"&gt;conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $32,000 based on the following weighted average assumptions: share price equal to $1.09; dividend yield of 0% for all years; expected volatility of 85.95%; risk-free interest rate of 3.025%; and expected life of six years.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, adopted amendments to the Plan to increase the number of shares of Common Stock available under the Plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of the Plan.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;At-the-Market (ATM) Offering&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the quarter ended June&#160;30, 2022, the Company sold, in the aggregate, 2,395,823 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $2.8&#160;million in connection with such sales.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A"
      decimals="INF"
      id="Narr_iX2Z28_h_EuP6AyudtbwHA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_xZtyvQccUESGBiPReGtrYg"
      decimals="INF"
      id="Narr_JtPeyIoLSUK-e46EvJqC8Q"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw"
      decimals="0"
      id="Narr_stNA1XL37U-J5lbTlROItA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">637531</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_s3s9T36ZOUmxo2-8ApRoyw"
      decimals="0"
      id="Narr_-ZhSJP0eLUW2KlqTHr7WzA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">523000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q"
      decimals="0"
      id="Narr_TrhAAzTQyEujl_jAy4m9gg"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">121951</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hMQQ3O7Y9EaCQrsTk27S2Q"
      decimals="0"
      id="Narr_X2R3nVEn4kCG6P1bnWAAgw"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      id="Narr_MJ3seZHRXkiU83BAHDXMhQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      decimals="INF"
      id="Narr_uJiuVysWlke_Ei5zazbZww"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA"
      decimals="2"
      id="Narr_j2nckBrxnkyBN4wI2qgQdw"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      id="Narr_olLxe8ZFME65s769aXgAmQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      decimals="INF"
      id="Narr_eDwVNz9ntE2qKMFt5GY09w"
      unitRef="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA"
      decimals="0"
      id="Narr_2TgHMRWnaUitu_QcopL1Kg"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">32000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_39ZLsj7Iwkms8WKd6VM-SA"
      decimals="2"
      id="Narr_zFgLxM7lbEiulIPwRtiWQg"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      decimals="2"
      id="Narr_yMRsgtslQkmxgW4gedK7hA"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      decimals="4"
      id="Narr_cbT2kuHFeU2FX430ICeq2g"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.8595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      decimals="5"
      id="Narr_OyvXyRLCGkmzcQcTKQogzw"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.03025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_r5FZ7SwMTECUxsocqOl2TQ"
      id="Narr_c6ePRJZPiUm8rCMxK8vv2A">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_29_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_bviBEkzn-kuxLoWbK74QKQ"
      decimals="INF"
      id="Narr_Qhya5MOA8kSxHeK-1BH9xA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">5725171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Ri85L_GQ6EGDyqBYwwU7vQ"
      decimals="INF"
      id="Narr_1i7mWJzCyEOkpaTQxZ3CBQ"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">8475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ"
      decimals="INF"
      id="Narr_TJCzjb9wu0uHBdiW-LygPA"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">2395823</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TgxBNOkliE-JObSuer3aIQ"
      decimals="-5"
      id="Narr_mqL3hPBW00KVJmv0HLzWug"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">2800000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg"
      id="Tb_5UP2ymHO9UuJw2Vlywr7uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On August&#160;1, 2022, the Company granted 10-year options to purchase 160,000 shares of Common Stock to a new employee of the Company under the Plan. The options have an exercise price equal to $1.06 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $124,000 based on the following weighted average assumptions: share price equal to $1.06; dividend yield of 0% for all years; expected volatility of 85.95%; risk-free interest rate of 2.65%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;During July and August 2022, the Company sold, in the aggregate, 1,040,457 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $1,152,650 in connection with such sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On July&#160;17, 2022, the Company collected approximately $1.1&#160;million from sales to Pfizer. On July&#160;18, 2022, the Company collected approximately $1.1&#160;million from expense reimbursements in connection with its collaboration with&#160;Chiesi.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      id="Narr_XNaja0sxhkKuIv_oegU3KQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      decimals="INF"
      id="Narr_cNEk97DMH0GeEXaUql2yrg"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w"
      decimals="2"
      id="Narr_FfV1S9-zgU6v3_FDGsTI_A"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      id="Narr_yEKn5u9pBkmYzusiyHeIaA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      decimals="INF"
      id="Narr_HmPZCQDy1EO-u3Q0InR71A"
      unitRef="Unit_Standard_item_xI_XQfpggE6Oj9BbAU8KtQ">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w"
      decimals="0"
      id="Narr_ZlV2DIZsfUG6BEVueKhQMA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">124000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FKFvoy5sZUard3YvM54C0w"
      decimals="2"
      id="Narr_V8OdU-4hi02e_NFNlY2XTA"
      unitRef="Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      decimals="2"
      id="Narr_VU7PPegvzUemLW_Ha_CxSA"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      decimals="4"
      id="Narr_S8ahHBFSDkCme74NumoXVQ"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.8595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      decimals="4"
      id="Narr_XNydszste0Ww9cr0VrrGfQ"
      unitRef="Unit_Standard_pure_bcDuRVXWNEyiI92h4cJ5xA">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA"
      id="Narr_3WgmXOPOwUOJzzIaih1yUA">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ"
      decimals="INF"
      id="Narr_iv4mFFJJG0mGRs6LEgsOnw"
      unitRef="Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig">1040457</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QkFcR5-AAkalf6m3yRF1oQ"
      decimals="0"
      id="Narr_g8SN16hi00in18gq7qgHBw"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1152650</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_8_15_2022_To_8_15_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_AagOsjXaHk2Tye8hFQUyyw"
      decimals="-5"
      id="Narr_uXeCvm49ukS-LsTbQYM1Kg"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1100000</plx:ProceedsFromSaleOfProducts>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_8_15_2022_To_8_15_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_zEYSsTSOvkScTP7J-kyj4w"
      decimals="-5"
      id="Narr_iylGe_flHE2EPUhJUJSIwA"
      unitRef="Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg">1100000</plx:ProceedsFromExpenseReimbursements>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2"
          xlink:label="Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of June&#160;30, 2022 and 2021 - 120,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Os0HQ_F-cU2mUqzxr4aPkw_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2"
          xlink:label="Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xRZtG9y_uUSVuyYrhNqGJg_9_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_TxlQgi6e1UilQwKit50P2Q_17_2"
          xlink:label="Tc_TxlQgi6e1UilQwKit50P2Q_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_TxlQgi6e1UilQwKit50P2Q_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3vv-v5_G20itN1papb-TNQ_32_2"
          xlink:label="Tc_3vv-v5_G20itN1papb-TNQ_32_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3vv-v5_G20itN1papb-TNQ_32_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2"
          xlink:label="Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ZH1H0UPx40mYZQSNIkAZYQ_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_yQlY42Huak6lD4nU7LzyUA_27_2"
          xlink:label="Tc_yQlY42Huak6lD4nU7LzyUA_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yQlY42Huak6lD4nU7LzyUA_27_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2"
          xlink:label="Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Nr4aZ0WSykKzLUrLIcRIuA_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GBV05_V7V0udz8OxRZmetA_35_2"
          xlink:label="Tc_GBV05_V7V0udz8OxRZmetA_35_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GBV05_V7V0udz8OxRZmetA_35_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_deucjwu8MU2X0nDSTJw4Mg_6_2"
          xlink:label="Tc_deucjwu8MU2X0nDSTJw4Mg_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_deucjwu8MU2X0nDSTJw4Mg_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_34L_v0wCxEuRaiizzFnAWA_23_2"
          xlink:label="Tc_34L_v0wCxEuRaiizzFnAWA_23_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_34L_v0wCxEuRaiizzFnAWA_23_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MjKT05CwDkW6P3tHv3OVIA_29_2"
          xlink:label="Tc_MjKT05CwDkW6P3tHv3OVIA_29_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MjKT05CwDkW6P3tHv3OVIA_29_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_WHZRU1HR00qNCR9SiWvxow_14_2"
          xlink:label="Tc_WHZRU1HR00qNCR9SiWvxow_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_WHZRU1HR00qNCR9SiWvxow_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AUdvBExCfUSmxApu5-3tOQ_15_2"
          xlink:label="Tc_AUdvBExCfUSmxApu5-3tOQ_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AUdvBExCfUSmxApu5-3tOQ_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2"
          xlink:label="Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_I3Va7n48kkSQLRaYrzJ8xQ_30_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_hTEWKEnK5k21aSTetjwslQ_37_2"
          xlink:label="Tc_hTEWKEnK5k21aSTetjwslQ_37_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_hTEWKEnK5k21aSTetjwslQ_37_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2"
          xlink:label="Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_OnSCmTsvu0SkjrRE4LR8NA_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_TcCS3W8KE06wqIphZkr7QA_8_2"
          xlink:label="Tc_TcCS3W8KE06wqIphZkr7QA_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_TcCS3W8KE06wqIphZkr7QA_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vqUcB4UXeES_j_LBvQNLjw_6_6"
          xlink:label="Tc_vqUcB4UXeES_j_LBvQNLjw_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vqUcB4UXeES_j_LBvQNLjw_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7iDs3mR8VUeuTr2byJbBbA_6_12"
          xlink:label="Tc_7iDs3mR8VUeuTr2byJbBbA_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7iDs3mR8VUeuTr2byJbBbA_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kT01q2rPC06oxUaemMWsbg_6_3"
          xlink:label="Tc_kT01q2rPC06oxUaemMWsbg_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kT01q2rPC06oxUaemMWsbg_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_l90QbEkG4kaEJOnguvFNpg_6_9"
          xlink:label="Tc_l90QbEkG4kaEJOnguvFNpg_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_l90QbEkG4kaEJOnguvFNpg_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6EOraGnSpka9y4YLOqWBXg_7_6"
          xlink:label="Tc_6EOraGnSpka9y4YLOqWBXg_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6EOraGnSpka9y4YLOqWBXg_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12"
          xlink:label="Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_HjabPOn81EiZ8OZwJ7aIpw_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_825CnEVwuU-5yyNVwXD5ZA_7_3"
          xlink:label="Tc_825CnEVwuU-5yyNVwXD5ZA_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_825CnEVwuU-5yyNVwXD5ZA_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9"
          xlink:label="Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yjAPma9hBEOcyFFq0iR4Jw_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_z8EulXXFtUCiFYYOQm1lTg_8_6"
          xlink:label="Tc_z8EulXXFtUCiFYYOQm1lTg_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_z8EulXXFtUCiFYYOQm1lTg_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_SSBGgak3jUuyZlmDOP1GIg_8_12"
          xlink:label="Tc_SSBGgak3jUuyZlmDOP1GIg_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_SSBGgak3jUuyZlmDOP1GIg_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_e78HqF1JMEa43P-La_R1JQ_8_3"
          xlink:label="Tc_e78HqF1JMEa43P-La_R1JQ_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_e78HqF1JMEa43P-La_R1JQ_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6Pl25RwX_ki7PiR5JudZYg_8_9"
          xlink:label="Tc_6Pl25RwX_ki7PiR5JudZYg_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6Pl25RwX_ki7PiR5JudZYg_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(9N7,EM5A_??LK+,EM7CC"53E@L __Z89>7KBZA@>R75^P=02P,$%     @
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ML-#[2"QA5C1+M77&F37)JYVQI;(CV( N5B02308;^!V'2E-)@;."9!<7%Z*
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M,52G%@MH&M@"K45UA&#3:0/X!,R6Q1=P^S%X@C>PCY>C)#=$8%.2) (F<)M
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MW36B("#.4\U5B\ H7BESN[5Z;NH6\8"FF_!<K]YQZN6M;\5THB D7+3$'HM
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MHTD5;OO5PILBW+!CX^F^'AXS^D!"RP+T?FFH//6"';2?7+._ 5!+ P04
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M9&3-N<6YUHA1M2Z5.+KL9@.@AR5#,*<6&A-#=7JQ@*:!+=!:4(</-ITV@$_
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M<Z":"]4\J.9#-0K5 I0F7^2Q#<!-=0#^<AS'IX3<\8(\,#&)>N-P6;5X;(5
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MF 'Z^8KK8ZD(S)%9_O$$?P%02P,$%     @ -3D/51F\_5(6 @  +P0  !D
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MB?C;NLA9LIBL-\ET*;.4EQ^8[ V$1G5#O3THS8;2'"B-06DNE.9!:1Q%4X=
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ME"1^!#"_@RC"$'@:<01S !XP)(KJ]^#>^RC<O*?"[K]XX]]02P,$%     @
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M\95[QD(8F_.9P,7AQGWXM^#V%U!+ P04    "  U.0]5K^R3I3@!   ?#P
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M<',O87!P+GAM;%!+ 0(4 Q0    ( #4Y#U6&A>3-[P   "L"   1
M      "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #4Y#U69
M7)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N
M>&UL4$L! A0#%     @ -3D/56 (L?/N!0  Y!\  !@              ("!
M#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #4Y#U65
M99[ B@4  &H7   8              " @3(.  !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"% ,4    "  U.0]5AD>#__\%  ">&@  &
M    @('R$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M-3D/56:G]9O$ P  =Q(  !@              ("!)QH  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #4Y#U6O2C8D\@@  -A"   8
M          " @2$>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  U.0]5;^*1DH "  !)!@  &               @(%))P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ -3D/50KADS?!"   <R8
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #4Y#U6<#>OD-@8  #</   9
M      " @4U7  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ -3D/58ENO@0 !   ^P@  !D              ("!NET  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  U.0]56]<<6)P8    20
M&0              @('Q80  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( #4Y#U4N.'W?JP(  "8&   9              " @<1Z  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ -3D/51PNT)EP
M @  ] 4  !D              ("!IGT  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  U.0]5;KTS"]<"   5!P  &0
M@(%-@   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #4Y
M#U4H5#RH!@T  %:A   9              " @5N#  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ -3D/54NW@C*) @  S 8  !D
M         ("!F)   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  U.0]5X(\MTLT"  #]"   &0              @(%8DP  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #4Y#U49O/U2%@(  "\$
M   9              " @5R6  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ -3D/5?H5U=.L P  <A(  !D              ("!J9@
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  U.0]5"X4$
M (0)  !5:@  &0              @(&,G   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( #4Y#U6XHV1B[08  +([   9
M  " @4>F  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M-3D/560OHN V P  TA,   T              ( !:ZT  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  U.0]5EXJ[',     3 @  "P              @ ',
ML   7W)E;',O+G)E;'-02P$"% ,4    "  U.0]5]69,.;@"  "Q$   #P
M            @ &UL0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -3D/
M5:_LDZ4X 0  'P\  !H              ( !FK0  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ -3D/5?[?4.AO 0  %A   !,
M         ( !"K8  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "  ( "7
)"   JK<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>163</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20220630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept EffectOfExchangeRateOnCashAndCashEquivalents in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. plx-20220630x10q.htm 14</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  plx-20220630x10q.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  plx-20220630x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="plx-20220630x10q.htm">plx-20220630x10q.htm</File>
    <File>plx-20220630.xsd</File>
    <File>plx-20220630_cal.xml</File>
    <File>plx-20220630_def.xml</File>
    <File>plx-20220630_lab.xml</File>
    <File>plx-20220630_pre.xml</File>
    <File>plx-20220630xex31d1.htm</File>
    <File>plx-20220630xex31d2.htm</File>
    <File>plx-20220630xex32d1.htm</File>
    <File>plx-20220630xex32d2.htm</File>
    <File>plx-20220630xex3d5.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20220630x10q005.jpg</File>
    <File>plx-20220630x10q006.jpg</File>
    <File>plx-20220630x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="312">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>46
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20220630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 108,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20220630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 266,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 15
   },
   "keyCustom": 32,
   "keyStandard": 131,
   "memberCustom": 16,
   "memberStandard": 21,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_pvd9Sj8MOUmTSlO4Nup3qA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_o3hI9jBTjEiV1YjSvQPk1A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_fgHHg9wfuEOBz7UfNagrzQ",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "shortName": "REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_RfgCYQ2Rr0qLtIgXDy8V0Q",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_8_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_xZtyvQccUESGBiPReGtrYg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gYuolOWRBUaBggZkxf54ig",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_8_1_2022_To_8_1_2022_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dUlZ_kEqtkCxMJU5nLF0oA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_GwwJjihCrk-OE07wQrjorQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uhOZTfuHqUul7Vgt1-PWYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_20jRaKFtzECeFAf3KKw_2Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "As_Of_6_30_2022_xAY212Tgi0-Y1dZOHjjo7A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_F-mknSB3fk2O4wYnOvPf9g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8yIYBCH3_kWEwE_8mo1Rdg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ALd-rCKQ7EayqPY61nbtrg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the product, alfataliglicerase.",
        "label": "Alfataliglicerase"
       }
      }
     },
     "localname": "AlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockIncentivePlan2006Member",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year",
        "terseLabel": "Maximum entitlement of development costs to cover per year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement [Member]",
        "label": "Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "PfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "localname": "ProceedsFromExpenseReimbursements",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number",
        "terseLabel": "Performance obligation number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20220630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director",
        "terseLabel": "New director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r149",
      "r169",
      "r202",
      "r203",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r304",
      "r307",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r149",
      "r169",
      "r202",
      "r203",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r304",
      "r307",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r118",
      "r186",
      "r188",
      "r283",
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r118",
      "r186",
      "r188",
      "r283",
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r149",
      "r169",
      "r193",
      "r202",
      "r203",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r304",
      "r307",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r149",
      "r169",
      "r193",
      "r202",
      "r203",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r304",
      "r307",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r186",
      "r189",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r186",
      "r189",
      "r306",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r122",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r220",
      "r221",
      "r222",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r204",
      "r206",
      "r225",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r206",
      "r218",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r68",
      "r162",
      "r166",
      "r167",
      "r258"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r107",
      "r110",
      "r116",
      "r126",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r232",
      "r236",
      "r247",
      "r265",
      "r267",
      "r285",
      "r296"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r42",
      "r77",
      "r126",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r232",
      "r236",
      "r247",
      "r265",
      "r267"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r207",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r70"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r250"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r134",
      "r289",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r184",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r184",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r52",
      "r77",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r247"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r76",
      "r78",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r259",
      "r286",
      "r287",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r163",
      "r287",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r76",
      "r78",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r14",
      "r190",
      "r191",
      "r192",
      "r201",
      "r284",
      "r295"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r130"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r50",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r93",
      "r95",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r241",
      "r242",
      "r291",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r50",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r95",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r241",
      "r242",
      "r291",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Option to purchase shares of common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r104",
      "r127",
      "r181",
      "r182",
      "r220",
      "r221",
      "r222",
      "r228",
      "r229",
      "r240",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r308",
      "r309",
      "r310",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r243",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r243",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r69",
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67",
      "r281"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r62",
      "r65",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r40",
      "r267"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r128"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r77",
      "r111",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r233",
      "r236",
      "r237",
      "r247",
      "r265",
      "r266"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r77",
      "r126",
      "r247",
      "r267",
      "r288",
      "r297"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES NET OF CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r77",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r233",
      "r236",
      "r237",
      "r247",
      "r265",
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r17",
      "r18",
      "r77",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r233",
      "r236",
      "r237",
      "r247",
      "r265",
      "r266"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r47",
      "r49",
      "r69",
      "r77",
      "r83",
      "r85",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r96",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r242",
      "r247",
      "r290",
      "r300"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES) - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r107",
      "r109",
      "r112",
      "r115",
      "r117"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41",
      "r267"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r190",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r207",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r47",
      "r63",
      "r77",
      "r83",
      "r91",
      "r92",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r231",
      "r234",
      "r235",
      "r238",
      "r239",
      "r242",
      "r247",
      "r292"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r131",
      "r267",
      "r293",
      "r298"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r227",
      "r282",
      "r323"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r127",
      "r220",
      "r221",
      "r222",
      "r228",
      "r229",
      "r240",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r48",
      "r77",
      "r105",
      "r106",
      "r108",
      "r113",
      "r114",
      "r118",
      "r119",
      "r121",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r247",
      "r292"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r207",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r213",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r45",
      "r46",
      "r47",
      "r80",
      "r81",
      "r82",
      "r84",
      "r90",
      "r92",
      "r104",
      "r127",
      "r181",
      "r182",
      "r220",
      "r221",
      "r222",
      "r228",
      "r229",
      "r240",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r308",
      "r309",
      "r310",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r104",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Number of restricted stock granted (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r181",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r20",
      "r21",
      "r181",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Value of restricted stock granted"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r77",
      "r125",
      "r126",
      "r247",
      "r267"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r94",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r324": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r325": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r326": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r327": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r328": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r329": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001558370-22-013560-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-013560-xbrl.zip
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MH<NI+V2T I,T&*:0G@3?;E=DZ9.R%YI[)S;9(9L0F3?]<GVP(P_UB5Y;3/V
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M$].S('SUSW_\[__\_'\G)_^^G-X:-K*"-7!]P\+ ](%M/$%_9<S19F.ZQAW
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MCI(YT!H16W#PSH26)[C)954!ZY$4&MTOJ=AHIT^TN>CJ8!_["Y.7V_W'7R#
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MXA$0H9V 0E4JMA<E-G)^5MM(]#4,X!=.[1F8;GE?:Y^?P5P[[@]-[!+C]"8
M[[*<H<61 @>V6VG4VMES*-!>*M?0"?S#T5.!7/;0W4JFUMZ?2X-VLOD=T.QC
M8 \>R<2V!/<!Y<)X$=T&& >^YYNN34@165+)/KJ58ZTP04G*CD6ZL3KFR"@G
M7WXOW4JX5B2A-&W%,O[Y5/51_X1@[9)EDD_?6Y4^]W]7[]S?^"$U[-^_KSR
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MGT^5.)#'X!7:XSR?(;GT,GH?)R_&$_L:%&96@\2LG-A0@B#E-K3:-Z4W)*2
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M%=<B?E^0(B6MT03@>HDZ50R8FQ#]$;Y#2V TSJ-#1*M8_:C=AY%%Z]/H5^1
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M<_M3"]BZ8YCVZM=/@7>F>;II?OKO__K?_^N7_S@[^Y_;V4/+</1@ VR_I;M
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MZ!"QPI2M&TZL(L08W2B*49<#HV[],<*+D!R3VRJ!-(0_3MV%\\/.@VA?LJ8
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M,Y>'N?4:R:QB4E?@0KL_F5^JM-?FV6.K3)#*]M;OY?B53X1W!'^EDX)LT%&
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M+GZ9<G7!DH($R=TD3TJU$*3Z1E Q9:C92)2+RJV86R>3JP-]5'.UT4@NE-<
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MKI3172O'+^D2ZJ975]R91!,TRK.P[RUB\BP>D/ACSPN <1>X4 &1M?$/S0K
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M1!,6K;AZ<!53=WH&YY98K3N%!?R&Z7*  I^O0,YE$+:L,J@*G7[9124:EZ3
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M\IA24D4X&/6:GCEYY&M K+:2L47K.7FR"R;HY:_4P&J%@Q I&$Y4 ;[EDZ;
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M6:4Q?1O!?'7#E7ZPOIC"JHW16[M<D:H'(6T(S4^GJ6J#[%8:&K+:T*+U99(
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M5JBW^7K[U'? G[^R]E2[?><_X/ZHSVGZAF9BUS4^;- 5Q;RA]W4;_05_#?Y
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M=-R53/:UU1#-%A@YK>AW\]HJ&GI @0*QJ+&#94Y&08U,VWAE90];RW#H 07
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M4^LOJQ)3&35,@W8I=;;@FE@-FA\JVC^_3M-,LGV>J&ER_.#DOL,[]720D^^
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M^P93Z*0GQIA/RP.T6_>&A0Z^JGHT#)NBMF$8>HWC25XD,11)W[!OY"[]IJ7
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M7L>,P(!8)4GCD!4@*Z2JHN"M*&>/O;QA=MJ=;'HG$K(^O5&5=W+(4*HCR_S
MHRM-H9\GU\!T!4H6V*E.+V2E*W<O<?AS8S4P0)VU^<)P@^2[97PC:<.8";TG
ML<M;@-\','WO?M+W4C\I,%H$HZ\IC[ZF>5(@?"!\T@N?M-NH*11FG@.WG#Z+
M@A \4]#U7KAS8MDEAAW_DUW7,>*7".)5(!G^RM*,O;'<,33/=).K)';S$4MY
MALI^9'6Z,Z14+N!-3:1F'ME64"31=/ SZKP0JI"_TLA?MRHAP:4#DZ]@\M75
MDZ^NL(>'.<&N,KJZ0OJ3Q5!B@FK1BY(]/)&[7MW$;RYKZRW*EF\$H6]IX&][
MD4M=QPOF=!K7(U/(9>H,I7D&8,0FU;W2[J@U6IIG *( H@ F^:1/2TIBI\!&
MRA_:E\]641);Y1*;J&F$XJ3H^1/#"B/_Z+$ 4E]I\UYW.T7FG2K96PBH&P2F
M@J) (B(IF H(V>4VV>56E9Y'7A2I[BUZ'ZU$T[[IGC+)Z*0;96NK1H)6SO,(
M/V'5<5F8]T5S#39*H,.\OE/>0]*1L#%\S0J2 W7QG/EJ; #!O*+[R2N"9_%.
M=Q:O_X2/9\P<*PTV*J-E1&YM"&0^'+6E9L7F1L,VJ&H/SN/1>):!Q3%@?/;Z
M)GK*6>C?$!(0$G<-B5MU9.'2@7B">()X@BE , 7H)9/MYA)4FD:8<;P@ $YB
M4D1HW\_J%I)/+EPV:.SYNN'G]H._HHM-)O <2\_\%Y+\[Z%A"I7^)VOH>FOD
MPJ?B(1H@&B :TH*&&[3^(3P@/"[TIN]"Q\F;^YXT!O1"L_&ZJJRP%B.9<L2H
MN6#$1&J!_/BI@-@IJ+B:-S?JL6?P6JO@H114=L%TQPG+QGI$* /*"2JF@N))
MHW&4RM)'8CY_0PXYG5SP$!R2@C=--8><^%#0F^%?,-%!W4(\VL;F:Y3J(]7N
MBEXG\"?> O][2"-YM7-X7G62FLUJ^%)K\)-V!K^AF7EFAY.\_8OI);^2!AZ3
MANY%8\=( VL<R(BOSM<9DE.X0!$G)\Q&4>5!VY/LJ(%$!1(I]B)D8=+K3S2I
M2UY%C,( O%S\:8XDG?3+HXZ,ECL(LFSR'5:R^JN-%S,0 9)."#)+DE26(N@C
M>2>G@MU-!3(.%M9U(X77AN>'V>M?)UH_+X8+KSTSER>NMYI"EV>M]W>SF,:O
M;OC!_DF.V$TBH2LC:6!:B-$N#R=";M?D$0ZP%AFSUK$L.<A6D*T@6ST:6[U^
M!$_KY;8SJ]&.!"M0";33G5)M_<S,195S W$W,0N(2@SLF;6:#-KYA+E  SR*
MSC+4L;+:D+X@?4'Z.HFV]#I]G5IX^AQ_O:!6N[/6V-::Y8$0S1LZZ<K+O*!\
MLI?G[\3UHF;50-JUP;+/N$ANMQ;)*KY%>VK"8$"RQBDBBU#,,=$*<M@%.>R%
MK*]K(S4%');2F;D=$PR?ZUC8(;VN;?1&XP+=+?".\,GVA7]T^'(5N3=OYQ1$
M5)%>:^GWJSUV3SJ@66&6(= _6$TWEUCX9EU<=2/5WV;0;";^/-A)]?"TOOX9
MQ.^[@_>[A6P44W#T-)J0V$=XW\HY>9EO5ABQ9-1GVNC,2C8GZZN\L.$GLC3?
M<(N(S.&AV%90\I)*-K1"TM3(Z()>T=W1Q_NL@XMRQ^G-BZDWK'I,N'9LR65R
MJ[Y5F.'8&G#'!?1DR!F0,R!GG$S5I0KU79$R6[Q=DT6W45J$K05Q9OZ8+1>]
MR#?P@JVJNSKOC!""\DW 'XFJRV29HXV4(8E $KEA$DF%M/IA%GE!6UWV6HMQ
MN].:V%BW8XBY>EB8J9?25A?.1.MN];)E]Q>%@E];%>8M-;%#$FV5)K(L3IQ9
M6X5,DJ9FE1<412&3?&>2>F1.\#4RKLM+(T*6\YKDKMLGECA?)(&Z1=4JLZHR
MEE7353W"ZZEJN"<!XLLW*HO@1W."/R]VWE#V*S]573.^DYY4VDK.70?6)A>[
MDN'TZ01VQG!U0W\A;1C["O.&[[0LW<%T[-_X9*<I;BT">;>U;-(#@S3618,P
M@#" ,( P@#" ,( P>)B"9&F"0?HJC[T1!C>7*P3*3B?Y0-X$=,F+W>#,OA->
M/._&OBR9I#KQW3C3-Q)I-)MQC? 6\H1N3S-,7S[1!0JS8S\?J,<^G010HN<,
M$@W"-;*<20YI-U?.*N3.4)@]@<5W5!Q)*^ING+9I408J6TY[7;-"$FEA;06E
M05H1EL59,LM@QXYLW+<<?Q]QO-LCEZL'_2[>#N;BS/+V=C+'B27IV_L"K_Q0
M^?56LS54AZ6VL#58'N]NN\B&,@&OD%^^03Z!? +Y)(5\\GKJ$8OWM25+;KJ(
MP>2;G&7Y[=T'JHA]FEO8VBB?(T<;!.FS=&5G4QXZU-: 6QA@LU#XX?DLR"^0
M7VZ27V#YSEO$28J[.EX+)X_6YO&W?9BKZSF?K[5I0=TN6T,*=<>A;UY^[Y24
M;E6L%!M-)++,Q1P?5@H-//'W0?9-O'D>/6EX3XDWB3"2&X,VF4!,_-XG,^,;
M3FPCZ9G0>U(7O07X_:TV?4R/5'Z--)H;V"1N*Z1TS53W1P7.U;I%0>#<W*1
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M==/.,_G$MF&^?,-I+$NAA\VX(>E TGDLTGG?O)Q<=_D<Z[P@#N]6#,^J"U5
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M*/[[T)CK"3EGSD.[UD)$K;J>=FPT'HH=7I4,9C(S6Q*H@#&CAKEHKT1[%S_
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M>GV7^N)P/:]'_6:X=DNK=MV;K'HRUE11/%H4ZP;7CA\,.-59G'T-KO?A4A=
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M+1]CMN5[*TLW]/Q6#D EP>\Q:^X[<E_CN8%=K=7*>1&Q59<;=+W>1"SC7/S
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MAN6U;%#ZA-<A']H(IM# 8P;A2 QFW46T;1A;6GQJF>##$61[0\1(2)=(!N(
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M);25S+8'5S<W!_'QS!M32M?U <=.,P4W831O>\($;D(X?#?(63KL=?)_0>E
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M1! 5*\DH2T6S):0&D/(.)!<Q#I"50>75KCT0)D;X8ZHCJT(E;QTA(K*6<.K
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M$Z6LXP,?T#9(_ZV %;^J#>@Y*A1&2>/#LDULS@>WZMK5FY3;#E8H<JZFS<_
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MG0.Q&N!*I.=!3L4B5P,D:W,W>X(SIZN1# '#9^=16%:[(<D?<5;?K(+C4ZW
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M3F'T_$RIHG)U;3KE%\IU7((5%]\Y2^Y<@C'WGH7,U8F!*'+*RXQ;9R2"]D]
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M=_ 4N,1%^U1(4Z7CK^"?$-F.#L^O$6V1:_W$ =;D/,K2!%<>L;[R8F0V%&5
M#:;PK1C!%50LU1^&RCP(M@QV),UAWVF(E+K,-G"QC(D2>WT64?3^W\Q\R4'E
M92%/RCLT=6ZGA/1NI$O@7I+ D,TN2Q$%)5%LCY@_><%@@84]'+Z=*;VH_!^&
MI]%MSPGNQSP*T>&"G^O7B]QA]%D*#!4EJC655!PM5<>I5>+6$TXUDF52#(7.
M:<'J-2\D;AVC!&,&/%W1AO -FUW+-TP'CIY1AX3?HZ;DL!"G,36^2A>1K2A=
MJ0*4+:@9+]\D89:NE#2#"S;,OXK7/_*#5YN4ZW6P0&X99#)4FW@;8$9NKC!Z
MO )M$!4E[HGL0)6[G,3NY:^O^%UKS'Q3=&6%11$/3?-F-=FQU1"X2!(YCXE2
M80$S9^HSHOLOR*[S-Q-=!T+E=O##FN=YI11+#M,2EYBZC1>ZZJIPI/#42I]=
M2/S0T504=@)Y#Q*%YHQ."2XNJ!2BB- 9!+=&B37BH:MZJ@'0P4]Z@#0$FTDP
M;1>%<%5N*'ILX#YE=/;=9HL(LT(F^AC;"?*LW0*SO+H'Y-7SQ6H[,O#27$"<
M*DG<M2[LC-(%17#GB!1G$7]_]XET38(71DN^1Y0KTDR&%_@?NJRG,GW,%\*P
MS0\[POVKWT&>E$"2,<*%SZPLDJO7G 6GOR%2*POI%EMI+'*&[2VS#3-(U\D
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MU>C'+'T)#M'K2\YJT!V)B7C _)+SV:*Q[N/:X\ [,75%L4YQR.G\-Z6%&R6
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MI*_;)V-=[QQ15;;B/#$Q.<R)TIF77@,V/H.Y4>2*0 ?5!>>'$9,(X L$FT9
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MP5VKUJ&/H%?GN7=H/_J9^OLFPO3V1C.]10T5-AAUF:'SJ-Z54^BEW[[UCF
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MI$\)"X!:O@BBF&-OE%&<4T$^"(Q3>9T(7(<3*)<X0$*6,?.!R9(P,*$"\G2
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M_\3PV@:12^M4W<F8;NK5@\)!'3A\A,,LG+I+'CZW[@S0T8VQ].'%8_):[A#
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M'5E3\HP7, YP"' (<'@$T@(<[@T..^T^P&%)X+"#'2MT(C=NG[J_3.P3 $<
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MZ%L ANG9<_YG&CP[?_X+4$L#!!0    ( #4Y#U6OM>@SZX,! *.[ 0 7
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M).CE>;,C*#U/KL^ J P,( 6HL@?YHX-T!$9!SR57T2YHFG\9?Z!_'(;F$+;
M !0=[OMC *>J>\NTUT,8 !D!@AX=L8@!C(*[$_]K"2$:(>/@7N41Z.[O^^Y6
M:+4[Y@*H#'#].YH# QA?!%]#D+K_,KQ,IX4"&=7LA[K.0VMB $/LA=Z@71Z4
M!'NOU0VS.P;P% ,@_H\"+OBNGF, E/3"&$">^/T(\#7GN5L,:@L#B A#QF(
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MU&6FUF_ IDT6R7W3,>K&J#/*SGDC[OK#T3^GKNU&1ZLU<#^4Z%6OU?7%% 8
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MY.3C)>"6X@3I:<W3T^&:!OZW:H/-R[9LD3A\J:U?3M"/,8#!/()_,0CO?^L
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M+.2]2#=YUT"U;<J:OE;6PVV>G5CMM$K2(91'@!*<EE>H%%M1 @>AH^9Z^I4
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MIZ[!.BZ[*]=4KQCU>/8V%VJ"]9EU B=Z#SH]M1VS:@F+.3ZY2*DA-?N!)P_
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M$2*X@VSR@MKKLG4N_+L][X>"X^8899;<'NY\>%ZO0 Z/"4*>ZO#*4A:.SG'
MFS:M?/_L+.#/[RHWLGHGYER:.%Y.^<P#E-D:H[S6)I38Y95K[H@:/9LW=9D]
M6!2[>N*3]$#@U@7X4V!\.R2F/I'<RG1_A7FVT:(DAQO^TX* C/^';J\XUAG
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M\OHVTV+L%N\@\)26YT1\92-"E%[S+^"#*WC(#4P+=I=E,EZ9/Y'[,2U2D0>
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M75JNOHS P"^Y,$]F)D$(#:P"DW7Y]A(+"M8SHM/3K!B%987-U&$<'I,O]N+
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MIFQ[F66V@P<NOP:_>H8LK(3T0T'3,@X_;(UDZ.J7JJV=BL?BN7?^T;./J97
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MK)C+M,)>Z$LDA'^MCQJY&2=[^M9%Q E#4K2,)B=,R/.T$KH.G1"B0$B>A#\
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M /+K M?%&,Z 0+C#L<KN#ZIX,L'@I$-GXQ]OSDP<2T?$FO?Y#OU83F\9#^^
M0'FZ]T_:(#FBTA6^#X 0N?@&'/+M!P"1A&"\GB&E^K"V\F;TG6Z#ER-PB6:#
M:-L8:*SJ8=*05D[?1SZTUF"C)AWB<>UC8]&[3+/+XY:_NTF]4YZ8E2>R$"<Q
MRUJ,Z[%G_/,/GZ%;.2B#_F;$8GR44OT/R2M-L;F?R+7V4]N4R4&[O.PK9L=7
MRR[%]'&VU\H7*PNTLN6@D6?5H](?!WL8R.^D]Y+FY[W2U.RN:H#.*<I,',I+
MT6?8LI61>PAJN9DOX9!-Z,*R3=(W7?[E86=KU[,G2BMV3LJWB!M=4E=:KLD:
M=W:J>P[+TX$8NMX<^IZ8N4@AK"@6IC!00L)PI/3'<T>:I0&VG@4VCD_FJDG<
M2S]IG[1 9!IC[3U./B3*JQT9*N=&.?=:&5<QHH.4-DW,X0N>J ]>0R1_;:*[
MV*)/'" &YP==2012PR?Y/#[52FJGE?U9$(UF,W"3$+[A1)JWK;1P22O5"DMQ
MKVGXG"0KK*XA86F.F-UT"R(V^Z>F_K0U[*N! %WC<2D&X!3\W4FV+]=Q6Q]"
MP"4U@ZB!-Y(&V'V2AS1'0JG(-E3?'D#&/G_2+A95&SH3\G^U""1LP%I22WFI
MS?:'6<3TX_E2Z - R53[I^P#H-6@A1*NTHWPRF.%_>AK7)#CX:\X@V$Q$+AL
M=M-P3S^_S4Y@YJ_):Y[E#5"=O:D3H;[5'=W\HEKH#;)^+'N8ECH&U?/I>6H%
MP (EICWP"HHIM<]<<TDWKU\MI\CF=+8X7@VG93P GK=+';[78E3_373P"<F]
M,4:H?T#JM5>U&P<<3WRO@U[[II_Y5(;*G8FZG9SWB"W?Q NF>SI0\^+C/FM"
MHG(*_\+2M2<Q@<_TFX]4HA7'"0-B$U[U-B"3W9$_(D,^:BC4XSQ^ =%"907R
M#L4M<N/AI.?QD!";XBYCWY$&66O*$9?8)ZM+20$Q\\HGNF"!#7K-):V&<_O/
MCAD8</AK)^J(=6'08 AN:5G^>-8WER:I(O\*AZ^3E[XITER+>?)EZ"T'Y0=
M7SN*$U/'B>LEYB^8XTR,.\U1YFUR;S[>@$WQ8H_@5P')3M0\B8,=CS=+S=A%
M.;V))/_HFDUCXGTW%L9S,M5B9)QTH?MOWHRZ/M+2X]9MQAB#LGDPQ^EF;T+;
M[0?\Q#=F,HJ7Y2NNGS_8H83P#!2<6*"Z[*S^FAZQ;Q7TD*>YK?1>#OS"CCFO
M9-;]3QX 5=KNAI^%VS:BOJ;U% !KXXE6R2]([>74F/J"5(KW31'+5XYP2551
M+H@W+<>V!9/TF__N5KYC/!UN(Q*.R;_C<\(=E;*JZJVBW9N4CKP<.,57\=PN
M>_)NW5_[COON);[_\&-8A]W+*:%#9\9"DI)]4H4K$PMI&:#_=YEE=?O_Z^&L
M\[AP1OS+$PJ4S*E'2Q&R]5QNRDT_'3C" P WK4-"_LA<;3&(N9K$O5]<OZX>
M\!J#<TD1S=3Z<0O:JQE-0S^S+1S5KKVD>SE$85,8HX0S6XL2KUH%.8U>MS),
M-TN8O^2PU33DB_>I2A ,QER./(/$4:9;AG7GA+F"&%X_ J=!C\H_^P\K?;;$
M-^9X.\IGT;=:4OP(W3 6),@_G2WF"R*YH:4..-0WD]<0V4/=-R8:1A45ET:'
MN;PIR%UU[R ,K3Z.DG (F55X(_;G2^#'&L5U<G<S'[-=H3/55%#NJFT.L1L2
MK&!9A#3J*5SI\2S:NQ,L]IMT$">V\S+\1O127)50C;RA:*W#9H-;J=M'*JL@
M _+,-@*<'A<:12^N'I+_9+/?*!GKU:MD7./VZQ$:AYZ*P[8*'C^1%G_'-'"+
M]YZ^% W"ZB=\A=I=11C"/U"0^(HIICG_KPA.,0<H RE74./UPO&2"F>I69:K
ML>+0I=([<]O<S.<H;NB3#XN7;K!]LU ATK?3R5;GUKXXQ.XR1E/ZQ7L$LY.<
M:PMZ[*JG_;GP)H,U%?L2V6+-]B.:ZSX 7K&YN\,NS0^>F@T^CY?]I\"6]AVS
MP4D58\S@7#HP?%<.P6F S4"7I%]OCT_\_C[IJRL#9/MGT@CG$E4?517M!$JN
M> D)W("%9&\KA9=+F.6=JYA80^\/NZD__W[R;%$5TSIZ E3;=(861E65^*7R
MS*%X;^9OFU5H167VC=S5O7,ME5Q^[P^+!7B3GS,DSC+0(QH-D3XGB@B3!E=/
MMXP4MF"3:IY*S^58ZHW/(??PP&N^Q=]@CE!OL,IZ<K#&Y.?N\65Q4+Q-"C_$
MAM_;<8?GEX%:LJ?]XJA DT-'D(W2*NSRGF4FUN3H,7CV[XE^,RA$>(ICF>J\
M(YN2L,V-CB2+#M(SFXM!>;=-I7:C7U3/;D^5N]GH["OSNI]DJ/$# K]^F__N
MK4?!WOP P#,CG1J4HK;Q:'V#8.NR%]<.O@.J1AYTJT>!FEP2TG[T5=.P_DOK
M?1$JYCR9J2NRB<1J63*Z/1VA^>6R3_P >"&AP_9=PO++IJ'X4-G3GZ]KFU,&
M4)> U)BZ:BJVZ NA\YQ06I6_&8I1/6M6:F%U/BG5MJ0:C/_4C7 _'P[QG"1H
MO?S!>HQI1OBA2O[^)[K=G^X@#*BK\N[ (!!&^$Q<HBNV>7-JB2QEU$07I;-^
M,36ZEG/#T'65YGV_[\3O_Z6]F%I=J;GQ._K*"W6P+1UF@CE>Q>5/-"*5C#E0
MHE;*<L</Z5O$2DX1;=O->X+Q?('.K93[I((+S%9DXY,QOX=FB.HQR&I;=$_I
M_0EZ+F 7*<_\"H?Y=</S9_]4GTK5_==CA7=:NJJC;?S6?U.=3^U;@B'0G>Y8
MNRAB<X$8D#72$/ARD_&->=(4W4R@,ZDUR:OV@2[";.B9= #+6 18!(3?:A]2
M%2U$#M6""2,*%'O"SS;19,R)]>O!";.58+[3T8QBY.=URRT:,-_*?JBO\7M'
M7EYWW"!-\Q\YK3\QG[O@V!I+G?08";>-G3JBX@I1?/ 5@9Y;?)K>#.<=FW.!
MWQ\WK3P:/G?L#69#/>QE>CSM20R!$I^Q67=$XH:B,)%_.V)][7'6R,\\0PI/
M1[/63;'V*#ES;2A>K-CBEBJ7*999T@\.MLM)*#VWXH1]2\HDQ(#7-',R5Q79
M"&]O)^(!<T@-E\KCJ23JW_/%R%M84MI@\9HI ).30'F.QS0&!;=-_I MOY0D
M)29R71VF1(P1T;0W+.$ 3Z%STZX*FJXN$48LWG+N_#_UTVY,]_DNP:#E0-N8
MN]G]>8F8%?&O+6W==3201XB[32Y,WJ*<%2O,**#TF.2JKI-=W&]?7U_?8I@I
M_' G_M_!B2?LK;YN+6VD!3R_XO6>8*M)EN6T(GIBD]Q!CB4]DM]3'XNTA:ML
MJUY* IB3^_P(U.?^OC@V2^ ,E;Y: R^:0BERGY"H42A*T(V3VRF^UCHW#CN%
M:S<97<,K%O\9T&?7>/*465K,4C"2,/#6FG26Q^="0Q3U0\DHGDO57^4JGL$N
M$0K^FI^8CV@O'P !:SOI-XQ I'@?C6.LX%U4$Y&P8.@9O"=QG:/!R^+;<@#N
M)H>3GR2G]XJZ9=J;ZW=526Y5A#:+G@$XX4=<>5&/'/K[E;NQ NGU ?4T]7/.
MRV>ZOV,?T?4@A[$6*?1Y71R8]OUJ$IFR8!&]B]]D^O+.5_/COI0];ULJJO?"
MY:SI[I& ,,W(3Z1=AVGFK.+$C2;36Z@/=ORXQGG=:I0]2$]K@!!..^4N#KAX
M -#(.!YNJM3],6B)Y!N,I> 534[S6U66L&J16R]>,#5$E+<RGCT -G!]ZZ7_
M$I0P6EH1QTETQ*4.K423W[C0DG%KHY+N)B%5ZT1*C@<>;7+3WQ&I',S&727+
M N\_)K);NEO2=_17I?(T\W)ZB<!;:_+G%<&/Y 67:T+R'XQ?M2[;PL2%W33'
M1F7K=T*V[[3.U;6(F&/4]BGTZJ?WQDGU?%03!-= 3-_9.2,HFMEN9,N1L$3@
MVL736=DVZ3CI;@9]PI]> QJI:IB_S322;T]X32P6WYD[[6C0.^J=#TN\TDOR
MJ@N,_X!N;^*(ZPFXKDJ0T&<,%8KY#,_TQXA</5"-ZVJTBT[_>!S,[G&,UC/!
M?8YKUM(Q)EIA&M'*,0FV]$487,NUAFE5/RX(Q\+3F3+'B+$L]E=Z3L[9SN.(
M_P3#;3=/5E=SXGAOT#@S$4[1[U.>;UE_^9)PHU[3.SC,K%DV'4I%?H[52MW0
M--G*;[M('SD K__D/+]2('[\6@[$F/8GX?R)>GUGO'*/:RMSY.IF>PZQQ;@0
M 87?2R]-N'@3A$"_V6/57[%+H#:,-+"),V9MM8],DG</T@F/:W$4<1SP+YYG
MM G#NBD-<%+=F,T\*_!:W6_8J]\4.O?//]WM L''2 QB2.8.@SOVW*]<*<Q%
M&)L9G$U"37#&KEL.4B+/?)=,"4V\6A\ <L9BFYTIV)V.I!U<O\_3'@"^6V\M
M'P ?V!P 0]E\<I-HTWO8HU<AO[LK7S\ CB WO.VWV[NQTFVOJ^Z&GUI".G6+
M<L@> )T2K&Q:=[Q+^(:J6+YUNY("V3/G;2$2](SA8%EG>_B!SAS/^JEVM=5,
M1=W CM4G<47]NGYLT0$SUWXAWG;HGYR>-B)W>Q-.Z]E+(JPE;]TYYZH<9_Z$
M)E!"BE.+]RC'M"-K$^1J#14'!WKH/GKO$N2&::6RV=N:*.8(Q4U0.+.3=_4
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M;P_?(N1\8!NF82:<\*1B6T>N=N'0S92N\6(E#LYL\QO6KS '+3HIW, ]JM!
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MDTI[4S;-_J%N;;]JOVUO(4KS-YUM1\F"HGZG@:(&UIIB&PQ8!WVH4[:*#\$
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M;'M^;.2"Q(\1'B.-8W3 !^(;+U78]'1AJ?A=$UY1GO.>#Y_BDT0\B\8PWQ<
M/N1WJ8@4B\>B^_2E]$E:I'@OK-0+$S+O5E_AS%BR.,A%J?'B4R?*2VT74M0X
MWX+[#>[@.@SO,,OI_-CQ&>P_TX:K:IB#+O+3'$ZYH5'Q\>=O>!3[T(L$'@%!
M5-A3^8&&8)I^!K&$P\/=0VNF$PO>\)\IXFFV-'LT>\S,J8XKSIY^%!!$_DV,
ML:?/(X *Y#MOZKBG@9"#R>7-9Q*!S0U+MC9_UI*XWH(_7>0$K_.G6&KK16XH
ML2Y ./**]YVNVJD\^KO)'JX3I<-52R@K(FI]I5CWJNOQ?%-]2'&O^X@=D5!
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M?HOY1$BE=UG,\AL-476@D"S)IJ3T_P[5_K]*W"Q9_&XSY6D>TSS"@.4Y'[R
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MKDF6FS<M)UP\I"W<YXM?>(Y(UL,HDY#?,1L+R[S60[=I\>S_ZP^=P%!NCEM
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M=5#73UULX5YS4&,AZ-=3W6%HD>AET1HS*U*SX\N=%LQ $M,;(Y9?(FM>Q@0
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M!,E N:IGE.]^XDN1\.@1 TZ*$!@VHF(TBUF[%*+Y35KF+0<WH$+$C:]-'G3
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M:B#[B':CFI+=BM3Z\S?K 67DND3 \DO^:P!H]N*H2<\?"H):BVQ.OC 9#GJ
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M'["W,_0:? VH5SLM?P4I\]%0!\/N[D@UVS7W[$HEK0=\JPG<!2Q[VQ_8QSV
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ML9?%?=^9XA_H4MV/V$LU:1V&BL2^2CR2YY%]G]C5 "EC]BZU*\V!D8(.QM^
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MLI9D$SZ(Y+AJM-F9*YQ&9-AS,BFL-1A3WW2D^8?*K[:.,VS@1:=T U[SVP>
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M1TD(!P0W!>M? B9? +"3@P X4I$:"B3_^CGZ;\$8,D>].FU\ ,3@-TIG;EM
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MH:"QPNMAM@-35E'+P,/E6V>.":Y\[I#!WMD:YD+L^;:O2'[MJU>B,'SQ-\^
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M8_,I@,;+<'C*J>(!$(Y^:VXLG8S&N<FY)]'1U?XG03QN]@ 85'2[?@ 4JSX
M]A\ S^)VT'("(-@]A^$#P!"IC47U'SW]9MO_+8?[^]&'<L?;=^+]>1YVXCA1
M0+@PWCC6![".+ UK\NK=)3?-E8G!][KO2E+%%934]'V[I><U#1J3C%._/]FD
M*MY-JC':NO5>7='HWW)\SV94X'X+9V>X*BXHJL/1=+#_=Q+Z?Z/P^_RKVTBG
M)O@.5%[PB?P_!I)]!/Z[_2B?0#AZ71-6 ;)W#+",/CI&B=GY>=A,2<VK9=H;
MIZI@!0H?XB>(.:_:D686H"<"%$L+[:_]A/W$/\XL59%[F2[V;A .$:NT,B5_
M_TCQR..[_MT#  /I.=#K.0]-<+OXVBBV?(ITE))[\B/7;NR&5-5_18"HC_2*
M;(ASJ'0)]>CT:#/@@]1LT>.\4OD2A2:CFSA!;]T5-NYH,29,T?54&._2C01:
MF*:36WCNW #%>\YI'C(9@C=UJ#%Z",UX_I:7A/SS$YMO+ ;V2Y@OGGU.G$[Z
M<J<%5_LY-_4E7"?#B&S"C;G-2"5*T![5U7PE$5R7*Y!55X'"F1#B''':;:35
MTYJN=N&N.@)SYQ*=5N&^+'^D_.WI>\['BT7>/RDJJ.8.C]82#8R.A5P,C=KJ
MP[ -H.WM2AJ#D4$K0FFC\DG*AN_84EM&]9J:B/;VD-ETM,BYM0< %="REZHS
M5&3!5#&R*'?ISV.<$9X6#J/WGPXNJX)EKB(G+G$329F@S=YM4R6PUI=PJ]_^
MCM&.CQ/\O_$HOCDZ,8&+1*&DUI:D[WK\0KCS=-MGU]@?%P8"FNWCG!]13! "
M,"4CAB3KK'60\6O)49+F!?89:?M3Q8V-15D^7V;G^&QEU_C?<,C7GH7V\\TQ
MQ&D%2\),T<+8]; +R%\\I/T B/IRZM^49$.5T.(4F2%:C=L(2]GR+]$H^@3(
M$IB^K!0!07@C#@VPOZY4]\[IFL3K.0:M#L8R$;7LU1O]L6:.HO&IHL5<W0FU
M;IU]']T'%2\^4/*B/75:,#^-[<5E?$7CR/0 2'[W\R<F]X"LB-#*IP#RF,@%
M6D.#)K6%9,C89S5<)?;7"D]UDXEYA+LCA$7*N1LSF?6FM+3Z'P#IX6@"%"8W
MR.$!@.MPZ]\\1[2AY-?9UAA&^>5QAB@-Y[ (X1EJ)&6.C4*T9J?+DA "CGE\
M _%NS9B=U6)?5GFJ;..Z1G%_Z'$SQRAR^ !8.^(A]' #.XF_;@J,5OM:P_"8
MPI9]2KY5.7N3*VXAR5QKR5VT9NIG)_5D$%_)TL+N=7*@F] BE$B%>?T#LW6&
M><_OV\W;+,=9- R,E)9%):6V:-&@N$ZAO=\N'-I5BI0J5 J7<$?(_&DEORF*
MW1BYTA"DU^,_5O#Q?G?9C.W^ "!"4RV@E#I.\SO#AJ_5)QN9 GT^@IYD2$2<
ML23P3#YA%HQ;? #XML7M!.ELW/^EPQF1[RN6!YR\JLV#DR;,NX^#$Q8W3Z7-
M[*;+]A5HM;U#$LXT[*ZL=>PJ]L1?3VR<'C@:W"Y%?0MTZF0_3H'Y/X^'[H1.
MIX2GMJQ:89@$6'8%Z_5D;67&>M.R==WB-[JRAD+N^2>.CFRB9-O;8WY\ZY)]
M\T=T\!K\3IK[=^]U;8Z=%K%1>6 9>CJ[>MJ'_SFJ<'$]/WD@A"I]@KC71*]M
M9).C^O M)&^17H3[:#8RT!AD+L.-<0"[G$,_/0?WK(2'\,Z@:4:%.OH2T]$M
M19:[K6&.[B/4\IW;GBR)@!V)\6&/+ARA!23Y*EGYFA;Y'E5'?[&=I+!ZWT:"
M]/9HT6N/E -"&3G..4:$9KQ'!2T_MT6W^5NRQZ,\VK_XYC;'@"=]/.!U%_J>
MHV?[68U)65,T;WEY=)D8+\Q[[4Y+\O3GT 0WM9D=L$OH#=,0FC((0RLZH/J+
MQVXN8=:(5JX#]V5:Z>,9<YHZ!3NX<'T4W-*+##-_U!YYL+K]8[TM.4;W3;#3
M$P1/FENI+#/>76ERB/&I..U&:7$  \(URD=A2K&A-$<AV[[A3M>_=T-T_OL.
M%EW.@?@#8%TK6O"$V %-'ZSYM#%P/FN)V\HG9<-';E,98]A=8O(P.E"$]Z!E
M71P:[F,90<>0;=K8FK2A,\TRK5I>WYQ%P&&KJ/_+OE?UV>D3^!(_AR4&"FMN
M"_D^V"G0P\T:5 W4'%%YK5[=NFR/ZO^ I)4!/GX<0'4%(D0I3DF*58!LO_(V
M2KV5OXJ&3+ED^3,EB^+_],8*3S:C*GH 4$B*L'XKMC :EZZ"9[7]93VG@@V#
M+];0FI604Z\$.G83Q>7XX]9[HZ;T.?!ZWFXR.4+FY[V\RD25H+T/'GR[<#TP
M>W>G(72>K'\#UX,FP1#WKCU)R^Q#1^DZ[R<6A&7DQ1T>/[#J^&*D,G!$GC^-
MT/[KB^HDW\]\*9--0:\VN 7Z#>;X]\Z461HS!UN;<@5H9L^L:).B/[N_N<:)
MJRM"IO:8P&:<JXM93]2_O_'!K9E5Y*#5E"@WP**+SE,-F.>9!?E4WP:C/]2O
MS"%<&D9=T?3(8S?"T75OV&^9)K#WW"2/2Y,Z]UKX+[O8E!L['YZ;0>UY6KXQ
MNNP[D17[97)$2:)+I>EPUDQG#C:DOO)1GET,$SD 1(B58-NQ'Z>F\/'>"?0K
ML UV4+J9LIY%__/(HL=RPK:ULRY80GU&2&*+C_S<)NF8U;R(]"?'Z+XGSMH[
M(=Y/(<RS[7S%0-L3@RERI=\;+7=8$TPWUT22_ KTWY]T8QN;2JBYBNY97"H0
MF%-,-;1*N]3>IQ]?W%0)44><7L> G8^/S8R<R+9-Q=YGL6OOL/?9&$0J6Y6&
M*07LVB%9UKFII@P> !$V2#O5---)0XV.QK#1HVJ7;^J1-J$O:!"<CTHI&6B2
MTH\%]=R^&<?:'\.J78$[O5K/M=; F,!'/CG9[TX;EQKZ7IJJ2;4UAZZ"!!6+
M9YZU!76IX+@];G$+!SUO7'+KH\I+\&F*F\6]F#X*2H_=\#/>C*F*J\+ C1E?
M!N3B<^X.LW<L%MVN( S>UZMX0]=\80+=EJN/&VIV35Q#P8XF@7OB/&E^)0XG
M]LG;OR;[MKCJ-]\_X\$G^9[K!:]$JETYP"9JK%NFA9K=V#*5FJ%M-@GH:^VO
MXHWCOYGJ0P?T+.X57@7.P2R1,CLWOO*:LU M)/W6O=G-/<@.]L(\2!H1%>U7
MMI>RXA0@E9M)\OD;E>@OPL/E>6UW61R AT4* O?G-9K)#<^12J.OW:0I-("7
M(>G$/<S*VGZ)HHS%L\I=5I2IV(]$7U53\_!+JH$%*"DZ?A^$&^01S!OC:JC_
M>_:D]Q98.VTDSZXFBUD&?#/^54Z,PB4_)5=<__V=I/F;M6H]A7"=3PMF3DU4
M"=RL1]VX/I&JPC@K+YFFDA0"$TDYM0X:6E&*EW.W,\9HG'$1RX:=>)X@B4*D
M_3Y<Z8HUMGC9(4//Y;.9>GWWA]@BBNYT+,PPKP3$9,DLR/9(SZ)A&E*9HSDJ
MV+: /#&QO[X908<UC?WP2*J@H+G>(;W )CF^= /?K)S37IW]O:,EZ7M7,(/T
M-^(YGUPFZJE$F7.,27#*U%5%VO;6-8RP*KY+CP'$?WXJF05;/PDS26I9/WFQ
MOS[7 Q_-+>/2=_:)V7J>^];SE4WZXP]!S8Q?B+OV+*84\%8\>/VL?X'6]/?K
M@T@M'R\>R+A.-ZTN+ZDPYQ-(_'K:4G](ZOZI2>69@+&)91>M:H_B)->"-L2N
M'F&VS."+43LA6;.&0Q_X'*>4]-!;KVU[&PW5NI"#MHW<.V;=:[$A&TXS#1&S
MC7Y^)<O&\GC'D<*)_$ODSR.+C4GG[,6VE!G66T[H0\9$I/D1]G,6YARGIL8.
M=:9_]K6_6668VN8!TY49"KDV\9]BV9&>"+ZK)E(K@<6#*JEGKP\> )BHE.U9
M^N<?FY .Z_0$"WN=M*>7RQ5I&&3A=INFBF.A[SH!_"*8W! ;*^NXC4OZ3\O,
M"'T(_T%61D;FE;AY9XK#%2-;QD1UKX :<\0G>9'/^>Q8^/YB&\OVI;/_5!6%
M:,3-&?S]FG/E4RF[59R8QCQ<.%)5PU0CN0?N,GW=E%8A [?U57GKP- _H\^?
M:JS"#7$7J\Q:^0LR6/I_Y#NJE2#M>OT, FA,A/K ,=5!?S"2T[.8ZF+$N)ZM
MNF)Y\EFL*;"47FZY#24>W/NOG$M[(BP/E]9I0\;.NEPAQ,[79)EDJ22YS+5&
MQA1=;LY/DUA83+=I4 /AW^?TZ;LM2># P-YE$LCTQ9?3V1HAG/.M)*6VQUO4
M3T,C,<S/VY@_\X7.=B3%:9@+WJ*;'@#,@C<F3J67M[F47J>F?6GV >@4LL(B
M4S@P:XQ:0U..V:]IX46<8O@6QC7#AN]2T77-]1KO)U:DUUKE*(=3S''0DN+V
ML4BR)',JF;;7(N:H[[3^4M.*ITN!>7+.H32N5LWNK49Z?V:)Y0I0ZUWGVX:Y
MH_81B0/_I1Q3"5.\*,NOF,.? ^9TUI.CTQ90-#/M4JQY17O"B:YS7+D4=1\)
M->N?$G]LIF\'E"UZXEJ="EAT*6@VU:-AI>7FK@\ \(%U-YK, @CNA1%**JVK
M'#EG47(Y'Q9\5I)J?ZX_7PRW21!CH#EK'L*4T@@ 4H%C(00O_JP8*Y6H,"W.
MPZ%?S=0(S<M?K5J+[8VK[MD7,Q?3&396_R6 EC&%P,Z/L!LZPX(@K-]!,J>_
M=C.H6*,_KE,*RI>H59H:#5 /O0H?L>,A$<-N$=N<SE+JX;:6G45Q5YB:&2VJ
M%0)]O&WC#+R-F7\9N\M]YWEQ-?ZR0RX.RKJY-?, Z'H "*O&Z>@<_<M-4PKW
MJ7*6RZNZ@DN+BXLA>[0YW8-&BS\2C;\FX#5_,(0M50>PE[/_\P;'_VJ/%: @
M[F^$@(OHMDZBJ8LR,H]*(%E-.5B9N&5J'[#<_(B:'388-W2+PD8&L2;W,WTS
MEP\%H5)R<3>Z!(E_$4LHA'-!@EM-JS7=]7BSJ;FS(UL?FL&^D1BAO:C&[+S#
M&V8\\ISFU1&H/X\V2*T**=_K4K*?I1CJWLK8VM1X5ARXS3JM:1L;'@KYF,FB
M*+Z9 IFIJ8F JEP^ "3H-74L^1=#)D)>-](QI;)[4U<&"VAU9-%Y<$)>^,>*
MO9'@2_R#+YQ$\7Y4!1SDA+ ,WYAQV>J8,#6Z4ZL?X8:@WX:Z;'A0*;',DJ0B
MU_H]/D=LI_D:!M<07E>[EDY.&R8!HS?PB^FC4.1E)HM[5$1.K6Y7$:U15<G<
M$(W-RAA#I])??3%84 5)XCZ'($)DY+I,K+:C26ZUFUV)<>_[)"EQ"3]RPK:%
M/DZWE#R<QW)\M=ZD035GYM"[HYM8B6*6Z4LJ]H+\]_\#<SS^OY+_D7D@&&O2
M/*>=^7H#6>JYE*VS0BX!6\530L!U/!I5:X5X[PCTP?!'-KIYFJQ?L]ZP6#(E
MXZDB]$+'E.!0N@LO%]A&!5R0TYN@(M]^P^0-U*6FZ'DD8/EV0H63N<U>8&L<
MWQXM'MT#SRU?S[&TF-2,M9:<U5URU%N0/<Y,$_R@_=&:P3ZH\?Y K(N2.6'.
M]<SI%OQ3HMI27T0-5/E+B#/;F#:VL=$_/8)#X"PR@IW!(V>@!>R0]>28R7XK
M\6-B:^&G-R@\__$^<"RY#,'QA2ACW%(U;T(E7^KBKV$2GD=E*3@(KS2#/*V#
M0!A,J]F@#78Y;SIEV;[CW<$H>*1E43\=1.T#'JIP++@=UXL2 EH\*M^RU57*
MW,)>@-Y_5O0R:\SLYJ486!W'>9NUW>3ZH3G;-]V#MF!A[Z[P*V>4,ID%+B\W
MD\^)><[ T:O"/5\7G\ ?^QF^&E=?(%^K;,PEB?UYRBHVP:,)9( /J0M77R=Y
MZ%7E\P]>4,];D OTIU1AFQMFV&*<MQ/6Y@KLZ68*%;3# -M;;9?WH%\#T?(B
M9,ND370DS;]!M4SIC:9W,62B<%[&2>6)\[L)IA?!HD,[I'[Z#0A)V!-)4AK0
M G>3<E)%%G,_YS;T;,5>4??)#:IJ-0ECG!+LQ&BC_H)2>=?_\1<  &#US&49
M[2+33)9Q47?66;F6')O5<5Q).SH&>ZE!,T1;]%LR9<31ZJ5@2M\@]%S$FH7A
M7(2@ RIT1(_MS2W?@Z:=SI]VL8%D:&BNVZ@\?JKH2KWK]-O^AX097=,S]H+/
MV/[@?CS\<YU92>PRD[TI1\*]K(FLC4-$+!W[,MR^9^.WQ _IG$##8AU9;Z>.
M!P#QAM,#( S]L@496+'GIXULTT9PY^94*-;%!SXY9$LUVM1^&_MHE#W-G5$]
M(JH_P%!CXR0<_@5NUZMU"'Z>!S$#.FE!I]1?E-DV)[-$A"04X0='!BLI"!Z!
M+^=0 _]<NWOHZ.%EL@D>2;7J_2MQNVC7ES/<*%_>DKGV6B;E AL'C#2Q(;.2
MY;O*ROL?@I9$R*@-\RGOI4<J1V!!,>XC<)7WGQJV7-NEN](,]9C/'BBQS=7P
MN&MN":6Z2>FI*VI1%^DI 3.-S7[R7RF=YTWB=3^W:]X) =E!EL^2=PF#ZK<M
M9ZOS7@&=UBQCK$XC%\^  >NTKEJ$]G-JG/U8:'7W!:[JMAIRYT_W>(Y WI_P
MSG0P2KRV_31]Y:HFMMQBI +XJ;?S7?<;1J)8@<QSD5<[/S8:@P44'+?\+6_G
M>7^/*K"?_3/)^=?90=X1+P9*$T'7!*=%-Y0X^385B'D/ML\S9I#Z\-7O,"I;
MO=G[OEU?3=P+UTH0!%,[YI*!>'8TLKHW-"8'LYP8[,Y?NK2[<C430 L#XJX<
M.<@R@F&KX&EH]1QH<F43J*>R?D1NAK!,.*P^]#:8W6H,FU*=6?-WY2&CB*%(
M$C&O5QY38CYZAQ4^V>J&"X&NT*(T_)[YN_?\,#)9B12S;+Q)4Z[,/:QK'F^H
M]LUE.=6*1MDTC8#M9\6[%_B "H>XO!F]5NF#J[-1><7&#FK\\R8]CJP@X3?/
ML)>1F!X#>I\>!T<*E8Z@JM$@"<Q9-&@'-$&V6Q G^W\MHOU_(_^K!;B =UX+
M?3Z42?:31N/O?)X3K#KQ]@L;M&9&"@6:SO+!U9Q>#NX_Y6C38J)!'%GR\W9K
M40/OE"=1;RJD"[V$SM0G38RTG# 5-SZ\X;M[QX\US.KY2;FX>4R#I;)V.6YG
MADV]@:_(=I* &U\_J+$[3YNO3_;,P:%\X$/W'TL53'ZY=VY\CS > )\V0Y%S
MHR:E76ZT*\ H-*A.DVA]\GAL?7M%+TRD53'Q[=OAX>/1]$WQF"Y)!JR4V:!7
M2+T:H%V_.%EUA;UO.6UC\5:59^' CDEE:SV9]F&AJ$=,ITY;_E"%ZO'X[0H:
M9UG>A1-\X':P&?AYJIJDCNQWV$AM"L56L'3N3$H%,KRGB:JCZ5N9F8E2F1D_
MA<N6MO$(4662>.H3%&=?D,9I6E]6%K(5UT5:V<WMN'VCYDT%QY"_TT[_ ^"C
MT7=^S*W*FH_FA:*; OJ\N$%X".&T=3>"Y?O<78>KS,]C$_LB&6"N)PT"I+A8
M'OV%.!(O7@A,3] 'S$U]R(TSV NDNX7WQWI4T!(6A9D.RJ4Y;!V?=6'5 '^N
MT@1SFC,I7SLKF ^P85(*G9_TTT?0<2'\XH+>!!;)E<"O!@83(W_'-/CCY^8G
M&7D96X@AL==Q.TQNN3EPFU'\KE1J+@)JK9"$2@A[I]NMNB<':JW^'0[6,:60
M"+7)/+WZA 7YZ<Y:="R*$Z'IHKO]RJXNXV4F5>3]F9D*[_&$H5,_D_5PJH'R
M($TZDRC8N\)QEE$BDD1'.?^_-N+\_R[_]WHF23[;!\")0;7MKEK3#&RYFN-?
M;[1QYB(,/T%DJ!H+G81M#^$9K]<--5KZ0_8H=\7GY!4 'IF6."BV0&LW.^$,
M$UP0A$()SO)80#+7)N*U<YCE9Z_TH[A*D9\/@"=FQ16CUGXR\_/9WJV)(X+S
M5CMCK.J_1  >K,?IRQ.*8VN;+\OT <\!KP'%_WX=CC,&F8;07%FK'H_^D?=V
MYC*\:KDZ53C393O>T^-\9!#>?G==LQPGGO_L?"4A%CQ>LHNPUQU]V7CJ="0]
M?.E\PNL2)KP9IJLXB^-$0\K\"B,R@/0]$MP5H)3(7?UCQN6OQ_+FN4D22PJ\
M87VR1!,C_ZJ+B2$)CU40N!..9K/8DQ:8"!+ [O_!;!)5=045=XM]Z=<Y54B6
M_%K_^^"RO:UZE,NB30!5N3]BIS_9S<L'+S>]U"%C#GIU4F'F,"=B\ !H_EJ@
MQ);.\'I+4;WH-6U:8T#$"K;D*ZF* 9;JA47NX64\V7UR>A>BBG2\JT2TW1)+
MR+5\7$4>H)T2+Z8!6M\!@4K[?6UJS?FEJ,/IFF+#R<!3%1 UN#GEMW*[]P#
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MCI;-"=V>%S0ZLO0/\_\%4$L#!!0    ( #4Y#U7P=JSR:'D! 'J) 0 7
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M*+M/NN'T^MZN5G9Y C>YS(AH\<&_?.U0^.W/.D#?+?FQ]XR:^M<M>]40\1K
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M8O^Q1#?5-NA)L?O*TD:KD(M-"*)LS<.F>MIM6$K9W<E+\'X;P)D^P6!G.X8
M>#NAP?0=ZM_!,Z'][]BNT\!G4_]+U*-KB;<61Y,)/K$?HP]M).*LVTO$D6C6
MUIE4?N^8&%L"B;"M(3E# [399K-0+QOF<EFO3CA:HVR51O;27E\R96NO239!
MV.S%R(;E"(PBA=D)#]ZL>G^W;:GXR#=Y9/JS\YS\KL^:MQV8VQMA5M"01:V
M]*&;!W/X4U5V"N' YS2 0F[?M0IT!PW :HM!8$XSJ[LK?[T=$\G Z61$]GAT
M?2"_8#\'NT*$=(*RFK+I]0QM8PIOBU8_&:D;'7_@X-':&;WE4GY:L#$^753Y
M6<"HVPZTJ[&K2Z:;T68GEU$O2PJ>N^I[?TDG>,-4X.37ITWSK?,^@;+O]X#L
M=B!_'J6!*XV_6WW7^:R;>_ H$?'%^5'N/Z:/2XT-1L"KD/17<7<\_6/-)F@
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MFS=$C%P\2XA'5U<@4UU@1N>DWS?Y #?Z].F^+#-!BD#?2$^/>]))WK/+$31
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M*W**D3Y%753JY?0T[]^#A+";2@PE4\D7([0[?]GO-%)1E(W-R:+R#1J@ CT
MK-H3Y)YA.@@E5363+(;HK%O2PWX[FWUVZU(_EY7QVIQ'\+.?0WY\;3JP]G2R
M<0E]*^N;C=&L'8M>[<2VHF'90;1%Z*S@N&.D[@-XRO=7FBNK\/7ZM$:X'>]:
MPK<[116%^/7 %TO9?N&&AO7VS(ER9KV_7H3KB82"E@>X#CI&BQNC)5?V)+'-
M-6D[(X1.FX7 U(X %V!_?=S]G<D/>(\AO@HC^H/$<0B%M0S:N-QY;'<0 2J*
M>RB9P [R)+QSN+\C;O9CN)>N_]6]6.6![MO2PDI3<.$=QYAQVY#<B*.<IIF$
M\Z[:[!IRCK.G;(QU(QLI_:'B205WM*<=]"D@OU;8N);Z.C:7Q7>;TZAHM6-P
M>EIU$RG+LDZRZ[[A(,_G+;3@F>/-)Q1>"Z$!7(S>V$ _ D<U)+D/0RF:T'>^
M+*N0YB;,&]PMZ.N_+Y)8 (9J*>%M*LMZ?OL$J@"\Y7*%DWMQ@RE0W3YDC'\[
M9>[4OK^#)UV(E]@]TNT?<*O ;,XEDLG'-. -#V#O+; BL+@+$36!9H==U'@L
M_6:,?W8F='"<;52AYJ[56,JAKFW*7WI3YS<G>!)^6]@6;@,Y%*S@7I*<1T0J
M-9Y?P"5\V)#VE5C4"7]0T7W &-?8._+3^HJLYV+*"G_SC@ENS9"%G:,37K R
M;S&\'Q1\QS;+[HU^X>W,>^N24U?;'[_D?E?TR#-:#7^\@GXN!,<"=_ZSO'F!
MIWG[N:RK@5?'%(P8>V@ R^8@4/##^2[..,'QYZ@O,JG,=%7O^>_JBT1G=<-K
M8ZD<U<2!M(K7WU>T;DV8N<):(,!P@G&TQ)?;*9L& AZPT/<R<_*)]0IT6Y\M
M^QT//I&$NX \%&T(,ZOD&3E8^JG%:N.<9C*M9M\>B<6+LPLQ+K[2?0+X\$*#
M\\00=$9%3HW0ZF# ^G$=NA1O;5(* KZIC9>0L0,.9,P)O##F/%<F#V &+%RL
M01+V3R$K[";K6$I"V0HBBP:8_5F^K= OL2&])U]J6-*:H;@X41N5W[,6=AC3
M;7&IG)%WL4_CE64-V;D;BPJYH+8=Z=/U9SG\MEA]J$#]5O[?C*/Y)#8^*]9.
M%161ZT)W[).\@F3)'C:U:=O4JVLNB S%[7@ME;']A'!<J2LG&=Y^/%'[P]VA
MF<M(L4Y@,4?^*N=6C^X$Q.M.3]B)LPL.24WWPCP(YK)H4JKSL 95F92)3__=
MM?[PV0+_[TML[(=_A?!60OI15%,P]HQ<>X^-H\_,?010& F/XDW1=\US-<K_
MJ/;DW7[]PIB4@7M[0YV3658TJ;9AX8U#U=E4/81&=+7R#G\G8B,8T27=WQZ5
MKT%*UQSD^7L%WKBM\VZ+W;AZ.F;_-78D4!*]#M]Q.B-N[/[DL4STT6@'NA8=
M30D*RE\]9@I]IUTK6QN@Z&KY;-Q&8H99-LU1JDI.?)0>\6TI2WPSJM"-'QAN
M:VS';C2&!*N?&+A03"OTBO#X;WX/0Q^6V_6+ ,[-TXO&1H-MX6=O@7N@J"W:
M \*ZPT!M,N@@NX7\[3J2R!Y1X9O]4%U?9I_3]T?D=]1%_#G,3<DHOH2IE0(O
M*TOKD[M0A T)U2[,!M*Z49^V;M6@S]J5(L%>_Z23 <!T%3.KDX/&^AY?7'<<
ME\B+?G3F&]__=_..9,P/L(BL1LE%]KFDT(3?$^^F[_X!UQWAIK-YYL,(_E?[
M#OJ*4H*8:U&**T7YY9'EY7Q6;^ZJ,KP(.K7H-W@<A.\/4O!&VLR]N(_Y\V97
M!Y''.#*>]J/\+TR_X.4YAW&I OJ$Y%GV_3+2KQ29E2D[$U_5*PH3,YE!['G1
MMR^=50CX[V?)NAJR\F/!M)ME=3F/7V+SKL$4YY7+^I3SMQ6OX/^QWII*R@;/
M5YS;[DZWOQKQHBX%B(QRSC*Q.-UPF;H:79-'SC4@7<%]L@'O62:[[F:!"F._
M=DL 4K7(-UOO_D'F<I%#:( S1<2#%&98.PX80T:Y[TO;+=7>;<WU>?'J8:CW
MW;^A,OQR\8$O!AY(2<-ND(:Z#D)N--9@]^*<MA4648T2-W/['G'\54GYK2TS
MP:394*:/GYZ2AF7/%[:('4:M2^J5C=98!!+&@W\?3QS."4?X;.I(R2"MOC4%
M(:H*S"3/[8()/SW[<-[=ZB:DI;#2M;I <-&W%/LI?)_OI1M/WD8K7=@,9:+[
MPM[3JC.A&&=B1DZG=^/Z[1S3(\$C[O58='4XN93Y2%=?Y<I0Q#0]DIPT1[B$
M@0>%9.9\GS5RD/LA1NF7<I<9YVQG'W\DI.:A>5Y14(8&0'A_L;3/I8XGH$ R
MPERNZ4(B]7_R&_7&P9L3:[:O#Y.55"RTS=@7[>F( IA&=#>0:^4@,!;%,4V^
MU[VQ7]_^QEJ1M4>)]73C0B<;.J0!$6N*_MAZ"V9#4@I;QJ\?Y'!$+PE\2M.3
MX_&W3+RUB;ZS.TK/5Y+>)#:N3F7&;R-/+T9[&?E:G.#U3[$G0Y42B.QF=9#S
M##Q&ZUP5L145\,,&U/@.R_^9R[YEY'=IJ=GRDKB[OLAB1Z[! #FG]18)C>FG
M 2X5V, :P>'1Z75^N/ F[\(R=77F6^8,QF]NA\W^9-QZ,'#9HGH;WG%(00]V
M%?L0BN=!(?#%8/:B%42LE@0YJSN$F6CR ?(.YLC6-"\9HR^U_698+ AOO?'@
M:*N>Y?>KY1!&X^ [VQ$:LK,5D#GA:(63(3XW;U=^R*<-1+D3=2+MKOYNS-2R
MO^@U(>AR4EO!GEFZ#KQC>P<8C-6U=)HFQ!CNPOU+M3KR6N^0'?TK80^QR^/(
M]0J#W>>C% '0#[RM]-C/_$F.OTE)3QB^TH?>#9;4FPU.B$6<Z6U&*)IZ69O-
MQ<S-O!<7MD^(<K^52;F2\ON]K?ZYGLI/[AUW,>F#NFZ%O#RCJU2P;-]Q0'+V
MF6&L2#GUV5X(CM*!.>47?9_)_6FS=HRW<0O<S.Y2"E$<;7XLL]>$[8']FP]Q
M6&_7P<F/88.)_*X:(J2+A,[ ENS3NJH?+D4D&; B>E-3YE3$A]6#A;JC+#86
MS_W$@='S8=P4NA*]N+YPV<^2VB@[<!R0JS<,E";7&(Y0#$GHN4^!V"C9C72#
MX<W*\DV',?MI%8%?3(. NPS+5?-CEGPS+-G>&/ZA2,53^UWSE@F?! ;K-3^>
M/F\I3^0?T,=K10JOKOZ,4Q%A\C=.S0S95M^$IY[Q$]XZ/V9IT=YPZ0A^)!I<
M)A5S"2*2^.-]#=??BT/$PT@?&H#;]>Y:H-VOJ;^_K?3N^8#+GU-+=6 %/VU6
MIWG)KN6N@:?4XG)H87.VM1!57V?#^-,OO+*#9D3C^6YO>[[:L4V**C&W@U]4
MB0;XFSF6B1SXK19>X^W,/?7;W$$EEE0>SS;PF],S^]/RQ^R7-NZ:YJ@A"ZH%
M?N@1M^@(Z"UBAXIF-4%N[<>HL^#559=VMF3ZI9AKLQ<NY=QOH[AMPCQ+^^=R
M6>*8C,<TC!P#2WQ+RTU=,LO30>"K[U-#K:TY,Q)I .B;YUH\R$9B2 K1W+R*
MQ'J:30-$;<C,CONRZA[K.[P^$$]ZX^2':^*[LD#7ICJ@]\]KCP*!] Z7*31G
MG>2@B>PUH!RLUG4HO--RUWHM\*N2/X=57XE!M?.A7^_] /:?4I++9_[-R',F
M09CL;8RUV%I_-@$N.M%"%:P3<&I^);7N]YHAN[J>O7^_![VMUG:%7UJMIIB0
M=$XPXGBFSBE=I]>>UP4^YCF[;]9W"LG%>X]=-#\$+Q72 ,D])KL/A /7*=JQ
MR:<FY5*RF_N&$K+28M:;Q0]$O8IUS7MOYOKZ<J?68KGJXR\\Z]V:XK[?IYT*
MBP(I%K</Z+6ER[D%UJJ]+9PMR]BW0YE(]II)MP^_3-5E*@)P?X0W$C#VEZM1
MH8<&(\V&LP,&04V&+<%;6Q".AXAKU7E55H,FSU\Q2\E],$8T#/2/G,D 91K@
MII'R[[S%"4(<^O>)]D.L5+-A@<U:IL_<4L\J0^*O%D&30+2],E%:88B1.I I
M/5)[<&#J&N<MCY'4OSZ3=L<J)YC)@&@XY3?_A&32"3;7X0^/@\P9JA^)JH4W
MNU=NSYY(]B;K7TQ[W'[1J]##6 [+_4+"V-16EJR]T&V\&YH.)_-2AE KB,AW
M4D@0>[CP11J@9JNH(:4;I65?X5T&LE0B&7L8/'9ZD=AS=086S;R:><PR(Y,P
MQ\Z&BO;9!%H,(Z1?-3]R+5P-+&^,67W?H_Q(-+DGH>^H[96Q0*6<$28]0RN=
M(@T?.OXCB\JE".]HBG2%2(PTBQ2SG+X]EM;ZW9L85:1BM^%1MB\Z5ZV(C@[A
M)BZ63KK9_%;RU)S]^>BFEKW'/5/=>\::*H@DBJ>CXUQNF#>YQFYB"]OMW"V'
M;ZF95NK">YS#'ZGB ->6^;8SL\R)I\5QK3?(=K[%3:U,F,:6+P,;O1;<=9.<
M!O4XNCU,L<& '15^K$<#B)WZ>KDI4QM-:( D:F.P[2P-$)/#0;+X?B H;AM.
M71ZXNQFN+ +EDVQR5PO"O@:R423J((QD4)O7"MB7 6NS5;+4)>/DF_7&[-UY
M0P[/8ZSY[+JFDLD_D@9(/&;_*@5<[L([,D W_N3$J>W2FQ<?$AAOWF5X;3#_
M==Q@."8=LH-> 4HN/]NF^FG]'/,5 -_LF#O8<4(A48]$J]&/G]W3+X]CP>"8
MHK:3APS&OK=D;[P>2W484MK9VBDX5IK C+3:DC_,]<ELA/#A],HU-GUG@XXJ
M;]@F3[OPQ(5[YF;E++>X4/NI?*.OR1E%:RS70HD4[3^%D^ZB(MY2I1CWS19.
M: ^3:9_J\*/IY&#M$SCU\4#_9&SZ"WB/-B5I[Q055=N/YK!;29P2S2PL,-0X
MF"]W(?CD5KA9]FKS)#7SD=CGF2)KE7)&;3X^K$MR3W:]UG$M<8=!RO+#T-.+
MVQKJSLXSVG'V;",:TN5VA-7&B1C-Z7RPXOQ4V:;<D:6J@U_ZY'SL;0Q]]"!+
MMM[0[CCU2<E)' U@)W)<LW)'<G$[2G(.?HWBBX5IQ10KAF<4ZG@[LN4C7JY^
M,'2&K2]T45^;)S1[R(_40Z):Q4G*GS8T.!+)L[YVH!<C%J-=_CC1A "7M'//
MRD)B 1<(<G9DO@4:@%7BI$^+!B#"^^T)XF_'L^S0,_"<[.ELTX-Q;E*S#5N8
M9RG%,@URU<TS@=W*=J@0?5 >+=T6]<68<4-5E*WAVEYIVN'T#9(Q8BZ78\UK
M379.4++MV*+X?*R_6?<UR^3[FR)?QMX;ZWH\6!V)R//:=-YQ10]'V37YTP J
MB-,&N(76:%[K(Z)6W%ROE(9FI7@,3&XV*]C2.,>PJ8%BY.DO3;I;M<L@_S R
M3@"&<7QU7K64*F1+ S!UGWXH<8/,G@99_WD3!+GR8$X6Y7)8>#&\T5M\B!G<
M%GI%1CAV+LM(J1$Q!-S9WYG4GQ(?IMK <XLS#L3,4!-26TC)L@M%!'\W[J($
M5X%'EQ J[4-(J'";/J%C6AM^:2V-/RR^RK<@IHT( N("P3A)"?E\Y6W.OE<>
M#TN8HF=;-=;44C%=D,NK56['8=FUF3T1C-+N]IJ1)"5BO8;[=C0X:#CZ!+@,
M^:V_>NL81#[SFAUYS8]F]EAGX;'3VL3"[(&Q3,'"BM2IEI:ISD&'I,.(&U_3
MVMOF%<Q6,M>T*K0B]$A<LR'%E=!1/1(\?+M<"HD7<*Y.4E3WRYR>8U2O^VEV
ME</K 5-#.3LOA7Y<2V+U6#=EWBA$X/0B8]K<3D\/?J,CH+?+"D_A_/IS4/^&
MOH8EXN6Z'T]@:E&NY@(G<"K<13KGONAG&65N^X)+L;F!3>9@Z='C4]_].UN'
MZZ<AF8'"MU>U6,BIA10/.RU"EY(E?Q@Z[%5M_;BL5(&+^Q4C"0L5D<-OK_9[
M3 SV( S4(>89- _4VSS!W+;,3MF@N:H^VHH:%.4N9LW_=(_^#A3C:3^@\V(+
MN4L)0!_=,FH"%\]"=C0<VX!,S;9$ZG3__='F1X6864.^C(HOJR?;7:+)/VOJ
MS.E5>E_.L+E]I0'H*#H(Z+(.5K'%45<VWZ[/'USBBO-/^F&8ZF2U^&Y#0OG2
M^WQU7=#D6E%9V=\5-=CA<?9F:[;CN:VTI:T7T1*8,GD.P/%(:\F^T*'=T,7Z
MTVS*V8KAZ"P#'==%0L#2,N \]$CM+L33?ZER<I+#+U%M\QFCMTT._6DN B:$
M.TJW"ET^,>FL.[ZY$9;NJ%M-?V,Y$=:.00:9J?5&][:GAC^B3]112]'O[M[8
M.[.S PD94]KK^:><I*VJV:S<#QS9(D])%VK'*V'JC%E^[CX-3N%'\PG]NG5.
MVE)? !R3EOXE9.<7?V@ !T%SW694UHFUAIP7@G&RKR4)?U6XNW=^HC6B5*T2
M]?H[AB$S;(''5:,/PIG1<93<@/O1L*:O06<,'HO-.TRG".]> 3/W&&[0 &TT
M@$@;6.L\.7=.-FRO@6(^QZ+JA!S.&3(R#+(PBKL#&#%*V54"7'W)[E;A?R(-
M6G4NM[9>;WR<N':LP/\<FS[!*CV 2*>+/,VN";,8]'C08ZR*R/,Y=389GUY\
M!ZE V$R8,ZQ#[O6^3O35:S^R"A1R6U1%JA_ *PAK$O;,,F54IB,A@9F$?\O/
MB$ATY,B\=5U]L.VCNI'G&!:)N+Q/NB\7=MCDH_^0P41S2[+O7!R[:8Q%35,M
MBDA1$]LSH8_PYI(73;HVZV6UH 1%..25]#5X^YXI QI@X<MGLX2;>*K &3WI
MQ4&79U"1BB97H0G6Q*4FQZ+N.4U-*46&ECI7NW.5?T@<]YF$&K@M9[$;^P$S
M?N.QC5V\#P\[E7#GSMH(ZA)C?#3T:"E>LPR_4K[1\#)04UM[UVGJK'/%1R++
MD7 G$>\\U\"W^14Z4G[V0@EZEQ\QLRX59$V8)D,'52K5NPG,%%L2T_SS'&&2
M?07D;B,1-FQKOSJ1<(WC27I:]0UPUV)&OIFNYX<V1(53ZO6HQ=0)E3\\SH[O
MO_F*3KS-FAO@M4J>4!>T^;5F^\-F:5JEDCO')36T-OK;XN?+C+,8D0E$1L.N
MMG:W(; ;G5@7UZ+-B.X3DO4]40.UWIO85Z<!^$ 3O*"@/+ACI +>(LJAT^G-
M^2C5%>,@+(1XV#ZM\ <BA05B%6(JU'JP&Z3NHE7J<Y3H*^9;?J+A )^GY_1[
M5^T3=$0W3P-I@"QNQ&F@[+"0X9SL)^IU)/E#*;2X0RTGU5FIZK]1]]Y137W?
MOF@4%! 5I1<!E::&(M*[R)<N(!UI44%IAM!K( K2FX" ($5 FI0(A%Y"!T%Z
MB=20T$L@H08(R>-WWGUOW'/N>>_</^ZX8]P_UA][C#WVWF.O-3]E[3GGIG9#
M6VU.Q<F[JH8E*?UX7;F5B+-HE3W/\@9%!A34YI<1"WXTCV[;V5S3NK>G7HX'
M#WMMUIL).8L" **8A9:QW.;F4 -$QN:F(PZ7J\9?K=-NR'P]E1\/N+-:A-$=
MP -]MX@X,FAR.!7*MZC"2_S6H\(B^;%\VL("9*,&@4FFZEL^[Z)J:1 "9&O*
ML:P'^&[/OG51B<,)M)B/D%3S+-9_S>;=%FB<[;U/(^PGM&:D,@]__0M9-RF,
M:4*DBXH4OB ,</0W9G_BU;';/+J]F>@$#W3-B*V4')U&_!3TF_@PQ"3WB/Z!
M$#L'3XV-G&+YL1@1IBH$?W)(,B:-*0YTH!F@004O.^U\L7&"0"M=L[JZU%Y=
MD+S9["?_Y]_"->\\ !Q7!.H0Z;#VA/<+#QNF$'H2772%VD6=OGD;V1;U#MYV
M OURC]:6%P& A;\LNY*&/F@9T#[R)(H_)16-.N&5=095[91CI0C<"[DECAD^
M)3__"L1+6K&%S^,QS;]-*H5)=A57WJ-) ,)E"V)"9X!Y)$X$RH4%3K6VA+N\
M<^F+_2JAR12* *:0[VK-N=OB3'8/LU1T,Z: LULNVJZ9O9<-GN0_;]=E>6KP
MYRGUH@_U:"#,-F%?#;U_(3[K"?XP!_HPO$P7Z.;L)KZG52CG3UUB[AN1-,<7
M[ ZKBCX52UB9CD/"<6>]HCQ$+VN^U,H [%?Z.;G#-#%RYTES@IJ-0$2L%[=>
MF=GXRU_U@8L]HW8-SU"7@@FQ#L)7;[IGFG7?/#K[5RV<I9(B!< ]?), :4=S
M$_>?5\GO1AT$-C71$R$B"$)1W5'@)S*'N0):*?B8IL 0?]RFPN$',2($E[I@
ME6Y#FE65?NPZ>S5/AT7S<3U[D;G-YT1]:\[#'P[+2T75@8B\RZ%U_T(^17HU
MXB4LY/K+30^GC**(_!S3YC.]G431KU:Z;V<T)I[O&@]Y<"7)_5S@.?\JQ4#=
MG;L9S#N)6(=J%@WZ[7(/EDIGCUKW<7_7:K\>6: QQR-W"(?FF%;5I&,S]A8X
MC"0D^)-^5GW?[&(:1Q?(:$]N2YW+WU![WE(W\5[(!C]OJ5/5??^T].'=A-Q"
MQ&0 M/;\TE$P$K7@[Y.+S^F63SG^)!63!=//L1P56VG\'!0S4.>X')?O./HB
MY#'[8J60DJ?U8-HV!NZ8/(-V:EQ(/R\HN) 5Y&\"@_F-BFQ)Z6_#%UU/?G6]
MJI"_=DJ;>3T[15,+A1B^U2X\8YOO5'*A7JB37@Y5_=0JNOZI1/:5W]V]!WH'
MY%IR:_"K0_0IFH0^2)";@%Y9FL5=9<^Q'1'=M?1)6NW?TKK:H=77%GLIZJI\
M:)-R#01CWMZGS$M2F% 4]U8T%]^4L#%PY_[)CL/L3\=H7F/:NQ_>QK)A8C0O
MA5:=WUBY$%;[RL&@Z:UNS\'%^2?[7:=0,@N^F]@0\M=2MKX^\NHE?O"L!Y7;
M4Y[#&CP%L'AA(YHO.13Y!0QT65H2S?5\6>'GV3P4P._?TTP*;Q\W]#P+#;MS
M"#<;;U8O<#ZNJ_61S\K"K<1$[N!P.XS:(G_W6-6I4Y1[6?+U=W=1J#^I*10
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M[F0#NL%$2(>\YJ=[+3&:5;KLNZ[+K?4F[Y3M]^XT92;_5LXTJS"'#*JT("B
M*UYJ5E;Y(.^"D]J</F*,(3%G2:&<OHN7"8EY-[\Q,Y5>II2"#*&"3]O'V<_P
M.1H(_U&8U//M(8NB2+J$'$-8#"?RTS*^I4LFP^=3G<[MWQ\M>DP;'C;Q.1,R
M42@4K'JW\R+.[Q3%NBKR%0U@U<'8DY3JIK-N3T2.AX0M!$,!3#.H3@3S$[>Z
MLN7')!-N=98ZCV[*O[AQ+W7>3,"('Z-I.C3WJRQ_%)Q_HM#KNJMQ*/E-;U\
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MND^&% ;Y*U)7\&Z.W(+R^^1AM40+Y;OGJ<$LQ)\]"DKF[4=UJ:/S!M#*YGV
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M>2F4B8@4^WAX9=R;@U./%?/+PW.Y[CBBKMQ?CR5%Q[V4C>X]6*=L?5"?P?A
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MN9]:KG/:#7W ZI8H:]T_=B"'"LVTCA%5SN[ZN;3IWB"WU'59]G4&'XI#;E,
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MHP!NP1Q$A+ILP:N1YCI(.3MVWD;/ QS1?,@6B%>N7FR:JIU\OT"5D_K\[9V
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M9&>+3(_OLST;X(OI975JQW'N^>A4JG@2"HQI"9[MEK^:4_:R+,HEZ++U/]6
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M$5A5[Q'M,11=GK*,B91IL6S"T[\K[OGU"L/JRU[%RA9XI=\+"DT-C5-D)4B
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M/'_E0 ]PT$:]XW0+)/V/MN]+*["$^'-Y,,A]6"U"T#7F@ WVWZ;Y]1$'Y&W
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MX-(I\R1@R9[]]!VB"7;DTN:"_+B+EX2B"N-'O?P[2W]R!#R+Z=)[QCR;#L\
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M,X"D$[F96^DQ,*^.2E3K2QDA:0^8^:2O]8R$9@L23C>.'8Y]Y%(2+>_E/+
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M&5T^V>*(YJE6>LE(G^NIT'+S[[; HF9[SQO9'.YL-TBE!- [0Q/1O[.'_ZD
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M]/> 8VB/F#/ +%3@UL@"(NL,P(K<#+0H<2#I5]8L,35L,6* UE(]O<Z*X/)
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M?[YD"&Q553?Z"GMM=+$^UH:%T>A[I.O/X+^[^0IR$P>M*HY1"E*K%>IW=J.
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M__S']_Z>8F(VI<J:$I[.A+@Y!_YR-.._JTN*6)>T*A_U&W!%PJ_?K-2?D0A
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MLSI#@/9;JBF%?A88]:J#QJ');+,N][KMU_<N<1/) F)4?/@IH/2I>J$3.LT
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MF>&%]J_G\;Z?H^FO/1]5:H"^QEOYEB_YD+UJQ8ITC)::=^(B4JV-.T+/DEP
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M9EI &^FV7U2)*TR/:D]HPA'T4CIXXQ2D85/1_$XK,\*5W=TXKU_B,7GWKW\
MLOWD1S-AWWX%\27 2 #Z)M]$=B?9  &XO\??Y:#^+,U!7_*GW7<3U1(ULT2E
M_V'!SI*U:%D).#*U"F'A/> PUI9,&+A0Z[>#B"MKND'\>PM$BZ7?P5]_/25!
MXABG& 8>X>D? ^R2\YX[WNN&6[!.].X_G&Q(=E-24_I:Q "BX'_<+N4-2<I
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M?M^\F=[:>V?9QPI(C,<[10-S1JV'/\3=M"?>QX,Q R2 9G7LQ(4^IA J=3)
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M+W_QNEA>]Q_BJN4/%O5<<!*0 @5+30V#P1[GG@/SHP]VX__\)*2 ;=W?VI,
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M3%%]9JG72P\>J_Q#YT+C/.UO<)D=0)6[%Z;9-.W,:-#(*.;-F>'.^\.;?&W
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M,)]LNFM</T[1)NH4MG/MW!+C<C_WR5,J DW/0Y</E<X >8'S-TZB_#6!^6>
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MK20ZX=57.Z!T)H%&(W2&5KKCTIYIG=4B;3N/E@T*_F7DO5K(W!/U0@ I56<
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M)>?<EVW^URB#*3T#\#/:=VJR!PG!U9O&/ VF59G87- %,=I=JP:5B4)73BN
MK<V3-?N\1N;>[)%>I$\FX_*\8BDV0VI/VNU&SF\?6FCXV?#!P#T*#S%]OZ8=
M]-P\;*MNX5A>\))(XL;ABS$UF^(Y\D>(0V6XJ6&\'I0U/53K 6<25CAS/TO\
MWS*XR,5NJJ$[ N9EXT0P?9$V>LF8%3EZ[;EZ1/9[<W>WU#H+?;5I&[O1U#-
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M6JU2"L,E;NT?YE8^<MB-Z)G2_E>[.-$,:K.EJ2%N1\*U\%RHC#*%@S#P]Z^
MFQ)Y -G!((]GZ+93E28'/(P9)%]+:U<>#JJO>J]6'7MW,?;HYH +_]ASJVE2
M[5'R5KWBP>A6 P;GT4V1.]$A?[20SS Z[EI\.;Q_V4]:J(HXEPTY31-H^T/P
MN./G(0-@5=SOZ7^(0TQ9=?C4-"@V>J"L72R-4+S6AJ@I7X]G']:'_1RU//QN
M^;V@!USCU09=#E?8$. D*RF%:U5_R90<AU'4G<N0QVK!K K:E]YY/^/1 J1?
M$7EIRTD6H7+55HZ,=OI7#X9))B_6#%N]T2[_*:0]D N/N/#+5,1S[T<@=(?B
MB0A'/ ^P6Z5"CFW#O_C&=<VICCN27^-+'QW_86)RN3]E>)J%$DDP9+.R<M%=
M)DD(N2N6,=['ZJ#@3J0<7X-V#=66S_I)[;9"&<*&=[BLK2>[)<3$Y3@[PH/K
MO:7E6I5+R6< QQ.W0M^ ?I)VD5NNLQ+FW<\1$=T^/>R25$R?AGUTYIVNC!-5
M<PNQ;R@#M(M2$-<(2HDG*%P"=&>V?GHWN+YM:4%6R#@_U6:K6;XA"(9Z-7$8
M6+H[,2\:"%(=#5*$/QV3'[RZ\<:.Z:J:3JE>3K?KNV4&6FD.=ZI3?TQ3P16W
MPS#?/5#X&8#;/E;PAJ7OMM6P9V\SDUF2 74H4:OBX^;ULI)BX0P4)#JF.\%T
M[PSP(=4Q(\_W!<C0B+!(/"CQ<K;^L6(F&MNUB.KS]^CTM&4C0U!D,Q.2PDX/
MMK1L0]P8J1KRO%Q%R["X^ZG$YJ:AE5T6=1IVVGC\4R,+NQN4CAD?*!C887@T
M 4RS6*RO27[<+2_-SP]Z='4A*C6UL##[Y67C7X!7U[UTV_YO] ?]V>2%4X;[
M+!"<VK%*-RP?%DWI.>].I^L&CQ4!M_M=A_7R14;O2'46U*I='SQX,Y;V8ABF
M(,AEJ=]@FN%6\!B*6H. 66+-VUR%GLXK__H]P/3T>M3@P>/1Q4I?:34=-V'I
M9,CK2T/35^>NE:[N+J8[?&7E8OH2.PM9NW.G;#L(<ZY\*ST5U9BRK*6XFX(7
MRJK7]XO/ )R^7R!3S=2OGE\=:WZ>2'+\W'$OY^9#SKCKN;8'6V@PG2;+8Z[;
M^5XA5/>FK3=)\?7>3&36K.+O<?#3L/\8S1YNUP"<!<IIDQ13\-?0^%%8=E-B
MFP?4LUSQZ;T%_M+MCQ)& YO'\Y3Y_D]ZQ>J8!40BA>ENVH(BJH2,UAFC/,;W
M5!<;WMJ;MW32U875>E2+U%O<_7.AZQ(D_?JFVFOB'QE.\FJ;QBTD^9>:QB'3
M 0CXOH[U%XG9ZOUTS-&:1Q2A6,:$))V6L\%C$T.8>NA3U/>J*C*N7R[$22B0
MW9S*UB!Q!K ).W2GEOA)A?^;5J\.2\:=Q'$8>"QDB"U9_UT[ [RFNY^0$2G:
M_=4G9_4#"^AIZG8+&T7-+I3*8GA-9B"'8R4@3JUS^0Q0DI#%]7N]D;O?T]^T
MTJ',2J$SIFVFK4)-:XR9IIC]]6#V)9,I'\B*6!("FW54V;V'GIR8Z-*,+ >5
M@>0UE!H25T!B@K<)2A*\)K7\?[MM@;WG 3M! 43CC$V=R509@UL%YI,]GH]*
MO1,99;T[;.!J(ARM/4E_E2^CLV[=SMS8XH_2YZA1 _A_#LC.R6K*VS\/Z*JH
MHSSXIY/[0;W^I=C0((%-6TF24;5T5MZO%.\6%DREN5;&;[[E 4&:BI^+$XW
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M[6QC@(GQW^N!;,]X_Y>:K/Q_. 3/)O\+4$L#!!0    ( #4Y#U6+S4Q%)&@
M .*+   7    <&QX+3(P,C(P-C,P>#$P<3 P-RYJ<&?LO =4%.N6/UJ(@$A2
MR1D%)8-D0:!%)0L(2!80 4F2<VP1 46@%004R4@66B3'5J* DG/N)N=N8@--
M][\\]]Q[C^?.??/^\]:\N3-K2HI57;7#;X=O?WL7JR6,$F:!<QHJZBH T2D
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M@*XRW;]_WM7TIQ0QF*"\_F  6NY, ! $(#89*%,V_%L2_7O9)&G@NL$*W2(
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M_3&/WD V9O7W/=>_0\H_">(MFPG *<O%@+,#11&6,6FGF A 5)D&6+P3\@A
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M-*U[GQ,G"HM,WY6U!Q<X'8@*B_4'C4B$@49H_MD(WS=&9+_(XT0W*G) >Q?
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MN&^0H>]S^% [ O"DK'D9[O8K $XT.$9>@"[U@&9\&?H'<Y&[1M5_@H"UAKZ
M["SE@6%Q_(<XH8\$)_\$X1?K]W<1[\B.:E*@O4+@9P:_8/K-/R'XQ?H_A4HQ
MZH#F%_7_F:ZOH", GVE:S#R(QT8I=UM1_YB3&O\Z.5D&;;X<=!,,DB8GCA),
M@K^C^K.9S%D-[W]9:K^@^G-\?M"OS_S3.O3G[&JSAS_ZU:Q?4/TI//^Y!6"
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ML!S-2D Q]Z#-1GXSQ[66?Q&N.E1(ME_)VK.IV);5* OVC248Q($7 D?JBA>
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M7$<GBM^/3*,./P898HQ.2&9^5PB+:N2'[##^ 6@ ")17.6A<4< O#_^TY^]
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M/G@Z&?'%ND\SM$)]ET>/\V7(.0X! O#L\5IEL\G,0O![*G#SGIJ)J6LH2\;
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M^ONHE7X4<5]XDA$V\8D[UJ%$QUMQYMCIQ'G"G')F6-:.YV@LP#-G0KDKV'M
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M0FLI2'".&5G].N".;/:VVSO[REY%TLK"T)1+X :=[OVE_']KE ER(@ DU 1
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M:PP<?T ]1^0V ]$:*OLS/S(YR,GH#*'&P]8Y-_[W14I&?'L'S8W.B/7$,C7
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MX^5IEI=A,&(+AN,:JTTR))9Q<"@1&6LUKA7A#'"O%Q'INGO>378TY5K0>:V
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M5Z8SK5J;.^E1 L6?],X[1GT;/C>XUPJS,-8\;A%C]D['8G6;8GF$=]F)#D6
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M]X:;?XY8SF>":3&38@Z&L+DT[,^::P!7+-!>*6W!&^R=TE,L%?S!5,:NM+*
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M2[[W;3WW4IM_\\V]2G?T?U!+ P04    "  U.0]5['(OB8T%  !S%P  %P
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MU>+:J=XJ@6IV8;XA JZKA,LN<I,<5?F=IPQM8R6GMMI:QK.<LPS.N<1RS/'
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MT&EW'<_U/.0>^5[;[QZBR27:O0D&'S7UV7@0_'LR-%(G-Z>?1P.T8SG.E\[
M<<Z",_, V+=1P'$NJ*0LQZGC#*]VT$XB9>$[SF*QL!<=F_&Y$TR=1&9IUTD9
M$\2.9;QSW%<K\$YP?-S/B,0H2C 71'[:N0G.K4.@D%2FY/BZ##,J!$A $\[8
M#%G(\ZRV=["W9[7[CB'J.X91R.+E<3^FMTC(94H^[628SVEN25;X';>0/6#K
MP.,UFCMK06.9^&W7?=\K<!S3?&ZE9";]=ML^V+]?XW2>W"\R<W*?DQ1+>DL4
M]P;?*"68^R&326]=Q&,[BWK?C.72FN&,IDO_0T S(M 56: IRW#^H656X+<@
MG,X^]#2UH/\A?MN# TIR)RV<TCDP5\KVC 7\ZO#A R$+HL\3LC2&A\.?+D:G
MH^"'=^U]M]>Q]_I."-8J-J29HGX@Q^Q43RLG@B4ER_R]^Q7E5O7UE@H:TI3*
MI9_0."8Y,/SAW:'G=GI]1S'[G<X10302OHT'<5]QD.>P<CZ^F087:#"<!J/S
MT> D&*+Q.3JY'%Z=P2M P5BCYSD6_9 ?OTBT)F!T-1A/)^/I23 :7\'"VPB9
M3,?!R>?13^AT- XNAM.3R? F& VN6R840*C]AK%P#X3*T$;*YAR[.RFY*#&@
M5#)T32*5B8P.7M=#D&%E0I3=_D5RPG&*!HP7C&-%AC[C146!KB44%/7E#)+8
M G/R<1L-]&LI))TMS1+-(>0@OQ^N:P"51P+]'3JE+$C *@4I)8U$C9 \LEL(
M2EC#4E#X< X28X3S&)$["G+R.2I!!-?V Z.))VW90B"%A$L4$0[Z43@>%FC&
MTI0MA+]=AJZLVME?%]>VC<#O?P>?H!QGI+9GTQ%4H%>X#^VJ?2K7>FZO@7B]
MTNY]M)&2,3#>B"IOP<:FQXWL9K@LE--H6O=JVM4$VC>)^?))WT./ABXQCY*J
M$KLMY+GM_99" )P1K!DC0(9,L%Q7Z$0]UCUBK+N]DW(.^#9\% ?#1^\$/1@
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M^^A5K>(?6GA>6Q<W-$M]_^!TRVC\TMSDF'_7T?\<=/Q?4$L! A0#%     @
M-3D/59*8R<# #   CVL  !               ( !     '!L>"TR,#(R,#8S
M,"YX<V102P$"% ,4    "  U.0]5:<H5PXX*  !*A@  %
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M2P$"% ,4    "  U.0]5K#M!O!YR 0#[OPX %               @ $BH0
M<&QX+3(P,C(P-C,P>#$P<2YH=&U02P$"% ,4    "  U.0]5K[7H,^N# 0"C
MNP$ %P              @ %R$P( <&QX+3(P,C(P-C,P>#$P<3 P-2YJ<&=0
M2P$"% ,4    "  U.0]5\':L\FAY 0!ZB0$ %P              @ &2EP,
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M,BYH=&U02P$"% ,4    "  U.0]5['(OB8T%  !S%P  %P
M@ '+B@4 <&QX+3(P,C(P-C,P>&5X,S)D,2YH=&U02P$"% ,4    "  U.0]5
M[WE&8H\%  "-%P  %P              @ &-D 4 <&QX+3(P,C(P-C,P>&5X
M,S)D,BYH=&U02P$"% ,4    "  U.0]55L&\*X '  #P)   %@
M    @ %1E@4 <&QX+3(P,C(P-C,P>&5X,V0U+FAT;5!+!08     #@ . *\#
(   %G@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
